Low molecular weight inhibitor of nf-κb-inducing kinaze
Specific compounds targeting NIK inhibit its activity, addressing limitations in current therapies and offering therapeutic benefits in treating cancers, inflammatory disorders, autoimmune disorders, and metabolic disorders by modulating immune responses and cell proliferation.
Patent Information
- Application Number
- JP2024146717
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-09-30
- Filing Date
- 2024-08-28
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-05-29
AI Technical Summary
Current therapies for diseases mediated by NF-κB-inducing kinase (NIK) are limited, and there is a need for effective inhibitors to target NIK pathways in conditions such as cancer, inflammatory disorders, autoimmune disorders, and metabolic disorders like obesity and diabetes.
Development of specific compounds that inhibit NIK activity, including various pharmaceutically acceptable salts, targeting the NIK pathway to regulate immune response and cell proliferation.
The compounds effectively inhibit NIK, providing therapeutic benefits in treating cancers, lymphomas, myelomas, inflammatory disorders, autoimmune diseases, and metabolic disorders by modulating immune responses and reducing undesirable effects associated with increased NIK levels.
Smart Images

Figure 2024167319000001 
Figure 2024167319000002 
Figure 2024167319000003
Abstract
Description
[Technical Field]
[0001] NF-κB-inducing kinase (NIK, also known as MAP3K14) is a non- Regulators and drivers of the canonical NIK cascade and therefore attractive for therapeutic intervention The present invention provides compounds that inhibit NIK and pharmaceutical compositions containing such compounds. These compounds and pharmaceutical compositions are directed to the treatment of cancer (including leukemia, lymphoma, and myeloma). B-cell malignancies, inflammatory disorders, autoimmune disorders, palmoplantar pustulosis, and hidradenitis suppurativa It is useful for the prevention or treatment of diseases such as immune-related skin disorders and metabolic disorders such as obesity and diabetes. The present invention also relates to methods for preventing or treating such diseases. do. [Background technology]
[0002] NIK is involved in immune response disorders, cell proliferation disorders, adhesion, apoptosis, carcinogenesis, etc. It is a serine / threonine kinase transcription factor that promotes the expression of various genes. Since NIK plays a role in regulating the immune system, inhibiting it reduces the production of inflammatory molecules. It is possible to block several downstream pathways. Clinical validation using biologics has demonstrated that Several NIK-dependent pathways have been identified as playing important roles in immune diseases. For example, SVNavarra, et al., The Lancet, 2 NIK-dependent transcriptional activation is mediated by phospholipase A (PTA)-dependent transcriptional activation. Tightly regulated signaling pathways through a series of events including cleavage and proteolysis In the non-canonical NIK activation pathway, the catalytic complex subunit IK Kα is phosphorylated, and the gene product p100 is partially proteolyzed and binds to DNA. The syncytial protein p52 is released, and this p52 binds to another DNA-binding protein, RelB, in a heterologous fashion. Activation is achieved by dimerization, translocation to the nucleus, and mediating gene expression. These include CD40 ligand, B-cell activating factor (BAFF), and TNF-related weak inducer of apoptosis (TWEAK) is a ligand for the inflammatory cytokine β receptor. tokine, tumor necrosis factor ligand superfamily member 11 (TNFSF11) Receptor activator of nuclear factor kappa-β ligand, also known as It is activated by ligands such as nuclear factor kappa-β ligand (RANKL). NIK has been shown to be required for pathway activation by these ligands (S.- C. Sun, Nat Rev Immunol.2017,17(9),545-558 Because of its role, NIK expression is tightly regulated. In this state, the NIK protein level is very low. P repeat-containing-3 (BIRC3, also known as CIAP2) and ubiquitin ligase A series of TNF receptor-associated factors (TRAF2 and TRAF3) are enzymes that lead to the degradation of NIK. 3) In pathological / abnormal conditions, the non-canonical pathway is activated by the ligand. When stimulated by TRAF, the activated receptors compete for TRAF, forming TRAF-BIRC. It is thought to dissociate the 3-NIK complex, thereby increasing NIK levels. (For a more detailed analysis of this background, see, for example, S.-C. Sun (cited above) and Thu and Richmond,Cytokine Growth FR201 As mentioned above, NIK is involved in immune response disorders, cell proliferation disorders, and Increased NIK levels are associated with increased risk of cell death, cell adhesion, apoptosis, and carcinogenesis. One way to reduce or eliminate the adverse effects associated with such an increase is through NIK inhibition. is.
[0003] BAFF / BAFF-R, whose inhibition is associated with systemic lupus erythematosus (SLE), Clinically validated therapeutic targets believed to be beneficial in the treatment of rheumatoid arthritis (rheumatoid arthritis, SLE) Belimumab (anti-BAFF antibody) is approved for treating seropositive SLE patients. It has been recognized (SV Navarra, et al., The Lancet, 201 1;377(9767):721-31). The CD40L / CD40 pathway is a T-dependent B It plays an important role in cell activation, maturation of dendritic cells, and tissue inflammation and immunity (R .Elgueta,et al.,Immunol.Rev.2009;229(1): 152-72) Anti-CD40L antibodies have been shown to be effective in phase 2 clinical trials in SLE patients. It has shown promising effects (PISidiropoulos and DTBou mpas, Lupus 2004 May;13(5):391-7). mice (R. Shinkura, et al., Nature Genetics 1 999;22(1):74-7;HDBrightbill,et al.,JI mmunol.2015;195(3):953-64), or NIK conditional knock Out (HD Brightbill, et al., J Immunol. 2015 ;195(3):953-64 or human patients with NIK gene mutations (KLWil lmann,et al.,Nature Comm.2014;5:5360) Deficiency of non-canonical NIK activation pathways, such as the AFF and CD40L pathways, and peripheral blood and lymphoid organs The decrease in B lymphocytes in the organs and the decline in T cell-dependent antibody responses were observed, and NIK was shown to be effective in treating SLE. This supports the idea that leukemia is a therapeutic target.
[0004] NIK is "important in the immune and bone destruction components of inflammatory arthritis and is a key player in the progression of these diseases." It has been characterized as "a potential therapeutic target." K. Aya, et al. (J. Clin.Invest.2005,115,1848-1854). Mice that do not have peripheral lymph nodes have impaired B and T cells, and show impaired receptor activation. It was also found that osteoclast formation induced by factor NIK ligand was impaired. t al.(J.Clin.Invest.2005,115,1848-1854) We investigated the role of NIK in a mouse model of inflammatory arthritis using NIK- / - mice. The serum transfer arthritis model reportedly involves the induction of inflammation by preformed antibodies. The recipient only needed intact neutrophils and the complement system. showed inflammation comparable to that of NIK+ / + controls, whereas Ada et al. (supra) found significantly more They showed less periarticular osteoclast formation and less bone erosion. The serotype is a potential risk factor for antigen-induced arthritis ( ), which requires intact antigen presentation and lymphocyte function. showed complete resistance to antigen-induced arthritis (AIA), but lymph nodes were not involved. Furthermore, NIK+ / + spleen cells or T cells were transfected into Rag2- / - mice. Transplantation of NIK- / - cells makes the patient susceptible to AIA, but transplantation of NIK- / - cells did not result in the disease. NIK- / - mice express both the KRN T cell receptor and H-2g7. It also showed resistance to a genetic spontaneous arthritis induced in mice. We used transgenic mice expressing NIK lacking the NT3 domain in the OC lineage. Constitutive activation of NIK inhibits osteoclast formation both basally and in response to inflammatory stimuli. and bone resorption. "The activation of IL-1 promotes osteoclastogenesis and bone resorption both in the basal state and in response to inflammatory stimuli." It is concluded that (C. Yang, et al., PLoS ONE 2010, 5(11):e15383,doi:10.1371 / journal.pone.00 15383).
[0005] We wonder if manipulating the levels of NIK in T cells could have a therapeutic effect. It is also thought that reducing NIK activity in T cells leads to the formation of another NI pathway called the canonical pathway. It prevents graft-versus-host disease (GvHD) without severely damaging the immune system like inhibitors of the K activation pathway. Graft-versus-host disease and transplant rejection may significantly improve the immune and alloresponse of Murray, et al, “NF-κB-inducing kinase play s an essential T cell-intrinsic role in graft-versus-host disease and lethal aut oimmunity in mice” J.Clin.Invest.2011;121 (12):4775-86) ("To avoid autoimmunity, strict control [of NIK] is necessary" (The data provided can be characterized as "suggesting that the The NIK activation pathway depends on the inducible degradation of IκB kinases, particularly IκBα, and is mediated by various N This leads to nuclear translocation of F-κB complexes, primarily p50 / RelA dimers. Degradation of IκBα , two catalytic subunits, IKKα and IKKβ, and a regulatory subunit, IKK γ (also known as NF-κB essential modulator or NEMO) Non-canonical NIK activity is mediated through phosphorylation by IκB kinase (IKK), a kinase that mediates the activation of NIK. The activation pathway involves a mechanism that relies on inducible processing of p100 instead of degradation of IκBα. Using the system, the RelB / p52 NF-κB complex is activated. For example, S.-C .Sun,Cell Res.2011 Jan;21(1):71-85).
[0006] NIK is a clinically significant risk factor for Sjögren's syndrome (J. Groom, et al., J. Clin. Inv est.2002;109(1):59-68), proliferative lupus glomerulonephritis (DTBo umpas,et al.,Arthritis&Rheumatism 2003;4 8(3):719-27), multiple sclerosis (J. Tan, et al., J. Neuro immunol,1999;97(1-2):77-85), J.Krumbholz, et al., J. Exp. Med. 2005; 201(2): 195-200), and Pemphigus vulgaris (Z.Liu,et al,J.Invest.Dermatol.200 6;126(1):11-3), other BAFF, CD40L or lymphotoxin β receptors It is also a promising therapeutic target for receptor ligand-driven autoimmune disorders. Summary of the Invention [Means for solving the problem]
[0007] Embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof:
[0008] [ka] During the ceremony, R 1 is H or -CH3, R 2 is H or -CH3, R 3 is H, -C1-C5 alkyl, -OCH3, or -O-C1-C3 haloalkyl and R 4 is H or -CH3, portion
[0009] [ka] teeth,
[0010] [ka] and R aa is H or -CH3, R bb is H, -CH3, or -CF3, R cc is -CH3, -CD3 or -CH2CF3, portion
[0011] [ka] teeth,
[0012] [ka] and E is N or CH; F is O, S, NH, or NCH3; R a is H or -CH3, R b is H, D, -OH, F, -C1-C5 alkyl, -CH2OCH3, -C1-C 5 haloalkyl, -NH2, cyclopropyl, or -CH2OH; R c is H, D, or CH3, R d is H, -CN, -CF3, -C1-C5 alkyl, -C3-C6 cycloalkyl , -O-C1-C3 alkyl, -N(R 6 )R 7 ,
[0013] [ka] and During the ceremony, R 6 is H or -C1-C3 alkyl, R 7 is H, -C1-C3 alkyl, -SO2CH3, -COCH3, -C1-C4 ha or R is -CHCN 6 and R 7 are the nitrogen atoms to which they are bonded. Together, portion
[0014] [ka] wherein m is 0 or 1 and p is 0 or 1; R 8 is H, F or -C1-C3 alkyl, R 9is H, F or -C1-C3 alkyl, R e is H, -CD3, Br, -C1-C5 alkyl 、 -C3-C6 cycloalkyl,
[0015] [ka] 1 to 3 R g is a —C1-C5 alkyl substituted with a group, wherein R g is -NH2, or F, R 10 is H or F, R 11 is H or F, R f is H, -CH3, or
[0016] [ka] and R h is -CH3, -NH2 or
[0017] [ka] and R i are H, -CH3, -CN, Br,
[0018] [ka] and R j is -NH2 or
[0019] [ka] and R k is H, -CF3, I, Cl, Br, -CN, -C1-C6 alkyl,
[0020] [ka] and R 12 is H or -CH3, R 13 is H, -CH3, -CH2(C)(CH3)2OH, -(CH2)3CN, or is -(CH2)2NH2, R 14 is H or -CH3, R l is H, -C1-C4 alkyl, -CF3,
[0021] [ka] and R m is H or -CH3, R n is -NH2, R o is H or -CH3, R p is H or -CH3, R q is H, —CN, F, Cl, —OCH3, —CF3, or —CH3, R s is -NH2 or
[0022] [ka] and However, part
[0023] [ka] but
[0024] [ka] and each R 1 , R 2 , R 3 and R 4If is H, then the part
[0025] [ka] teeth
[0026] [ka] This is subject to the condition that:
[0027] An exemplary embodiment of the compound of formula (I) is the compound (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) -4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl] )phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-6-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopteridin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-aminoquinazolin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] Phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl -2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne- 2-all, (R)-3-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-(((8-amino-3,4-dihydro-2,7-naphthyridine-2(1H )-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(3-amino-1-methyl-pyrazolo[4,3-b]pyridin phenyl)ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-3-[2-[3-(3-amino-1H-pyrazolo[4,3-b]pyridine-5 -yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-ethoxypyrido[3,2-d]pyrimidin-6-yl)phenyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin) (phenyl-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-hydroxy-1-methyl-3-((3-(4-(methylamino)pyrido[ 3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one, (S)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl yl]-2-thiazol-2-yl-but-3-yn-2-ol, 1-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl ]ethynyl]cyclopentanol, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl -2-(5-methylisoxazol-3-yl)but-3-yn-2-ol, 4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2 -methyl-but-3-yn-2-ol, (R)-3-[2-[3-(1-amino-7-isoquinolyl)phenyl]ethynyl]- 3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d ]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((5-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-5 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (R)-2-[3-[2-(7-hydroxy-5,6-dihydrocyclopenta[[b] Pyridin-7-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidine- 8-on, (R)-4-(3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2- yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-4-(3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d] (pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yne-2 -Oar, (R)-4-(3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2- yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-4-(3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2- yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] -5-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridine- 7-all, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -isobutylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidone) (3H)-pyridin-3-yl)ethynyl)phenyl)pyrido[3,4-d]pyrimidine-4(3H)- on, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-((3-(8-amino-4-morpholinopyrido[3,4-d]pyrimidine -2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-3-((3-(8-amino-4-(dimethylamino)pyrido[3,4-d] ... 2-(phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-[2-[3-(4-amino-1H-imidazo[4,5-c]pyridine-2 -yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-7-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d ]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopentene ta[b]pyridin-7-ol, (R)-7-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-7-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] Phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin phenyl-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidine- 2-on, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidine- 2-on, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -thiazol-2-yl-but-3-yn-2-ol, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- (methylphenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one , (S)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one , (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidone lysin-2-one, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidone lysin-2-one, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- Methylphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)buta -3-in-2-all, (R)-7-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 (Methylphenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin phenyl-2-yl)-5-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidine- 2-on, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -(5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- Methylphenyl)-2-(5-methylisoxazol-3-yl)but-3-yne-2 -Oar, (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d3)pyrrolidine-2 -on, (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imida zoll-7-ol, (R)-3-((3-(8-amino-4-(methylamino)pyrido[3,4-d]pyridyl) (2-(2-(4 ... -on, (R)-7-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin (2-phenyl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazo ol-7-ol, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin phenyl)ethynyl]-3-hydroxy-1-(trideuteriomethyl) ) pyrrolidin-2-one, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -(5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -thiazol-2-yl-but-3-yn-2-ol, (R)-7-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl ]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol, (R)-3-[2-[3-(8-amino-4-methyl-pyrido[3,4-d]pyrimidin 3-hydroxy-1-(2,2,2-trifluorophenyl)ethynyl (triethyl)pyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(8-amino-5-bromopyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-3-[2-[3-(4-aminophthalazin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) -2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne- 2-all, (R)-3-((3-(8-amino-4-isopropylpyrido[3,4-d]pyrimidin (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-[2-[3-[8-amino-5-(trifluoromethyl)pyrido[3,4 -d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidone) (3-(ethynyl)phenyl)pyrido[3,4-d]pyrimidine-5-carbonyl Trill, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)phenyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-iodopyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methyl isoxazol-3-yl)but-3-yn-2-ol, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-thiazole -2-yl-but-3-yn-2-ol, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methyl (1,3,4-oxadiazol-2-yl)but-3-yn-2-ol, 2-(3-((1H-pyrazol-5-yl)ethynyl)phenyl)-4-methylpyrazole do[3,4-d]pyrimidin-8-amine, (R)-4-(3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl) (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-methylquinazolin-6-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrido[3,4-d]pyrimidin-6-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-5-bromo-1,7-naphthyridin-2-yl] phenyl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-8-fluoro-quinazolin-6-yl)phenyl]phenyl] ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-8-methoxyquinazolin-6-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(trifluoromethyl)quinazoline-6-yl) (phenyl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminothiazolo[4,5-c]pyridin-2-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-chloroquinazolin-6-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-8-amino-2-[3-[2-(3-hydroxy-1-methyl-2-oxo- Pyrrolidin-3-yl)ethynyl]phenyl]-1,7-naphthyridine-5-carbonite Lil, (R)-3-[2-[3-(5-amino-2,6-naphthyridin-3-yl)phenyl] ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-5-methyl-1,7-naphthyridin-2-yl] phenyl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-5-phenylpyrido[3,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(1-methylpyrazol-4-yl)pyrazole Lido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1 -methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-[1-(2-hydroxy-2-methyl- Propyl)pyrazol-4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl yl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(1H-pyrazol-4-yl)pyrido [3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl thyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(3,5-dimethyl-1H-pyrazole -4-yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3- hydroxy-1-methyl-pyrrolidin-2-one, (R)-4-amino-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidone) (din-3-yl)ethynyl)phenyl)quinazoline-8-carbonitrile, (R)-3-[2-[3-[8-amino-5-(5-methyl-1H-pyrazole-4- yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydro oxy-1-methyl-pyrrolidin-2-one, (R)-phenyl 8-amino-2-[3-[2-(3-hydroxy-1-methyl-2 -Oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidin benzophenone-5-carboxylate, (R)-3-((3-(8-amino-5-ethylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-isobutylpyrido[3,4-d]pyrimidine -2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone, (S)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone, (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)pyridin [3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl thyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-[1-(2-aminoethyl)pyrazole -4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3- hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)pyrido[3, 4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-8-methyl-pyrido[3,4-d]pyrimidinyl] phenyl)ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-4-(3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl) (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(8-amino-4,5-dimethylpyrido[3,4-d]pyrimidin (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[4-[8-amino-2-[3-[2-(3-hydroxy-1-methyl- 2-Oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidin di-n-5-yl]pyrazol-1-yl]butanenitrile, (R)-3-((3-(4-aminothieno[2,3-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminooxazolo[5,4-d]pyrimidin-2-yl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(6-amino-9-methyl-9H-purin-8-yl)phenyl )ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl) (phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol Lu, (R)-3-[2-[3-[8-amino-5-(1-piperidylmethyl)pyrido[3, 4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-7-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl )phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Rule, (R)-3-[2-[3-[8-amino-5-[6-(trifluoromethyl)-3-pi Lysyl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-2-methyl-pteridin-6-yl)phenyl] yl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d)-4-Methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-((3-(8-amino-5-neopentylpyrido[3,4-d]pyrimidin (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((5-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 5-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl) (phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol Lu, (R)-3-((3-(8-amino-4,6-dimethylpyrimido[5,4-d]pyrimido) (2-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (2-methylthiazol-5-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (2-methylthiazol-5-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidin (6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d)-4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-5-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-5-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, Racemic-8-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-5,6,7,8-tetrahydroquinolin-8-ol, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methylthiazol-2-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methylthiazol-2-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl-6-(d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, (R)-tert-butyl 3-amino-5-[3-[2-(3-hydroxy-1-methyl) ethyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]indazole-1-carboxylate carboxylate, (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pi (Irimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)-1, 7-Naphthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)-1,7-na Phthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-((3-(4-amino-2-(hydroxymethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-[2-[3-(3-amino-1H-indazol-5-yl)phenyl] ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-2-cyclopropylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-2-(trifluoromethyl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)- 4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-3-((3-(4-amino-2,7-dimethylpyrido[3,2-d]pyrimidin (phenyl-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-2H-pyrazolo[3,4-d]pyrimidine-2- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-2-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol Lu, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-2-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-3-[2-[3-(7-amino-5-methyl-thiazolo[5,4-d]pyrimidinyl] ethynyl)-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-Methyl-phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imida zoll-7-ol, (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-Methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridine -7-all, 1-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4- methyl-phenyl]ethynyl]cyclopentanol, (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-7-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-(trifluoromethyl)thiazol-2-yl)buta-3 -in-2-all, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-(trifluoromethyl)thiazol-2-yl)buta-3 -in-2-all, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , 1-Allyl-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one, Racemic-1-allyl-3-((3-(4-aminopyrido[3,2-d]pyrimidine-6 -yl-2-d)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol, Racemic-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- 1H-imidazol-4-yl)phenyl)-2-(1H-imidazol-4-yl)but-3-yn-2-ol , (R)-3-((3-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl )phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)- (ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-(methoxymethyl)pyrido[3,2-d]pi (Irimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) ethynyl)-3-methoxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pi (Irimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d3)pi roridin-2-one, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol, (R)-3-((3-(4-amino-2-ethylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-hydroxypyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)buta -3-in-2-all, (R)-3-((3-(7-aminothiazolo[4,5-d]pyrimidin-2-yl)phenyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-methyl-7,8-dihydropyrido[4,3- d]pyrimidin-6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl) 1-pyrrolidin-2-one, (R)-4-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4 -methyl-phenyl]-2-(5-methylisoxazol-3-yl)but-3-yne -2-all, (R)-6-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-imidazo[1,5-a]pyrazin-8-one, (R)-3-((3-(8-amino-1,5-naphthyridin-2-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidin (6(5H)-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) phenyl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4(3H)-one, (R)-3-hydroxy-1-methyl-3-((3-(4-(pyrrolidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-ol hmm, ((R)-3-hydroxy-1-methyl-3-((3-(pyrido[3,2-d]pyrimidinyl) (phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-amino-5,7,8,9-tetrahydro-6H-pyrimido) [5,4-c]azepin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-(piperidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-ol hmm, (R)-3-((3-(4-(3,3-dimethylazetidin-1-yl)pyrido[3, 2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrimidin roridin-2-one, (R)-3-((3-(4-(ethylamino)pyrido[3,2-d]pyrimidine-6- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-hydroxy-3-((3-(4-(3-hydroxyazetidin-1-yl) )pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrro lysin-2-one, (R)-3-Hydroxy-1-methyl-3-((3-(4-oxetan-3-yl) amino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidine- 2-on, (R)-3-hydroxy-3-((3-(4-(3-methoxyazetidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolyl Jin-2-On, (S)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin) (phenyl-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-(3,3-difluoroazetidin-1-yl)pyrido[3 ,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-((3-(8-(azetidin-1-yl)-1,7-naphthyridine-2- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(1-(azetidin-1-yl)isoquinolin-7-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(azetidin-1-yl)quinolin-6-yl)phenyl )ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(cyclobutylamino)pyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1- methylpyrrolidin-2-one, (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)acetate Mido, (R)-3-((3-(4-(3-fluoroazetidin-1-yl)pyrido[3,2- d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-2-((6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine -3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)amino ) acetonitrile, (R)-3-((3-(4-((2,2-difluoroethyl)amino)pyrido[3,2 -d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrro lysin-2-one, (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)azetidin benzo-3-carbonitrile, (R)-3-((3-(4-(azetidin-1-yl)quinazolin-6-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(3-chloroazetidin-1-yl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-hydroxy-1-methyl-3-((3-(4-(3-(methylsulfonyl )Azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethy (nyl)pyrrolidin-2-one, (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)-N-methyl thiazetidine-3-carboxamide, (R)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidin) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (S)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidin) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(5-bromo-8-methyl-1,7-naphthyridin-2-yl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4,8-dimethylpyrido[3,2-d]pyrimidin-6-yl )phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) (phenyl)ethynyl)phenyl)-8-methyl-1,7-naphthyridine-5-carbonitrile, (R)-3-((3-(5,8-dimethyl-1,7-naphthyridin-2-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy- 1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy- 1-methylpyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-phenylpyrido[3,2- d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl acetamide, (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d) acetamide, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (3R,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3R,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3S,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3R,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3R,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3S,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3S,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3R,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d) methanesulfonamide, (R)-3-((3-(4-cyclopropylpyrido[3,2-d]pyrimidin-6-yl) (phenyl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-Hydroxy-3-((3-(4-isopropylpyrido[[3,2-d] ... rimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidin-2-one, (1R,4R,5S)-4-((3-(4-amino-2-methylpyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (1S,4S,5R)-4-((3-(4-amino-2-methylpyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (1S,4S,5R)-4-((3-(4-aminopyrido[3,2-d]pyrimidine- 6-yl-2-(d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[4.2.1.2] chloro[3.1.0]hexan-3-one, (1R,4R,5S)-4-((3-(4-aminopyrido[3,2-d]pyrimidine- 6-yl-2-(d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[4.2.1.2] chloro[3.1.0]hexan-3-one, (R)-3-((3-(4-amino-8-cyclopentylpyrido[3,2-d]pyrimidin 2-(2-phenyl)ethynyl-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-hydroxy-1-methyl-3-((3-(4-(trifluoromethyl)pyrrolidone) Lido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one , (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) phenyl)ethynyl)phenyl)pyrido[3,2-d]pyrimidine-4-carbonitrile, (R)-3-hydroxy-1-methyl-3-((3-(8-methyl-1,7-naphthyl) (phenyl)ethynyl)pyrrolidin-2-one, (1R,4R,5S)-4-((3-(4-amino-8-methylpyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (R)-3-((3-(4-amino-8-(aminomethyl)pyrido[3,2-d]pyridyl) Myridine-6-yl-2-(d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-((3-(4-amino-8-isopropylpyrido[3,2-d]pyrimidin 2-(phenyl)ethynyl-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-((3-(4-amino-8-(trifluoromethyl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(4-amino-2,8-dimethylpyrido[3,2-d]pyrimidin (phenyl-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-8-(methyl-d3)pyrido[3,2-d]pyridyl) (6-amino-3-hydroxy-1-methylpyrrolidine-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, (R)-3-((3-(4-amino-8-(piperidin-4-yl)pyrido[3,2- d]pyrimidin-6-yl-2-(d)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-((3-(4-amino-2-fluoropyrido[3,2-d]pyrimidine- 6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (S)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (3R,4S * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3R, 4R * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3S,4S * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3S, 4R * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (R)-3-[2-[3-[4-amino-8-(dimethylamino)pyrido[3,2-d ]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin Jin-2-On, (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d] Pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-[2-[3-[4-amino-8-(isopropylamino)pyrido[3,2 -d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-[4-amino-8-(cyclopropylamino)pyrido[3, 2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(difluoromethoxy)pyrido[3,2 -d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-[4-amino-8-(3,3-difluoroazetidine-1- yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydro oxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-4-methyl-pyrimido[5,4-d]pyrimido] ethynyl)-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-((3-(4-amino-8-cyclopropylpyrido[3,2-d]pyrimidinyl) (6-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-[2-[3-(4-amino-8-pyrazol-1-yl-pyrido[3,2 -d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-[4-amino-8-(cyclopropoxy)pyrido[3,2- d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyro lysin-2-one, (R)-3-[2-[3-[4-amino-8-[1-(difluoromethyl)pyrazole -4-yl]oxy-pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl ]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(3,3,3-trifluoropropoxy )pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy -1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(2,2-difluoro-5-azaspiro [2.3]Hexan-5-yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-8-ethylpyrido[3,2-d]pyrimidine-6 -yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-8-cyclobutylpyrido[3,2-d]pyrimidin (phenyl-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-8-phenylpyrido[3,2-d]pyrimidine- 6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(thiophen-2-yl)pyrido[3,2- d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-((3-(4-amino-8-(furan-2-yl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (3R)-3-((3-(4-amino-8-(azetidin-2-yl)pyrido[3,2 -d]pyrimidin-6-yl-2-(d)phenyl)ethynyl)-3-hydroxy-1-methyl thylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-vinylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-[3-(trifluoromethyl)azetidin phenyl]pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3 -hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(azetidin-1-yl)pyrido[3, 2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-((3-(4-amino-8-((2,2,2-trifluoroethyl)amino)amino Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy thio-1-methylpyrrolidin-2-one, (1R,4R,5S)-4-((3-(7-aminothiazolo[5,4-d]pyrimidine -2-yl)-4-methylphenyl)ethynyl)-4-hydroxy-2-methyl-2- Zabicyclo[3.1.0]hexan-3-one, (3R,5R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidine-2- (yl)-4-methylphenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine ion-2-one, and These are pharmaceutically acceptable salts.
[0028] Embodiments of the present invention include compounds, pharmaceutical compositions containing them, and methods for making and purifying them. methods for their use as NIK inhibitors, and pathologies mediated by NIK; and methods for their use in the treatment of injuries and conditions.
[0029] A further embodiment of the present invention is a method for treating NIK using a compound of the present invention or an active agent of the present invention. suffers from or has been diagnosed with a disease, disorder, or medical condition transmitted by The present invention is a method of treating a subject suffering from a pulmonary embolism.
[0030] Further aspects of the present invention will become apparent from the following detailed description and by practice of the invention. Embodiments, features and advantages will become apparent. DETAILED DESCRIPTION OF THE INVENTION
[0031] As used herein, the terms "comprise," "contain," and "include" mean Used in a broad, non-limiting sense.
[0032] To provide a more precise description, some of the quantitative expressions used herein may be prefixed with "about." The term "about" is not used to qualify the information. All quantities given herein are meant to refer to actual given values and are not intended to be limiting unless otherwise specified. The technical specifications, including experimental and / or measurement equivalents and approximations to the given values, Refers to an approximation of such given value that can be reasonably inferred based on ordinary skill in the field. is also understood to mean
[0033] Unless specifically limited in a particular application, the term "alkyl" refers to one or more alkyl groups in the chain. It refers to a straight or branched chain alkyl group having up to 8 carbon atoms. Examples of alkyl groups include: Methyl (Me), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl butyl, hexyl, isohexyl, and the like, as used herein, are examples of butyl, hexyl, isohexyl, and the like, as used herein, and are examples of butyl, hexyl, isohexyl, and the like, as used herein, In light of the disclosure, groups that are considered to correspond to any one of the above examples are included. "C1-C4 alkyl" means a straight or branched chain alkyl group having 1 to 4 carbon atoms in the chain Refers to...
[0034] The term "halo" refers to chloro, fluoro, bromo or iodo.
[0035] The term "haloalkyl" refers to an alkyl group in which one or more hydrogens are optionally replaced with halogen. This refers to a straight or branched chain alkyl group having 1 to 6 carbon atoms in the chain. As used herein, the term "C1-C4 haloalkyl" refers to an alkyl group that is optionally joined to one or more is a straight chain or refers to a branched chain alkyl group. An example of a "haloalkyl" group is trifluoromethyl (CF 3), difluoromethyl (CF2H), monofluoromethyl (CH2F), pentafluoro Fluoroethyl (CF2CF3), tetrafluoroethyl (CHFCF3), monofluoroethyl trifluoroethyl (CH2CF3), tetrafluorotrifluoromethyl (CH2CH2F), Fluoromethylethyl (CF(CF3)2), and the conventional techniques in the art and the present specification A group that would be considered equivalent to any one of the above examples in light of the teachings provided in Examples include:
[0036] The term "cycloalkyl" refers to a saturated or unsaturated alkyl group having 3 to 10 ring atoms per carbon ring. or partially saturated monocyclic, fused polycyclic, or spiropolycyclic carbocycles. Illustrative examples of the appropriately bonded moieties include cyclopropyl, cyclobutyl, cyclopentyl ... The following entities are in the form of butyl, cyclohexyl, cycloheptyl, and cyclooctyl: Examples include:
[0037] The term "substituted" means that the specified group or moiety has one or more substituents. The term "unsubstituted" means that the specified group has no substituents. The term "optionally substituted" means that the specified group is unsubstituted. "Substituted" means that the group is substituted with one or more substituents. When the term "contained" is used to describe a structural system, the substitutions are This means that the bond may occur at any position where valency is allowed.
[0038] Any formula given herein refers to a compound having the structure depicted by that structural formula. In addition to the product, the specific variations or configurations are also intended to be representative. Compounds of any formula may have asymmetric centers and may therefore be present in different enantiomers. Optical isomers and stereoisomers of compounds of the general formula and mixtures thereof are all considered to be within the scope of such formula. Compounds of the invention may contain one or more As such compounds may have asymmetric centers, they may be individually (R)- or (S)- - It may occur as stereoisomers or as a mixture of these. Any formula given in the specification may be used in any form, including racemic, enantiomeric, or non-racemic forms, unless expressly indicated otherwise. one or more of its diastereomeric forms, and It is intended to represent hydroxybenzoates and mixtures thereof.
[0039] In certain embodiments, (R * ) or (S * ) terms. * ) or (S * ) is used in the name or chemical description of a compound, the compound is It is intended to mean a single isomer at a stereocenter, but the isomer at that stereocenter is The pairwise configuration has not been established. Therefore, (R * ) is a compound represented by (R A compound that is a single isomer at its stereocenter, with either the (S) or (S) absolute configuration. (S * ) compounds have either (R) or ( S) refers to a compound that is a single isomer with absolute configuration of either When established, use (R) or (S) to name the structure. The use of the term "racemic" (R,S) or "racemic" indicates that the compound is racemic. show.
[0040] Reference to a compound described herein includes (a) the actual described form of such compound; and (b) the form of such compound in the medium in which such compound is believed to exist at the time of naming. For example, in this specification, Reference to a compound such as R-COOH is, for example, R-COOH (s) , R-COOH (sol) and R-COO - (sol) This example includes a reference to any one of the following: So, R-COOH (s) may be, for example, a tablet or some other solid pharmaceutical composition or refers to solid compounds that may be present in the preparation, and R-COOH (sol) is in the solvent R-COO refers to the undissociated form of the compound in - (sol) is the concentration of the compound in the solvent Dissociated forms, for example, whether such dissociated forms are derived from R—COOH or from salts thereof; When R-COO is considered to have undergone dissociation in the medium, - due to any other entity that produces "Dissociated form" refers to the dissociated form of a compound, whether in aqueous environment or not. In another example, a phrase such as "exposing the entity to a compound of formula R-COOH" may be used to describe how such exposure occurs. exposing such entity to the form(s) of the compound R-COOH present in the resulting medium; Yet another example is a statement such as "reacting the entity with a compound of formula R-COOH." The present invention includes (a) chemically relevant forms of such entities present in the medium in which such reactions occur; (b) the compound R—COOH present in the medium in which such a reaction occurs; In this context, the term "reacting with" refers to reacting with chemically related form(s) of If the body is, for example, present in an aqueous environment, the compound R-COOH will also be present in such same medium. Therefore, the entity is R-COOH (aq) and / or R-COO - (aq) (Subscript "(aq)" means "aqueous" according to its conventional meaning in chemistry and biochemistry In these nomenclature examples, the carboxylic acid functional group is selected. Although this selection is not intended to be limiting, it is merely illustrative. Hydroxyl, basic nitrogen members, such as nitrogen members in amines, and compounds containing and any other group that interacts or transforms in a known manner in a given medium. It is understood that other functional groups, including but not limited to, may also be provided. and transformations such as dissociation, association, tautomerization, solvolysis (including hydrolysis), solvation (water These include, but are not limited to, protonation, deprotonation, and cleavage. The specification does not provide further examples in this regard, because the These interactions and transformations are known to those skilled in the art.
[0041] Any formula given herein also includes isotopically labeled forms as well as unlabeled forms of the compounds. isotopically labeled compounds are compounds in which one or more atoms are enriched in , except that the atom is substituted with an atom having a selected atomic mass or mass number. The compounds of the present invention have a structure depicted by the formula given below: Examples of isotopes that can be incorporated into are: 2 H, 3 H, 11 C. 13 C. 14 C , 15 N, 18 O, and 17 These include isotopes of hydrogen, carbon, nitrogen, and oxygen, such as O Such isotope-labeled compounds are useful in metabolic studies (preferably 14 C), reaction rate test (e.g., deuterium (i.e., D or 2 H); or tritium (i.e., T Or 3 H), detection or imaging techniques [such as positron emission tomography (PET) or Single-photon emission computed tomography (SPECT) (drug or substrate tissue distribution analysis) In particular, they are useful in the treatment of cancer cells, including cancer therapy, or radiation therapy of patients. 18 F or 1 1 C-labeled compounds may be particularly suitable for PET or SPECT studies. Substitution with heavier isotopes, such as deuterium, results in greater metabolic stability, e.g. This may result in improved efficacy for certain therapeutics, such as longer in vivo half-lives or reduced dosage requirements. Isotopically labeled compounds of the present invention generally contain readily available isotopes. By using a labeling reagent instead of a non-isotopic labeling reagent, the following scheme can be implemented: Alternatively, it can be prepared by carrying out the procedures disclosed in the Examples and Preparations.
[0042] When the same substituents are assigned to various groups, the specific The assignment of specific individual substituents to the remaining groups is not construed as a specific individual substituent assignment. By way of example, and not by way of limitation, the Q and R groups If each can be H or F, the choice of H or F for Q is The choice of allocation for Q is not explicitly stated separately, since it is made independently of the choice. Insofar as this is the case, it does not determine or condition the choice of allocation to R, or vice versa. In this regard, the exemplary claim recitation reads, "Q and R are each independently H or F." or "each of Q and R is independently selected from the group consisting of H and F." It will be interpreted as follows.
[0043] "Tautomers" are interchangeable forms of a particular compound structure, where hydrogen and electron displacements Therefore, two structures with H elements in different positions are different in the valence law. For example, enols and ketones can be in equilibrium with either an acid or a base. They are tautomers because they are rapidly interconverted by treatment with at least When referring to any formula provided herein that includes one tautomer, it is understood that such given formula is meant to encompass all related tautomers unless expressly stated otherwise .
[0044] When referring to any formula given herein, the possible species for the specified variables are The selection of a particular part from the list of variables does not necessarily imply the same selection of that kind for variables appearing elsewhere. In other words, if a variable appears more than once, the specified Selection of species from the given list shall not affect the same variables elsewhere in the formula unless otherwise specified. It is independent of the species selection in terms of numbers.
[0045] As a first example of the term substituent, the substituent S 1 example However, S1 and S2 and the substituent S 2 example is one of S3 and S4 In this case, these allocations are 1 example is S1 and S 2 example but S3, S 1 example is S1 and S 2 example is S4, S 1 example is S2 and S 2 example is S3, S 1 exam ple is S2 and S 2 example The choice is S4, and The various alternatives refer to embodiments of the invention provided by their respective equivalents. Shorter "S 1 example is one of S1 and S2, and S 2 example is one of S3 and S4" or "S 1 example is S1 or S2, S 2 example The term "is S3 or S4" is used for brevity and not as a limitation. The above-mentioned terms for substituents described in general terms are used herein to refer to the same or similar groups. The first example is meant to illustrate the various substituent assignments described herein.
[0046] Furthermore, when more than one assignment is given for any member or substituent, the present invention The disclosed embodiments may be interpreted independently to encompass the listed assignments and their A second example of the term substituent is substituted. base S example is described herein as one of S1, S2, and S3. If so, this enumeration is example is S1;S example is S2 Ru;S example is S3;S example is one of S1 and S2 Ru;S example is one of S1 and S3; S example is S2 and One of S3;S example is one of S1, S2 and S3; and S example is any equivalent of each of these alternatives. It refers to the embodiment of the Ming. example is S1, S2, or S3 "It is one of the" or "S example is S1, S2, or S3" The term is used herein for brevity and not as a term of limitation. The second example above of substituent terminology is intended to provide a general understanding of the various substituent assignments described herein. This is intended to illustrate the above.
[0047] Nomenclature “C i -C j" (j>i) is used herein to refer to a class of substituents. If the number of carbon members is i to j, inclusive, then each and every one of them is independently realized. By way of example, the terms C1 to C3 are meant to refer to embodiments of the present invention that are independent of one another. Examples include embodiments having one carbon member (C1), embodiments having two carbon members (C2), and embodiments having one carbon member (C3). and embodiments having three carbon members (C3). For example, C i ~C j The term alkyl refers to any group in the chain, whether straight or branched. It refers to an aliphatic chain in which the total number of carbon members, N, satisfies i≦N≦j (where i>j).
[0048] A "pharmaceutically acceptable salt" is a salt that is non-toxic, biologically acceptable, or otherwise A salt of a compound that is biologically suitable for administration to a subject. ge, et al., “Pharmaceutical Salts”, J.Pharm .Sci.66,1-19(1977), Handbook of Pharmaceu tical Salts,Properties,Selection,and Use ,Stahl and Wermuth,Eds.,Wiley-VCH and VH. CA, Zurich, 2002, and GSPaulekuhn, et al., "P harmaceutical Ingredient Salt Selection based on analysis of the Orange Book dat abase," J. Med. Chem. 50, 6665-72 (2007) The compounds of the present invention may contain sufficiently acidic groups, sufficiently basic groups, or both types of functional groups. It can react with many inorganic or organic bases, as well as inorganic and organic acids, to produce pharmaceutical compounds. Examples of pharmaceutically acceptable salts include sulfates and pyrosulfates. , bisulfate, sulfite, bisulfite, phosphate, monohydrogen phosphate, dihydrogen phosphate, meta Phosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decane acid salt, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate , propiolate, oxalate, malonate, succinate, suberate, sebacic acid Salt, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, Benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates Benzoates, methoxybenzoates, phthalates, sulfonates, xylene sulfonates, phenanthate phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, γ-hydroxybenzoate Roxybutyrate, glycolate, tartrate, methanesulfonate, propanesulfonate Salts, naphthalene-1-sulfonate, naphthalene-2-sulfonate, and mandelate Examples include:
[0049] When the compounds of the present invention contain at least one basic nitrogen, the desired pharmaceutically acceptable The salts can be prepared by any suitable method available in the art. (e.g., inorganic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, and phosphoric acid), or organic acids (e.g., acetic acid, phenylacetic acid, propionic acid, stearic acid , lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionate, sucrose Acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, Oleic acid, palmitic acid, lauric acid, pyranosidic acid (e.g., glucuronic acid or galacturonic acid), alpha-hydroxy acids (e.g., mandelic acid, citric acid, or alcohol tartaric acid), amino acids (e.g., aspartic acid or glutamic acid), aromatic acids (e.g., benzoic acid), benzoic acid, 2-acetoxybenzoic acid, naphthoic acid, or cinnamic acid), sulfonic acids (e.g. For example, lauryl sulfonic acid, p-toluene sulfonic acid, methane sulfonic acid, ethane sulfonic acid ), any compatible mixture of acids such as those given as examples herein, as well as any suitable mixture of acids suitable for use in the art. Other products that are considered equivalents or acceptable substitutes in the light of ordinary skill in the art by treating the free base with any acid and mixtures thereof).
[0050] Embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof:
[0051] [ka] During the ceremony, R 1 is H or -CH3, R 2 is H or -CH3, R 3 is H, -C1-C5 alkyl, -OCH3, or -O-C1-C3 haloalkyl and R 4 is H or -CH3, portion
[0052] [ka] teeth,
[0053] [ka] and Raa is H or -CH3, R bb is H, -CH3, or -CF3, R 5 is -CH3, -CD3 or -CH2CF3, portion
[0054] [ka] teeth,
[0055] [ka] and E is N or CH; F is O, S, NH, or NCH3; R a is H or -CH3, R b H is D, -OH, F, -C1-C5 alkyl, -CH2OCH3, -C1-C5 haloalkyl, -NH, cyclopropyl, or -CHOH; R c is H, D, or CH3, R d is H, -CN, -CF3, -C1-C5 alkyl, -C3-C6 cycloalkyl , -O-C1-C3 alkyl, -N(R 6 )R 7 ,
[0056] [ka] and During the ceremony, R 6 is H or -C1-C3 alkyl, R 7 is H, -C1-C3 alkyl, -SO2CH3, -COCH3, -C1-C4 ha alkyl or CHCN, R 6 and R 7together with the carbons to which they are attached, portion
[0057] [ka] wherein m is 0 or 1 and p is 0 or 1; R 8 is H, F or C1-C3 alkyl, R 9 is H, F or -C1-C3 alkyl, R e is H, -CD3, Br, -C1-C5 alkyl 、 -C3-C6 cycloalkyl,
[0058] [ka] 1 to 3 R g is a —C1-C5 alkyl substituted with a group, wherein R g is -NH2 , or F, R 10 is H or F, R 11 is H or F, R f is H, -CH3, or
[0059] [ka] and R h is -CH3, -NH2 or
[0060] [ka] and R i are H, -CH3, -CN, Br,
[0061] [ka] and R j is -NH2 or
[0062] [ka] and R k is H, -CF3, I, Cl, Br, -CN, -C1-C6 alkyl,
[0063] [ka] and R 12 is H or -CH3, R 13 is H, -CH3, -CH2(C)(CH3)2OH, -(CH2)3CN, or is -(CH2)2NH2, R 14 is H or -CH3, R l is H, C1-C4 alkyl, -CF3,
[0064] [ka] and R m is H or CH3, R n is -NH2, R o is H or CH3, R p is H or CH3, R q is H, —CN, F, Cl, —OCH3, —CF3, or —CH3, R s is -NH2 or
[0065] [ka] and However, part
[0066] [ka] but
[0067] [ka] and R 1 , R 2 , R 3 and R 4 If is H, then the part
[0068] [ka] teeth
[0069] [ka] This is subject to the condition that:
[0070] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: and in the formula portion
[0071] [ka] teeth
[0072] [ka] and portion
[0073] [ka] teeth,
[0074] [ka] However, the part
[0075] [ka] but
[0076] [ka] and R 1 , R 2 , R 3 and R 4 If is H, then the part
[0077] [ka] teeth
[0078] [ka] This is subject to the condition that:
[0079] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: and in the formula portion
[0080] [ka] teeth
[0081] [ka] and portion
[0082] [ka] teeth
[0083] [ka] is.
[0084] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0085] [ka] teeth
[0086] [ka] and portion
[0087] [ka] teeth
[0088] [ka] is.
[0089] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: and in the formula portion
[0090] [ka] teeth
[0091] [ka] and portion
[0092] [ka] teeth
[0093] [ka] is.
[0094] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where R 1 is H and R 2 is H and R 3 is H and R 4 is H the law of nature, portion
[0095] [ka] teeth
[0096] [ka] and portion
[0097] [ka] teeth
[0098] [ka] is.
[0099] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where R 1 is H and R 2 is H and R 3 is H or C1-C5 alkyl R 4 is H, portion
[0100] [ka] teeth
[0101] [ka] and portion
[0102] [ka] teeth
[0103] [ka] is.
[0104] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: and in the formula R 1 is H and R 2 is H and R 3 is H or C1-C5 alkyl, and R 4 is H, portion
[0105] [ka] teeth
[0106] [ka] and portion
[0107] [ka] teeth
[0108] [ka] is.
[0109] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: and in the formula R 1 is H and R 2 is H and R3 is H and R 4 is H, portion
[0110] [ka] teeth
[0111] [ka] and portion
[0112] [ka] teeth
[0113] [ka] is.
[0114] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: and in the formula R 1 is H and R 2 is H and R 3 is H and R 4 is H, portion
[0115] [ka] teeth
[0116] [ka] and R cc is -CH3, portion
[0117] [ka] teeth
[0118] [ka] and R b is -CH3.
[0119] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: and in the formula R 1 is H and R 2 is H and R 3 is H and R 4 is H, portion
[0120] [ka] teeth
[0121] [ka] and R cc is -CD3, portion
[0122] [ka] teeth
[0123] [ka] and R b is -CH3.
[0124] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0125] [ka] teeth
[0126] [ka] is.
[0127] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0128] [ka] teeth,
[0129] [ka] is.
[0130] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0131] [ka] teeth,
[0132] [ka] is.
[0133] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0134] [ka] teeth
[0135] [ka] is.
[0136] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0137] [ka] teeth
[0138] [ka] is.
[0139] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0140] [ka] teeth
[0141] [ka] is.
[0142] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0143] [ka] teeth
[0144] [ka] is.
[0145] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0146] [ka] teeth
[0147] [ka] is.
[0148] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0149] [ka] teeth
[0150] [ka] is.
[0151] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0152] [ka] teeth
[0153] [ka] is.
[0154] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0155] [ka] teeth
[0156] [ka] is.
[0157] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0158] [ka] teeth
[0159] [ka] is.
[0160] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0161] [ka] teeth
[0162] [ka] is.
[0163] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0164] [ka] teeth
[0165] [ka] is.
[0166] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0167] [ka] teeth
[0168] [ka] is.
[0169] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0170] [ka] teeth
[0171] [ka] is.
[0172] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: and in the formula portion
[0173] [ka] teeth
[0174] [ka] is.
[0175] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0176] [ka] teeth
[0177] [ka] An additional exemplary embodiment of the present invention is a compound of formula (I) and its pharmaceutically acceptable salts thereof. wherein the moiety
[0178] [ka] teeth
[0179] [ka] is.
[0180] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: and in the formula portion
[0181] [ka] teeth
[0182] [ka] is.
[0183] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: and in the formula portion
[0184] [ka] teeth
[0185] [ka] is.
[0186] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: and in the formula portion
[0187] [ka] teeth
[0188] [ka] is.
[0189] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: and in the formula portion
[0190] [ka] teeth
[0191] [ka] is.
[0192] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0193] [ka] teeth
[0194] [ka] is.
[0195] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0196] [ka] teeth
[0197] [ka] is.
[0198] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0199] [ka] teeth
[0200] [ka] is.
[0201] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0202] [ka] teeth
[0203] [ka] is.
[0204] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0205] [ka] teeth
[0206] [ka] is.
[0207] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0208] [ka] teeth
[0209] [ka] is.
[0210] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0211] [ka] teeth
[0212] [ka] is.
[0213] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0214] [ka] teeth
[0215] [ka] is.
[0216] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0217] [ka] teeth
[0218] [ka] is.
[0219] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0220] [ka] teeth
[0221] [ka] is.
[0222] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0223] [ka] teeth
[0224] [ka] and the part
[0225] [ka] teeth
[0226] [ka] is.
[0227] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0228] [ka] teeth
[0229] [ka] and the part
[0230] [ka] teeth
[0231] [ka] is.
[0232] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0233] [ka] teeth
[0234] [ka] and the part
[0235] [ka] teeth
[0236] [ka] is.
[0237] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0238] [ka] teeth
[0239] [ka] and the part
[0240] [ka] teeth
[0241] [ka] is.
[0242] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0243] [ka] teeth
[0244] [ka] and the part
[0245] [ka] teeth
[0246] [ka] is.
[0247] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0248] [ka] teeth
[0249] [ka] and the part
[0250] [ka] teeth
[0251] [ka] is.
[0252] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0253] [ka] teeth
[0254] [ka] and the part
[0255] [ka] teeth
[0256] [ka] is.
[0257] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0258] [ka] teeth
[0259] [ka] and the part
[0260] [ka] teeth
[0261] [ka] is.
[0262] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0263] [ka] teeth
[0264] [ka] and the part
[0265] [ka] teeth
[0266] [ka] is.
[0267] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0268] [ka] teeth
[0269] [ka] and the part
[0270] [ka] teeth
[0271] [ka] is.
[0272] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0273] [ka] teeth
[0274] [ka] and the part
[0275] [ka] teeth
[0276] [ka] and R 3 is H.
[0277] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0278] [ka] teeth
[0279] [ka] and the part
[0280] [ka] teeth
[0281] [ka] and R 3 is H and R e is H.
[0282] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0283] [ka] teeth
[0284] [ka] and the part
[0285] [ka] teeth
[0286] [ka] and R 3 is H and Re is H and R d is N(R 6 )R 7 is.
[0287] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0288] [ka] teeth
[0289] [ka] and the part
[0290] [ka] teeth
[0291] [ka] and R 3 is H and R e is H and R d is N(R 6 )R 7 and R b is CH It is 3.
[0292] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0293] [ka] teeth
[0294] [ka] and the part
[0295] [ka] teeth
[0296] [ka] and R 3 is H and R a is H and R e is H and R d is N(R 6 )R 7 in Yes, R b is CH3 and R 6 is H or C1-C3 alkyl, and R 7 is H or C1 -C3 alkyl.
[0297] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0298] [ka] teeth
[0299] [ka] and the part
[0300] [ka] teeth
[0301] [ka] and R 3 is H and R a is H and R e is H and R d is N(R 6 )R 7 in Yes, Rb is CH3 and R 6 is C1-C3 alkyl, and R 7 is C1-C3 alkyl It is.
[0302] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0303] [ka] teeth
[0304] [ka] and the part
[0305] [ka] teeth
[0306] [ka] and R 3 is H and R a is H and R e is H and R d is N(R 6 )R 7 in Yes, R b is CH3 and R 6 is H and R 7 is H.
[0307] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0308] [ka] teeth
[0309] [ka] and the part
[0310] [ka] teeth
[0311] [ka] and R 3 is H and R a is H and R e is H and R d is N(R 6 )R 7 in Yes, R b is CH3 and R 6 and R 7 together with the nitrogen to which they are attached portion
[0312] [ka] where m is 0 or 1 and p is 0 or 1.
[0313] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0314] [ka] teeth
[0315] [ka] and the part
[0316] [ka] teeth
[0317] [ka] and R 3 is H and R a is H and R e is H and R d is N(R 6 )R 7 in Yes, R b is CH3 and R 6 and R 7 together with the nitrogen to which they are attached portion
[0318] [ka] wherein m is 0 and p is 0.
[0319] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0320] [ka] teeth
[0321] [ka] and the part
[0322] [ka] teeth
[0323] [ka] and R 3 is H and R a is H and R e is H and R d is N(R 6 )R 7 in Yes, R b is CH3 and R 6 and R 7 together with the nitrogen to which they are attached portion
[0324] [ka] where m is 1 and p is 0.
[0325] Additional exemplary embodiments of the present invention include compounds of formula (I) and pharmaceutically acceptable salts thereof: where
[0326] [ka] teeth
[0327] [ka] and the part
[0328] [ka] teeth
[0329] [ka] and R 3 is H and R a is H and R e is H and R d is N(R 6 )R 7 in Yes, R b is CH3 and R 6 and R 7 together with the nitrogen to which they are attached portion
[0330] [ka] where m is 1 and p is 1.
[0331] An exemplary embodiment of the compound of formula (I) is the compound (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) -4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl] )phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-6-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopteridin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-aminoquinazolin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] Phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl -2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne- 2-all, (R)-3-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-(((8-amino-3,4-dihydro-2,7-naphthyridine-2(1H )-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(3-amino-1-methyl-pyrazolo[4,3-b]pyridin phenyl)ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-3-[2-[3-(3-amino-1H-pyrazolo[4,3-b]pyridine-5 -yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-ethoxypyrido[3,2-d]pyrimidin-6-yl)phenyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin) (phenyl-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-hydroxy-1-methyl-3-((3-(4-(methylamino)pyrido[ 3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one, (S)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl yl]-2-thiazol-2-yl-but-3-yn-2-ol, 1-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl ]ethynyl]cyclopentanol, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl -2-(5-methylisoxazol-3-yl)but-3-yn-2-ol, 4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2 -methyl-but-3-yn-2-ol, (R)-3-[2-[3-(1-amino-7-isoquinolyl)phenyl]ethynyl]- 3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d ]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((5-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-5 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (R)-2-[3-[2-(7-hydroxy-5,6-dihydrocyclopenta[[b] Pyridin-7-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidine- 8-on, (R)-4-(3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2- yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-4-(3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d] (pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yne-2 -Oar, (R)-4-(3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2- yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-4-(3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2- yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] -5-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridine- 7-all, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -isobutylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidone) (3H)-pyridin-3-yl)ethynyl)phenyl)pyrido[3,4-d]pyrimidine-4(3H)- on, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-((3-(8-amino-4-morpholinopyrido[3,4-d]pyrimidine -2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-3-((3-(8-amino-4-(dimethylamino)pyrido[3,4-d] ... 2-(phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-[2-[3-(4-amino-1H-imidazo[4,5-c]pyridine-2 -yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-7-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d ]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopentene ta[b]pyridin-7-ol, (R)-7-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-7-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] Phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin phenyl-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidine- 2-on, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidine- 2-on, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -thiazol-2-yl-but-3-yn-2-ol, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- (methylphenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one , (S)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one , (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidone lysin-2-one, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidone lysin-2-one, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- Methylphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)buta -3-in-2-all, (R)-7-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 (Methylphenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin phenyl-2-yl)-5-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidine- 2-on, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -(5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- Methylphenyl)-2-(5-methylisoxazol-3-yl)but-3-yne-2 -Oar, (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d3)pyrrolidine-2 -on, (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imida zoll-7-ol, (R)-3-((3-(8-amino-4-(methylamino)pyrido[3,4-d]pyridyl) (2-(2-(4 ... -on, (R)-7-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin (2-phenyl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazo ol-7-ol, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin phenyl)ethynyl]-3-hydroxy-1-(trideuteriomethyl) ) pyrrolidin-2-one, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -(5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -thiazol-2-yl-but-3-yn-2-ol, (R)-7-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl ]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol, (R)-3-[2-[3-(8-amino-4-methyl-pyrido[3,4-d]pyrimidin 3-hydroxy-1-(2,2,2-trifluorophenyl)ethynyl (triethyl)pyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(8-amino-5-bromopyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-3-[2-[3-(4-aminophthalazin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) -2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne- 2-all, (R)-3-((3-(8-amino-4-isopropylpyrido[3,4-d]pyrimidin (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-[2-[3-[8-amino-5-(trifluoromethyl)pyrido[3,4 -d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidone) (3-(ethynyl)phenyl)pyrido[3,4-d]pyrimidine-5-carbonyl Trill, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)phenyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-iodopyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methyl isoxazol-3-yl)but-3-yn-2-ol, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-thiazole -2-yl-but-3-yn-2-ol, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methyl (1,3,4-oxadiazol-2-yl)but-3-yn-2-ol, 2-(3-((1H-pyrazol-5-yl)ethynyl)phenyl)-4-methylpyrazole do[3,4-d]pyrimidin-8-amine, (R)-4-(3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl) (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-methylquinazolin-6-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrido[3,4-d]pyrimidin-6-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-5-bromo-1,7-naphthyridin-2-yl] phenyl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-8-fluoro-quinazolin-6-yl)phenyl]phenyl] ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-8-methoxyquinazolin-6-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(trifluoromethyl)quinazoline-6-yl) (phenyl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminothiazolo[4,5-c]pyridin-2-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-chloroquinazolin-6-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-8-amino-2-[3-[2-(3-hydroxy-1-methyl-2-oxo- Pyrrolidin-3-yl)ethynyl]phenyl]-1,7-naphthyridine-5-carbonite Lil, (R)-3-[2-[3-(5-amino-2,6-naphthyridin-3-yl)phenyl] ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-5-methyl-1,7-naphthyridin-2-yl] phenyl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-5-phenylpyrido[3,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(1-methylpyrazol-4-yl)pyrazole Lido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1 -methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-[1-(2-hydroxy-2-methyl- Propyl)pyrazol-4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl yl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(1H-pyrazol-4-yl)pyrido [3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl thyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(3,5-dimethyl-1H-pyrazole -4-yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3- hydroxy-1-methyl-pyrrolidin-2-one, (R)-4-amino-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidone) (din-3-yl)ethynyl)phenyl)quinazoline-8-carbonitrile, (R)-3-[2-[3-[8-amino-5-(5-methyl-1H-pyrazole-4- yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydro oxy-1-methyl-pyrrolidin-2-one, (R)-phenyl 8-amino-2-[3-[2-(3-hydroxy-1-methyl-2 -Oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidin benzophenone-5-carboxylate, (R)-3-((3-(8-amino-5-ethylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-isobutylpyrido[3,4-d]pyrimidine -2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone, (S)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone, (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)pyridin [3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl thyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-[1-(2-aminoethyl)pyrazole -4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3- hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)pyrido[3, 4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-8-methyl-pyrido[3,4-d]pyrimidinyl] phenyl)ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-4-(3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl) (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(8-amino-4,5-dimethylpyrido[3,4-d]pyrimidin (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[4-[8-amino-2-[3-[2-(3-hydroxy-1-methyl- 2-Oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidin di-n-5-yl]pyrazol-1-yl]butanenitrile, (R)-3-((3-(4-aminothieno[2,3-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminooxazolo[5,4-d]pyrimidin-2-yl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(6-amino-9-methyl-9H-purin-8-yl)phenyl )ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl) (phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol Lu, (R)-3-[2-[3-[8-amino-5-(1-piperidylmethyl)pyrido[3, 4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-7-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl )phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Rule, (R)-3-[2-[3-[8-amino-5-[6-(trifluoromethyl)-3-pi Lysyl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-2-methyl-pteridin-6-yl)phenyl] yl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d)-4-Methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-((3-(8-amino-5-neopentylpyrido[3,4-d]pyrimidin (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((5-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 5-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl) (phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol Lu, (R)-3-((3-(8-amino-4,6-dimethylpyrimido[5,4-d]pyrimido) (2-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (2-methylthiazol-5-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (2-methylthiazol-5-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidin (6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d)-4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-5-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-5-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, Racemic-8-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-5,6,7,8-tetrahydroquinolin-8-ol, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methylthiazol-2-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methylthiazol-2-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl-6-(d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, (R)-tert-butyl 3-amino-5-[3-[2-(3-hydroxy-1-methyl) ethyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]indazole-1-carboxylate carboxylate, (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pi (Irimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)-1, 7-Naphthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)-1,7-na Phthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-((3-(4-amino-2-(hydroxymethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-[2-[3-(3-amino-1H-indazol-5-yl)phenyl] ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-2-cyclopropylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-2-(trifluoromethyl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)- 4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-3-((3-(4-amino-2,7-dimethylpyrido[3,2-d]pyrimidin (phenyl-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-2H-pyrazolo[3,4-d]pyrimidine-2- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-2-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol Lu, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-2-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-3-[2-[3-(7-amino-5-methyl-thiazolo[5,4-d]pyrimidinyl] ethynyl)-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-Methyl-phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imida zoll-7-ol, (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-Methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridine -7-all, 1-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4- methyl-phenyl]ethynyl]cyclopentanol, (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-7-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-(trifluoromethyl)thiazol-2-yl)buta-3 -in-2-all, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-(trifluoromethyl)thiazol-2-yl)buta-3 -in-2-all, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , 1-Allyl-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one, Racemic-1-allyl-3-((3-(4-aminopyrido[3,2-d]pyrimidine-6 -yl-2-d)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol, Racemic-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- 1H-imidazol-4-yl)phenyl)-2-(1H-imidazol-4-yl)but-3-yn-2-ol , (R)-3-((3-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl )phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)- (ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-(methoxymethyl)pyrido[3,2-d]pi (Irimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) ethynyl)-3-methoxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pi (Irimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d3)pi roridin-2-one, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol, (R)-3-((3-(4-amino-2-ethylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-hydroxypyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)buta -3-in-2-all, (R)-3-((3-(7-aminothiazolo[4,5-d]pyrimidin-2-yl)phenyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-methyl-7,8-dihydropyrido[4,3- d]pyrimidin-6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl) 1-pyrrolidin-2-one, (R)-4-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4 -methyl-phenyl]-2-(5-methylisoxazol-3-yl)but-3-yne -2-all, (R)-6-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-imidazo[1,5-a]pyrazin-8-one, (R)-3-((3-(8-amino-1,5-naphthyridin-2-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidin (6(5H)-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) phenyl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4(3H)-one, (R)-3-hydroxy-1-methyl-3-((3-(4-(pyrrolidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-ol hmm, ((R)-3-hydroxy-1-methyl-3-((3-(pyrido[3,2-d]pyrimidinyl) (phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-amino-5,7,8,9-tetrahydro-6H-pyrimido) [5,4-c]azepin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-(piperidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-ol hmm, (R)-3-((3-(4-(3,3-dimethylazetidin-1-yl)pyrido[3, 2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrimidin roridin-2-one, (R)-3-((3-(4-(ethylamino)pyrido[3,2-d]pyrimidine-6- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-hydroxy-3-((3-(4-(3-hydroxyazetidin-1-yl) )pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrro lysin-2-one, (R)-3-Hydroxy-1-methyl-3-((3-(4-oxetan-3-yl) amino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidine- 2-on, (R)-3-hydroxy-3-((3-(4-(3-methoxyazetidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolyl Jin-2-On, (S)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin) (phenyl-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-(3,3-difluoroazetidin-1-yl)pyrido[3 ,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-((3-(8-(azetidin-1-yl)-1,7-naphthyridine-2- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(1-(azetidin-1-yl)isoquinolin-7-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(azetidin-1-yl)quinolin-6-yl)phenyl )ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(cyclobutylamino)pyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1- methylpyrrolidin-2-one, (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)acetate Mido, (R)-3-((3-(4-(3-fluoroazetidin-1-yl)pyrido[3,2- d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-2-((6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine -3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)amino ) acetonitrile, (R)-3-((3-(4-((2,2-difluoroethyl)amino)pyrido[3,2 -d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrro lysin-2-one, (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)azetidin benzo-3-carbonitrile, (R)-3-((3-(4-(azetidin-1-yl)quinazolin-6-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(3-chloroazetidin-1-yl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-hydroxy-1-methyl-3-((3-(4-(3-(methylsulfonyl )Azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethy (nyl)pyrrolidin-2-one, (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)-N-methyl thiazetidine-3-carboxamide, (R)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidin) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (S)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidin) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(5-bromo-8-methyl-1,7-naphthyridin-2-yl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4,8-dimethylpyrido[3,2-d]pyrimidin-6-yl )phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) (phenyl)ethynyl)phenyl)-8-methyl-1,7-naphthyridine-5-carbonitrile, (R)-3-((3-(5,8-dimethyl-1,7-naphthyridin-2-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy- 1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy- 1-methylpyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-phenylpyrido[3,2- d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl acetamide, (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d) acetamide, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (3R,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3R,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3S,S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl -2-d) phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2- on, (3S,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3R,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3S,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3S,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3R,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d) methanesulfonamide, (R)-3-((3-(4-cyclopropylpyrido[3,2-d]pyrimidin-6-yl) (phenyl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-Hydroxy-3-((3-(4-isopropylpyrido[[3,2-d] ... rimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidin-2-one, (1R,4R,5S)-4-((3-(4-amino-2-methylpyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (1S,4S,5R)-4-((3-(4-amino-2-methylpyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (1S,4S,5R)-4-((3-(4-aminopyrido[3,2-d]pyrimidine- 6-yl-2-(d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[4.2.1.2] chloro[3.1.0]hexan-3-one, (1R,4R,5S)-4-((3-(4-aminopyrido[3,2-d]pyrimidine- 6-yl-2-(d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[4.2.1.2] chloro[3.1.0]hexan-3-one, (R)-3-((3-(4-amino-8-cyclopentylpyrido[3,2-d]pyrimidin 2-(2-phenyl)ethynyl-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-hydroxy-1-methyl-3-((3-(4-(trifluoromethyl)pyrrolidone) Lido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one , (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) phenyl)ethynyl)phenyl)pyrido[3,2-d]pyrimidine-4-carbonitrile, (R)-3-hydroxy-1-methyl-3-((3-(8-methyl-1,7-naphthyl) (phenyl)ethynyl)pyrrolidin-2-one, (1R,4R,5S)-4-((3-(4-amino-8-methylpyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (R)-3-((3-(4-amino-8-(aminomethyl)pyrido[3,2-d]pyridyl) Myridine-6-yl-2-(d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-((3-(4-amino-8-isopropylpyrido[3,2-d]pyrimidin 2-(phenyl)ethynyl-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-((3-(4-amino-8-(trifluoromethyl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(4-amino-2,8-dimethylpyrido[3,2-d]pyrimidin (phenyl-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-8-(methyl-d3)pyrido[3,2-d]pyridyl) (6-amino-3-hydroxy-1-methylpyrrolidine-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, (R)-3-((3-(4-amino-8-(piperidin-4-yl)pyrido[3,2- d]pyrimidin-6-yl-2-(d)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-((3-(4-amino-2-fluoropyrido[3,2-d]pyrimidine- 6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (S)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (3R,4S * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3R, 4R * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3S,4S * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3S, 4R *)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (R)-3-[2-[3-[4-amino-8-(dimethylamino)pyrido[3,2-d ]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin Jin-2-On, (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d] Pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-[2-[3-[4-amino-8-(isopropylamino)pyrido[3,2 -d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-[4-amino-8-(cyclopropylamino)pyrido[3, 2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(difluoromethoxy)pyrido[3,2 -d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-[4-amino-8-(3,3-difluoroazetidine-1- yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydro oxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-4-methyl-pyrimido[5,4-d]pyrimido] ethynyl)-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-((3-(4-amino-8-cyclopropylpyrido[3,2-d]pyrimidinyl) (6-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-[2-[3-(4-amino-8-pyrazol-1-yl-pyrido[3,2 -d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-[4-amino-8-(cyclopropoxy)pyrido[3,2- d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyro lysin-2-one, (R)-3-[2-[3-[4-amino-8-[1-(difluoromethyl)pyrazole -4-yl]oxy-pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl ]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(3,3,3-trifluoropropoxy )pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy -1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(2,2-difluoro-5-azaspiro [2.3]Hexan-5-yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-8-ethylpyrido[3,2-d]pyrimidine-6 -yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-8-cyclobutylpyrido[3,2-d]pyrimidin (phenyl-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-8-phenylpyrido[3,2-d]pyrimidine- 6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(thiophen-2-yl)pyrido[3,2- d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-((3-(4-amino-8-(furan-2-yl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (3R)-3-((3-(4-amino-8-(azetidin-2-yl)pyrido[3,2 -d]pyrimidin-6-yl-2-(d)phenyl)ethynyl)-3-hydroxy-1-methyl thylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-vinylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-[3-(trifluoromethyl)azetidin phenyl]pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3 -hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(azetidin-1-yl)pyrido[3, 2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-((3-(4-amino-8-((2,2,2-trifluoroethyl)amino)amino Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy thio-1-methylpyrrolidin-2-one, (1R,4R,5S)-4-((3-(7-aminothiazolo[5,4-d]pyrimidine -2-yl)-4-methylphenyl)ethynyl)-4-hydroxy-2-methyl-2- Zabicyclo[3.1.0]hexan-3-one, (3R,5R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidine-2- (yl)-4-methylphenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine ion-2-one, and These are pharmaceutically acceptable salts.
[0332] An exemplary embodiment of the compound of formula (I) is the compound (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) -4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl] )phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-6-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopteridin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-aminoquinazolin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] Phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl -2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne- 2-all, (R)-3-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-(((8-amino-3,4-dihydro-2,7-naphthyridine-2(1H )-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(3-amino-1-methyl-pyrazolo[4,3-b]pyridin phenyl)ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-3-[2-[3-(3-amino-1H-pyrazolo[4,3-b]pyridine-5 -yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-ethoxypyrido[3,2-d]pyrimidin-6-yl)phenyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin) (phenyl-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-hydroxy-1-methyl-3-((3-(4-(methylamino)pyrido[ 3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one, (S)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl yl]-2-thiazol-2-yl-but-3-yn-2-ol, 1-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl ]ethynyl]cyclopentanol, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl -2-(5-methylisoxazol-3-yl)but-3-yn-2-ol, 4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2 -methyl-but-3-yn-2-ol, (R)-3-[2-[3-(1-amino-7-isoquinolyl)phenyl]ethynyl]- 3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d ]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((5-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-5 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (R)-2-[3-[2-(7-hydroxy-5,6-dihydrocyclopenta[[b] Pyridin-7-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidine- 8-on, (R)-4-(3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2- yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-4-(3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d] (pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yne-2 -Oar, (R)-4-(3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2- yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-4-(3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2- yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] -5-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridine- 7-all, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -isobutylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidone) (3H)-pyridin-3-yl)ethynyl)phenyl)pyrido[3,4-d]pyrimidine-4(3H)- on, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-((3-(8-amino-4-morpholinopyrido[3,4-d]pyrimidine -2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-3-((3-(8-amino-4-(dimethylamino)pyrido[3,4-d] ... 2-(phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-[2-[3-(4-amino-1H-imidazo[4,5-c]pyridine-2 -yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-7-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d ]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopentene ta[b]pyridin-7-ol, (R)-7-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-7-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] Phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin phenyl-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidine- 2-on, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidine- 2-on, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -thiazol-2-yl-but-3-yn-2-ol, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- (methylphenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one , (S)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one , (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidone lysin-2-one, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidone lysin-2-one, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- Methylphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)buta -3-in-2-all, (R)-7-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 (Methylphenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin phenyl-2-yl)-5-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidine- 2-on, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -(5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- Methylphenyl)-2-(5-methylisoxazol-3-yl)but-3-yne-2 -Oar, (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d3)pyrrolidine-2 -on, (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imida zoll-7-ol, (R)-3-((3-(8-amino-4-(methylamino)pyrido[3,4-d]pyridyl) (2-(2-(4 ... -on, (R)-7-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin (2-phenyl)phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazo ol-7-ol, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidin phenyl)ethynyl]-3-hydroxy-1-(trideuteriomethyl) ) pyrrolidin-2-one, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -(5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -thiazol-2-yl-but-3-yn-2-ol, (R)-7-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl ]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol, (R)-3-[2-[3-(8-amino-4-methyl-pyrido[3,4-d]pyrimidin 3-hydroxy-1-(2,2,2-trifluorophenyl)ethynyl (triethyl)pyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(8-amino-5-bromopyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-3-[2-[3-(4-aminophthalazin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) -2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne- 2-all, (R)-3-((3-(8-amino-4-isopropylpyrido[3,4-d]pyrimidin (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-[2-[3-[8-amino-5-(trifluoromethyl)pyrido[3,4 -d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidone) (3-(ethynyl)phenyl)pyrido[3,4-d]pyrimidine-5-carbonyl Trill, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)phenyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-iodopyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methyl isoxazol-3-yl)but-3-yn-2-ol, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-thiazole -2-yl-but-3-yn-2-ol, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methyl (1,3,4-oxadiazol-2-yl)but-3-yn-2-ol, 2-(3-((1H-pyrazol-5-yl)ethynyl)phenyl)-4-methylpyrazole do[3,4-d]pyrimidin-8-amine, (R)-4-(3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl) (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-methylquinazolin-6-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrido[3,4-d]pyrimidin-6-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-5-bromo-1,7-naphthyridin-2-yl] phenyl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-8-fluoro-quinazolin-6-yl)phenyl]phenyl] ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-8-methoxyquinazolin-6-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(trifluoromethyl)quinazoline-6-yl) (phenyl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminothiazolo[4,5-c]pyridin-2-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-chloroquinazolin-6-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-8-amino-2-[3-[2-(3-hydroxy-1-methyl-2-oxo- Pyrrolidin-3-yl)ethynyl]phenyl]-1,7-naphthyridine-5-carbonite Lil, (R)-3-[2-[3-(5-amino-2,6-naphthyridin-3-yl)phenyl] ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-5-methyl-1,7-naphthyridin-2-yl] phenyl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-5-phenylpyrido[3,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(1-methylpyrazol-4-yl)pyrazole Lido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1 -methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-[1-(2-hydroxy-2-methyl- Propyl)pyrazol-4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl yl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(1H-pyrazol-4-yl)pyrido [3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl thyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(3,5-dimethyl-1H-pyrazole -4-yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3- hydroxy-1-methyl-pyrrolidin-2-one, (R)-4-amino-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidone) (din-3-yl)ethynyl)phenyl)quinazoline-8-carbonitrile, (R)-3-[2-[3-[8-amino-5-(5-methyl-1H-pyrazole-4- yl)pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydro oxy-1-methyl-pyrrolidin-2-one, (R)-phenyl 8-amino-2-[3-[2-(3-hydroxy-1-methyl-2 -Oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidin benzophenone-5-carboxylate, (R)-3-((3-(8-amino-5-ethylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-isobutylpyrido[3,4-d]pyrimidine -2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone, (S)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone, (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)pyridin [3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl thyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-[1-(2-aminoethyl)pyrazole -4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3- hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)pyrido[3, 4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-8-methyl-pyrido[3,4-d]pyrimidinyl] phenyl)ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-4-(3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl) (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(8-amino-4,5-dimethylpyrido[3,4-d]pyrimidin (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[4-[8-amino-2-[3-[2-(3-hydroxy-1-methyl- 2-Oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidin di-n-5-yl]pyrazol-1-yl]butanenitrile, (R)-3-((3-(4-aminothieno[2,3-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminooxazolo[5,4-d]pyrimidin-2-yl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(6-amino-9-methyl-9H-purin-8-yl)phenyl )ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl) (phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol Lu, (R)-3-[2-[3-[8-amino-5-(1-piperidylmethyl)pyrido[3, 4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-7-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl )phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Rule, (R)-3-[2-[3-[8-amino-5-[6-(trifluoromethyl)-3-pi Lysyl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-2-methyl-pteridin-6-yl)phenyl] yl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d)-4-Methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-((3-(8-amino-5-neopentylpyrido[3,4-d]pyrimidin (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((5-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 5-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl) (phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol Lu, (R)-3-((3-(8-amino-4,6-dimethylpyrimido[5,4-d]pyrimido) (2-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (2-methylthiazol-5-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (2-methylthiazol-5-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidin (6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d)-4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-5-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-5-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, Racemic-8-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-5,6,7,8-tetrahydroquinolin-8-ol, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methylthiazol-2-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methylthiazol-2-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl-6-(d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, (R)-tert-butyl 3-amino-5-[3-[2-(3-hydroxy-1-methyl) ethyl-2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]indazole-1-carboxylate carboxylate, (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pi (Irimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)-1, 7-Naphthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)-1,7-na Phthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-((3-(4-amino-2-(hydroxymethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-[2-[3-(3-amino-1H-indazol-5-yl)phenyl] ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-2-cyclopropylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-2-(trifluoromethyl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)- 4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-3-((3-(4-amino-2,7-dimethylpyrido[3,2-d]pyrimidin (phenyl-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-2H-pyrazolo[3,4-d]pyrimidine-2- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-2-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol Lu, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-2-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-3-[2-[3-(7-amino-5-methyl-thiazolo[5,4-d]pyrimidinyl] ethynyl)-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-Methyl-phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imida zoll-7-ol, (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-Methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridine -7-all, 1-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4- methyl-phenyl]ethynyl]cyclopentanol, (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-7-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-(trifluoromethyl)thiazol-2-yl)buta-3 -in-2-all, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-(trifluoromethyl)thiazol-2-yl)buta-3 -in-2-all, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , 1-Allyl-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one, Racemic-1-allyl-3-((3-(4-aminopyrido[3,2-d]pyrimidine-6 -yl-2-d)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol, Racemic-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- 1H-imidazol-4-yl)phenyl)-2-(1H-imidazol-4-yl)but-3-yn-2-ol , (R)-3-((3-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl )phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl)- (ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-(methoxymethyl)pyrido[3,2-d]pi (Irimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) ethynyl)-3-methoxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pi (Irimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d3)pi roridin-2-one, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol, (R)-3-((3-(4-amino-2-ethylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-hydroxypyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methyl-1,3,4-oxadiazol-2-yl)phenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)buta -3-in-2-all, (R)-3-((3-(7-aminothiazolo[4,5-d]pyrimidin-2-yl)phenyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-methyl-7,8-dihydropyrido[4,3- d]pyrimidin-6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl) 1-pyrrolidin-2-one, (R)-4-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4 -methyl-phenyl]-2-(5-methylisoxazol-3-yl)but-3-yne -2-all, (R)-6-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-imidazo[1,5-a]pyrazin-8-one, (R)-3-((3-(8-amino-1,5-naphthyridin-2-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidin (6(5H)-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) phenyl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4(3H)-one, (R)-3-hydroxy-1-methyl-3-((3-(4-(pyrrolidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-ol hmm, ((R)-3-hydroxy-1-methyl-3-((3-(pyrido[3,2-d]pyrimidinyl) (phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-amino-5,7,8,9-tetrahydro-6H-pyrimido) [5,4-c]azepin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-(piperidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-ol hmm, (R)-3-((3-(4-(3,3-dimethylazetidin-1-yl)pyrido[3, 2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrimidin roridin-2-one, (R)-3-((3-(4-(ethylamino)pyrido[3,2-d]pyrimidine-6- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-hydroxy-3-((3-(4-(3-hydroxyazetidin-1-yl) )pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrro lysin-2-one, (R)-3-Hydroxy-1-methyl-3-((3-(4-oxetan-3-yl) amino)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidine- 2-on, (R)-3-hydroxy-3-((3-(4-(3-methoxyazetidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolyl Jin-2-On, (S)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin) (phenyl-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-(3,3-difluoroazetidin-1-yl)pyrido[3 ,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-((3-(8-(azetidin-1-yl)-1,7-naphthyridine-2- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(1-(azetidin-1-yl)isoquinolin-7-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(azetidin-1-yl)quinolin-6-yl)phenyl )ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(cyclobutylamino)pyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one , (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1- methylpyrrolidin-2-one, (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)acetate Mido, (R)-3-((3-(4-(3-fluoroazetidin-1-yl)pyrido[3,2- d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-2-((6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine -3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)amino ) acetonitrile, (R)-3-((3-(4-((2,2-difluoroethyl)amino)pyrido[3,2 -d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrro lysin-2-one, (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)azetidin benzo-3-carbonitrile, (R)-3-((3-(4-(azetidin-1-yl)quinazolin-6-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(3-chloroazetidin-1-yl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-hydroxy-1-methyl-3-((3-(4-(3-(methylsulfonyl )Azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethy (nyl)pyrrolidin-2-one, (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)-N-methyl thiazetidine-3-carboxamide, (R)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidin) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (S)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidin) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(5-bromo-8-methyl-1,7-naphthyridin-2-yl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4,8-dimethylpyrido[3,2-d]pyrimidin-6-yl )phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) (phenyl)ethynyl)phenyl)-8-methyl-1,7-naphthyridine-5-carbonitrile, (R)-3-((3-(5,8-dimethyl-1,7-naphthyridin-2-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy- 1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy- 1-methylpyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-phenylpyrido[3,2- d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl acetamide, (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d) acetamide, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (3R,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3R,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3S,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3S,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3R,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3S,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3S,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3R,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (R)-N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d) methanesulfonamide, (R)-3-((3-(4-cyclopropylpyrido[3,2-d]pyrimidin-6-yl) (phenyl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-Hydroxy-3-((3-(4-isopropylpyrido[[3,2-d] ... rimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidin-2-one, (1R,4R,5S)-4-((3-(4-amino-2-methylpyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (1S,4S,5R)-4-((3-(4-amino-2-methylpyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (1S,4S,5R)-4-((3-(4-aminopyrido[3,2-d]pyrimidine- 6-yl-2-(d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[4.2.1.2] chloro[3.1.0]hexan-3-one, (1R,4R,5S)-4-((3-(4-aminopyrido[3,2-d]pyrimidine- 6-yl-2-(d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[4.2.1.2] chloro[3.1.0]hexan-3-one, (R)-3-((3-(4-amino-8-cyclopentylpyrido[3,2-d]pyrimidin 2-(2-phenyl)ethynyl-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-hydroxy-1-methyl-3-((3-(4-(trifluoromethyl)pyrrolidone) Lido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one , (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) phenyl)ethynyl)phenyl)pyrido[3,2-d]pyrimidine-4-carbonitrile, (R)-3-hydroxy-1-methyl-3-((3-(8-methyl-1,7-naphthyl) (phenyl)ethynyl)pyrrolidin-2-one, (1R,4R,5S)-4-((3-(4-amino-8-methylpyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (R)-3-((3-(4-amino-8-(aminomethyl)pyrido[3,2-d]pyridyl) Myridine-6-yl-2-(d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-((3-(4-amino-8-isopropylpyrido[3,2-d]pyrimidin 2-(phenyl)ethynyl-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-((3-(4-amino-8-(trifluoromethyl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(4-amino-2,8-dimethylpyrido[3,2-d]pyrimidin (phenyl-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-8-(methyl-d3)pyrido[3,2-d]pyridyl) (6-amino-3-hydroxy-1-methylpyrrolidine-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, (R)-3-((3-(4-amino-8-(piperidin-4-yl)pyrido[3,2- d]pyrimidin-6-yl-2-(d)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-((3-(4-amino-2-fluoropyrido[3,2-d]pyrimidine- 6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (S)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (3R,4S * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3R, 4R* )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3S,4S * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3S, 4R * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (R)-3-[2-[3-[4-amino-8-(dimethylamino)pyrido[3,2-d ]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin Jin-2-On, (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d] Pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-[2-[3-[4-amino-8-(isopropylamino)pyrido[3,2 -d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-[4-amino-8-(cyclopropylamino)pyrido[3, 2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(difluoromethoxy)pyrido[3,2 -d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-[4-amino-8-(3,3-difluoroazetidine-1- yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydro oxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-4-methyl-pyrimido[5,4-d]pyrimido] ethynyl)-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-((3-(4-amino-8-cyclopropylpyrido[3,2-d]pyrimidinyl) (6-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-[2-[3-(4-amino-8-pyrazol-1-yl-pyrido[3,2 -d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl- roridin-2-one, (R)-3-[2-[3-[4-amino-8-(cyclopropoxy)pyrido[3,2- d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyro lysin-2-one, (R)-3-[2-[3-[4-amino-8-[1-(difluoromethyl)pyrazole -4-yl]oxy-pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl ]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(3,3,3-trifluoropropoxy )pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy -1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(2,2-difluoro-5-azaspiro [2.3]Hexan-5-yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-8-ethylpyrido[3,2-d]pyrimidine-6 -yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-8-cyclobutylpyrido[3,2-d]pyrimidin (phenyl-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-8-phenylpyrido[3,2-d]pyrimidine- 6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(thiophen-2-yl)pyrido[3,2- d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-((3-(4-amino-8-(furan-2-yl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (3R)-3-((3-(4-amino-8-(azetidin-2-yl)pyrido[3,2 -d]pyrimidin-6-yl-2-(d)phenyl)ethynyl)-3-hydroxy-1-methyl thylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-vinylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-[3-(trifluoromethyl)azetidin phenyl]pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3 -hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(azetidin-1-yl)pyrido[3, 2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, and These are pharmaceutically acceptable salts.
[0333] An exemplary embodiment of the compound of formula (I) is the compound (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) -4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl] )phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-6-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopteridin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-aminoquinazolin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] Phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl -2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne- 2-all, (R)-3-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-(((8-amino-3,4-dihydro-2,7-naphthyridine-2(1H )-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(3-amino-1-methyl-pyrazolo[4,3-b]pyridin phenyl)ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-3-[2-[3-(3-amino-1H-pyrazolo[4,3-b]pyridine-5 -yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-ethoxypyrido[3,2-d]pyrimidin-6-yl)phenyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin) (phenyl-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-hydroxy-1-methyl-3-((3-(4-(methylamino)pyrido[ 3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, and These are pharmaceutically acceptable salts.
[0334] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] Phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-(((8-amino-3,4-dihydro-2,7-naphthyridine-2(1H )-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, and These are pharmaceutically acceptable salts.
[0335] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, and These are pharmaceutically acceptable salts.
[0336] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and These are pharmaceutically acceptable salts.
[0337] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] Phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and These are pharmaceutically acceptable salts.
[0338] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, and These are pharmaceutically acceptable salts.
[0339] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] Phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, and These are pharmaceutically acceptable salts.
[0340] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and Beauty These are pharmaceutically acceptable salts.
[0341] An additional exemplary embodiment of the compound of Formula (I) is the compound (S)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and These are pharmaceutically acceptable salts.
[0342] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and These are pharmaceutically acceptable salts.
[0343] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and Beauty These are pharmaceutically acceptable salts.
[0344] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and These are pharmaceutically acceptable salts.
[0345] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and Beauty These are pharmaceutically acceptable salts.
[0346] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-((3-(8-amino-3,4-dihydro-2,7-naphthyridine-2( 1H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol N, and These are pharmaceutically acceptable salts.
[0347] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, and These are pharmaceutically acceptable salts.
[0348] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, and These are pharmaceutically acceptable salts.
[0349] An additional exemplary embodiment of the compound of Formula (I) is the compound (3R,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl] )phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-5-ethylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d] Pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-((3-(8-amino-5-ethylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-ethylpyrido[3,2-d]pyrimidine-6 -yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-cyclopentylpyrido[3,2-d]pyrimidin 2-(2-phenyl)ethynyl-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminoquinazolin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-8-cyclopropylpyrido[3,2-d]pyrimidinyl) (6-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidin (6(5H)-yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-((3-(4-amino-8-(methyl-d3)pyrido[3,2-d]pyridyl) (6-amino-3-hydroxy-1-methylpyrrolidine-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, and These are pharmaceutically acceptable salts.
[0350] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d] Pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-8-(methyl-d3)pyrido[3,2-d]pyridyl) (6-amino-3-hydroxy-1-methylpyrrolidine-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, and These are pharmaceutically acceptable salts.
[0351] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d] Pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimid[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and pharmaceutically acceptable salts thereof.
[0352] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d] Pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine ion-2-one, and These are pharmaceutically acceptable salts.
[0353] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and Beauty and pharmaceutically acceptable salts thereof.
[0354] An additional exemplary embodiment of the compound of Formula (I) is the compound (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and and pharmaceutically acceptable salts thereof. An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and Beauty and pharmaceutically acceptable salts thereof.
[0355] An additional exemplary embodiment of the compound of Formula (I) is the compound (R)-3-((3-(4-amino-8-(methyl-d3)pyrido[3,2-d]pyridyl) (6-amino-3-hydroxy-1-methylpyrrolidine-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, and These are pharmaceutically acceptable salts.
[0356] Additional exemplary embodiments of the present invention are directed to treating diseases, disorders, or conditions mediated by NIK activity. or a method of treating a subject suffering from or diagnosed with a medical condition, and administering to a subject in need of such treatment an effective amount of at least one of the compounds described above. Includes:
[0357] Additional exemplary embodiments of the present invention are directed to treating diseases, disorders, or conditions mediated by NIK activity. 1. A method of treating a subject suffering from or diagnosed with a medical condition, comprising: A subject in need of such treatment is administered an effective amount of at least one of the compounds described above. wherein the disease, disorder, or condition is cancer, an inflammatory disorder, an autoimmune disorder, an immunosuppressant, and / or a metabolic disorder.
[0358] Additional exemplary embodiments of the present invention are directed to treating diseases, disorders, or conditions mediated by NIK activity. or a method of treating a subject suffering from or diagnosed with a medical condition, and administering to a subject in need of such treatment an effective amount of at least one of the compounds described above. wherein the disease, disorder or medical condition is selected from the group consisting of SLE, RA, GvHD, transplant rejection, Sjögren's syndrome, pemphigus vulgaris, palmoplantar pustulosis, hidradenitis suppurativa, obesity, and diabetes At least one of the following is true.
[0359] A further embodiment of the present invention is a compound comprising an effective amount of the above compound or a pharmaceutically acceptable salt thereof. and a pharmaceutical composition comprising at least one of the following.
[0360] The compounds of the present invention, including pharmaceutically acceptable salts thereof, may be used alone or in combination. Useful as NIK inhibitors in the methods of the invention (collectively "active agent(s)") Such methods of modulating NIK activity include administering NIK to an effective amount of at least one compound of the present invention. This involves exposing the material to an activator.
[0361] In some embodiments, the NIK inhibitor is a NIK inhibitor, as described herein. diagnosed with or suffering from a disease, disorder, or medical condition mediated through the activity of Symptoms or symptoms fall under the category of "diseases, disorders, or medical conditions." It is intended to be encompassed within.
[0362] Thus, the present invention relates to a disease, disorder, or medical condition mediated through NIK. To treat patients diagnosed with or suffering from the As used herein, "treating" or "treatment" refers to a method of treating a disease or condition that involves the use of an active agent selected from the group consisting of: The term "antibody" refers to a compound of the present invention intended to affect a therapeutic or prophylactic benefit through modulation of NIK. The term "treatment" is intended to mean administering to a patient an active agent or composition of the present invention. A disease, disorder, or condition mediated through modulation of IK activity, or a disease, disorder, or condition mediated through modulation of IK activity To reverse, improve, or alleviate one or more symptoms of a disease or condition and inhibiting the progression, reducing the severity, or preventing the disease. The term "inhibitor" refers to a mammalian patient, e.g., a human, in need of such treatment. The term "inhibitory" or "inhibitory" refers to a compound that reduces, prevents, or inactivates NIK expression or activity. By "anti-inflammatory" is meant a compound that blunts, dampens, or down-regulates an expression of an inflammatory protein.
[0363] When referring to target inhibition, an "effective amount" is an amount sufficient to inhibit the activity of NIK. It means a reasonable amount.
[0364] In the methods of treatment according to the present invention, a patient suffering from such a disease, disorder, or medical condition a subject having or diagnosed as having the disease, and administering an effective amount of at least one An "effective amount" is an amount of an active agent administered to a patient in an amount effective to treat a specified disease, disorder, or medical condition. generally produce the desired therapeutic or prophylactic effect in patients in need of such treatment For a 70 kg human, an exemplary range of suitable doses is is about 1 to 1000 mg / day in a single or multiple dose unit.
[0365] Once improvement of the patient's disease, disorder, or condition has occurred, for preventative or maintenance treatment: The dosage may be adjusted, e.g., the dosage or frequency of administration, or both, depending on the symptoms. The number may be reduced to a level at which the desired therapeutic or prophylactic effect is maintained. However, once symptoms have been alleviated to an adequate level, treatment may be discontinued. However, patients may require intermittent treatment on a long-term basis if symptoms recur.
[0366] The pharmaceutical compositions of the present invention comprise an effective amount of at least one active agent according to the present invention.
[0367] Pharmaceutically acceptable excipients commonly used in pharmaceutical compositions are added to pharmacological compositions. or otherwise used as a vehicle, carrier, or diluent to facilitate administration of a drug. facile, drug compatible, non-toxic, biologically acceptable, and otherwise Such excipients are biologically suitable for administration to a subject, e.g., inert substances. Examples include calcium carbonate, calcium phosphate, various sugars and various types of starch. , cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
[0368] The delivery form of a pharmaceutical composition containing one or more dosage units of an active agent is pharmaceutically Using acceptable excipients and compounding techniques known or available to those skilled in the art, The composition can be prepared in accordance with the method of the present invention by a suitable delivery route, e.g. For example, it may be administered orally, parenterally, rectally, topically, or ocularly, or by inhalation. That's fine.
[0369] The preparations may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, reconstituted tablets, or the like. The composition may be in the form of a powder, a liquid preparation, or a suppository. any one of these, for example, formulated for intravenous injection, subcutaneous injection, topical administration, or oral administration It is possible.
[0370] For oral administration, the active agents of the present invention are administered in the form of tablets, capsules, or beads, or The oral composition of the present invention can be provided as a solution, emulsion, or suspension. To prepare the composition, the active agent may be administered in an amount of, for example, 100 mg / kg of water for a 70 kg human, as an exemplary range. , and formulated to provide a daily dose of approximately 1 to 1000 mg in single or multiple dose units. It is possible.
[0371] Oral tablets may contain the active ingredient(s) and may be administered in a compatible pharmaceutically acceptable form. acceptable excipients, such as diluents, disintegrants, binders, lubricants, sweeteners, flavoring agents, coloring agents, and They may be mixed with preservatives, etc. Suitable inert fillers include sodium carbonate and calcium carbonate. calcium, sodium and calcium phosphate, lactose, starch, sugar, glucose cellulose, methylcellulose, magnesium stearate, mannitol, sorbitol, etc. Illustrative examples of oral liquid excipients include ethanol, glycerol, Water, starch, polyvinylpyrrolidone (PVP), sodium glycolate Examples of disintegrating agents include cellulose, cellulose acetate, and alginic acid. Examples of lubricants include starch and gelatin. The lubricant, if present, may be stearic acid. The tablets may be monohydrated or talc. Coating with substances such as glyceryl stearate or glyceryl distearate, May be coated with an enteric coating to delay absorption in the digestive tract Additional coatings that can be used include chemical coatings that react as a function of time, pH, or bacterial content. These may include a compound or a coating designed to release the active agent.
[0372] Oral capsules are available in hard and soft gelatin or (hydroxypropyl ) methylcellulose capsules. In the preparation of hard gelatin capsules, The ingredient(s) may be mixed with a solid, semi-solid, or liquid diluent. The capsules contain the active ingredient in oils such as peanut oil or olive oil, liquid paraffin, and short-chain fats. Mixture of mono- and diglycerides of acids, polyethylene glycol 400, or propylene Oral liquids can be prepared as suspensions, solutions, or by mixing with glycols. It may be in the form of a liquid concentrate, emulsion, or syrup, or may be mixed with water or other suitable liquid before use. It may be lyophilized or presented as a dry product for reconstitution with a vehicle. Such liquid compositions may optionally contain pharmaceutically acceptable excipients, such as suspending agents (e.g., For example, sorbitol, methylcellulose, sodium alginate, gelatin, hydroxyethyl cellulose, ethyl cellulose, carboxymethyl cellulose, aluminum stearate gel, etc.); Non-aqueous vehicles, such as oils (e.g., almond oil or fractionated coconut oil), propylene glycol Coal, ethyl alcohol, or water; preservatives (e.g., methyl p-hydroxybenzoate or or propyl p-hydroxybenzoate, or sorbic acid); a humectant such as lecithin; and If desired, flavoring or coloring agents may be included.
[0373] The active agents of the present invention may also be administered parenterally. For example, It may be formulated as a suppository, enema, or foam for rectal administration. For parenteral use, including subcutaneous administration, the agents of the present invention are administered in a suitable solution at suitable pH and isotonicity. as sterile aqueous solutions or suspensions, buffered as described above, or as parenterally acceptable solutions. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride solution. Such forms may be in a single unit such as an ampoule or a disposable injection device. single-dose forms, multiple-dose forms such as vials from which the appropriate dose can be taken; or presented in a solid or pre-concentrated form that can be used to prepare an injectable formulation. Specific infusion dosages range from minutes to several days, with the drug in admixture with the pharmaceutical carrier. The amount infused is in the range of approximately 1 to 1000 μg / kg / min over a period of time.
[0374] For topical administration, the agent may be mixed with a pharmaceutical carrier. In some embodiments, a patch formulation may be utilized for transdermal delivery.
[0375] Alternatively, the methods of the present invention may be administered via the nasal or oral route, for example in a spray formulation (including suitable carriers The active agent may also be administered by inhalation, such as in a liquid formulation containing a steroid.
[0376] Embodiments of the present invention are directed to preventing and / or controlling excessive inflammatory responses. An inhibitor is provided.
[0377] Exemplary compounds useful in the methods of the present invention are described in detail below. The methods are described below by reference to synthetic schemes ("Schemes") and specific examples. do.
[0378] [ka]
[0379] By way of example, but not limitation, compounds of formula (I) can be prepared according to Schemes 1-2. The various compounds herein are prepared according to the following general preparative procedures. The reaction scheme is carried out with or without appropriate protection of the final desired substituents to give It will be appreciated that starting materials can be suitably selected so that they can be retained through to give the desired product. Those skilled in the art will understand that, alternatively, instead of the ultimately desired substituent, It is also possible to use an appropriate group substituted with a desired substituent as needed through the above procedure. Unless otherwise indicated, variables are as defined in Schemes 1-2 with reference to Formula (I).
[0380] [ka]
[0381] As shown in Scheme 1, the cross-coupling reaction of compound II with compound III provides the compound of formula (I). Pd(PPh3)2Cl2 or (PdCl2[P(c y)3]2) the addition of compound II to compound III using a suitable palladium catalyst, such as A base such as diisopropylethylamine, TEA, or a mixture thereof, THF, 1,4 CuI in a solvent such as dioxane, acetonitrile, DMF or a mixture thereof Copper catalyst. Heat using microwave or conventional heating at a temperature of about 40°C to 100°C for about 2 to 4 hours. The compound of formula (I) is provided for a period of time.
[0382] [ka]
[0383] Compounds of formula (I) can also be prepared by alternative cross-coupling reactions using compounds IV and V. The substituent Y in compound V is chloro, bromo, iodo, or -S In these reactions, compounds IV and V are reacted with palladium(II) bis( Triphenylphosphine) dichloride (Pd(PPh3)2Cl2), XPhos-Pd -G2 Precatalyst (chloro(2-dicyclohexylphosphino-2',4',6'-triyl) isopropyl-1,1'-biphenyl) [2-(2'-amino-1,1'-biphenyl)] Palladium(II)), [1,1'-bis(diphenylphosphino)ferrocene]dichloro Palladium(II) (PdCl2(dppf)), PdP(Ph3)4, PdCl2( dtbpf)2 or mesylate [(di(1-adamantyl)-n-butylphosphine)- 2-(2'-amino-1,1'-biphenyl)]palladium(II), [(di(1-ad Mantyl)-butylphosphine)-2-(2'-amino-1,1'-biphenyl)]para Suitable palladium catalysts such as palladium(II) methanesulfonate, Cs2CO3, K3P A base such as O4, NaHCO3, Na2CO3, K2CO3 or a mixture thereof, and H2 O, 1,4-dioxane, ethanol, toluene, 1,2-dimethoxyethane or any of these in a solvent such as a mixture of The mixture is combined using microwave or conventional heating.
[0384] If a protecting group is present in the compound of formula (IV) or formula (V), it may be removed using conditions known to those skilled in the art. A final deprotection step is then added to give the compound of formula (I). When a benzyl group is used to protect the anilino group, DDQ or ammonium nitrate are preferred. Which reagent can be used and removed in a solvent such as DCM, water, or a mixture thereof? When the protecting group is phenylsulfonamide, LiOH, NaOH, KOH, etc. The base is combined with water and / or MeOH in a suitable solvent such as THF, 1,4-dioxane, etc. It can be used in any suitable solvent.
[0385] The following specific examples are provided to further illustrate embodiments within the scope of the present invention.
[0386] The compounds described in the following examples and the corresponding analytical data were obtained using the methods described below, unless otherwise indicated. The following experimental and analytical protocols were followed.
[0387] Unless otherwise stated herein, reaction solutions were 2(g) or Ar (g) Under the atmosphere The solution was "concentrated to dryness" by rotary evaporation under reduced pressure. When the solution is concentrated and dried using a porator, it is usually dried using MgSO4 or Na2SO4 Normal phase flash column chromatography (FCC) was performed using a different Unless otherwise indicated, the eluents were ethyl acetate (EtOAc) / hexane, CH2Cl2 / RediSep (registered trademark) was used to elucidate the 2N NH3 in MeOH or CH2Cl2 / MeOH. The assay was performed on prepackaged silica gel such as (Registered Trademark).
[0388] Thin layer chromatography was performed using Merck silica gel 60 F 254 , 2.5cm x 7. 5cm 250μm coated or 5.0cm x 10.0cm 250μm coated Preparative thin-layer chromatography was performed using pre-coated silica gel plates. M Science Silica Gel 60 F 254 20cm x 20cm 0.5mm cord The assay was performed using a coated plate with a concentration zone of 20 cm x 4 cm. Microwave reactions are performed at specific temperatures using CEM Discover®, a Bio Tagage Initiator™ or Optimizer™ microwave, etc. Mass spectrometry was performed in a microwave reactor using an Agilent system unless otherwise indicated. A Leeds 1100MSD was used with electrospray ionization (ESI) in positive mode. The calculated mass corresponds to the exact mass. The NMR spectrum was obtained from Bruckheimer's r Model DPX400 (400MHz), DPX500 (500MHz), DRX600 (600MHz) spectrometer. 1 H NMR The data format is a low-field chemical shift using tetramethylsilane as the reference material. (ppm) (multiplicity, coupling constant J (Hz), integral value).
[0389] The trifluoroacetate salt was obtained by purification of the crude reaction product by preparative reverse-phase HPLC. The resulting final product was isolated as either the mono-, di-, or trifluoroacetate salt. It was.
[0390] The trifluoroacetate or hydrochloride salt of the compound of formula (I) may be prepared by saturating either such salt. Partition between the sodium bicarbonate phase and a suitable organic solvent such as ethyl acetate or dichloromethane After partitioning, the organic layer is separated and the aqueous layer is The combined organic extracts are then extracted twice with a suitable organic solvent. Some of the examples provided below were prepared using trifluoromethyl ... The free base is prepared by completing the corresponding instructions with the preparation of the corresponding salt, such as the acetate or hydrochloride salt. The free base of such examples can be prepared by one of ordinary skill in the art following the distribution and drying process described above. It is understood that this can be obtained by known methods.
[0391] Whenever a yield is given as a percentage, such yield is the percentage of the product obtained under the specified stoichiometric conditions. The yield refers to the mass of the entity for which a yield is given, relative to the maximum amount of the same entity that can be obtained by Reagent concentrations given as percentages refer to mass ratios unless otherwise specified. The yields given in the following examples, whether or not they are based on the results of a given experiment, are not necessarily accurate. The amount is calculated with respect to the dry form of the compound obtained.
[0392] Compound names were calculated using ChemDraw Ultra 17.1 (CambridgeSoft Corp., Cambridge, MA) or OEMetaChem V1.4.0. 4 (Open Eye).
[0393] Abbreviations and acronyms used herein are as follows:
[0394] [Table 1-1]
[0395] [Table 1-2]
[0396] Intermediate 1: 2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-8-amine .
[0397] [ka]
[0398] Step A: 3-amino-2-chloroisonicotinic acid. In a 5 L round bottom flask, add methyl 3-amino-2-chloroisonicotinate (240 g, 1. 29 mmol), MeOH (1.44 L), and water (0.48 L) were added. To the solution, NaOH (139 g, 3.47 mmol) in water (1.20 L) was added, and the mixture was The mixture was stirred at 25-30°C. After 2 hours, the mixture was diluted with water (0.72 L) and concentrated hydrochloric acid (29 The resulting mixture was stirred for 30 minutes. The solid was isolated by filtration. The resulting mixture was separated, washed with water (240 mL × 2), and vacuum dried at 50-55 °C to give 3-amino-2- Chloroisonicotinic acid (224 g, 100%) was obtained as an off-white solid. MS( ESI): Calculated mass of C7H7ClN2O2, 186.0; m / z, found, 187.0 [M+H]+. 1 H NMR(400MHz,DMSO-d6)δ 13.66(br s,1H),7.62(d,J=4.0Hz,1H),7.59(d,J=4.0Hz, 1H),6.84(br s,2H).
[0399] Step B: 3-amino-2-chloroisonicotinamide. In a 3 L round-bottom flask equipped with a 1000 cc HCl solution, add 3-amino-2-chloroisonicotinic acid (210 g, 1.2 mL) 2 mol), acetonitrile (2.10 L), and carbonyldiimidazole (236 g The resulting mixture was stirred at 20-30°C for 1 hour, and then cooled. The mixture was poured into 20% by weight aqueous ammonia (2.56 L). The resulting mixture was stirred for 30 minutes. After that, the solid was separated by filtration, washed with water (0.42 L x 2), and dried in vacuum at 50-55°C. After drying, 3-amino-2-chloroisonicotinamide (142 g, 68.1%) was obtained as a white solid. MS (ESI): mass calculated for C6H6ClN3O, 171.0; m / z Actual value: 172.0 [M+H] + .1 H NMR (400 MHz, DMSO-d6) δ 8.18(br s,1H),7.67(br s,1H),7.61(d,J=4.0 Hz,1H),7.50(d,J=4.0Hz,1H),6.76(br s,2H).
[0400] Step C: 4-(aminomethyl)-2-chloropyridin-3-amine hydrochloride. In a 2 L round bottom flask equipped with a 1000 volt stirrer, add 3-amino-2-chloroisonicotinic acid amide (24.3 g, 142 mmol) and THF (100 mL) were added. The flask was pressurized with nitrogen. The mixture was purged with HCl and heated to 40-45°C. While maintaining the internal temperature at 40-45°C, A THF solution (1.00 L, 1 M) was added dropwise over 1 hour. The resulting mixture was stirred for 1 hour. The mixture was stirred for 1 hour, and then quenched with MeOH (95.3 g, 2.98 mol). The reaction was cooled and 30 wt % HCl solution in EtOH (31.3 g, 284 mmol) was added. The suspension was filtered and the resulting solid was washed with THF (48 mL × 2). After washing, it was dried in vacuum at 50-55°C to obtain 4-(aminomethyl)-2-chloropyridine- The 3-amine hydrochloride (26.5 g, 81%) was obtained as a yellow solid and was carried on to the next synthetic step. Used as is.
[0401] Step D: 8-Chloro-2-(3-iodophenyl)pyrido[3,4-d]pyrimidin In a 250 mL round-bottom flask, add 3-iodobenzaldehyde (18.1 g, 115 m mol), PhI(OAc)2 (62.9g, 195mmol), DCM (150mL) , and 4-(aminomethyl)-2-chloropyridin-3-amine hydrochloride (15.0 g, 6 5 mmol) was added at 25° C. After 2 hours, the resulting mixture was concentrated to dryness, and the residue was Purify with 8-chloro-2-(3-iodophenyl)pyrido[3,4-d]pyrimidine (9.0 g, 38%). MS(ESI): C 13 Calculated mass of H7ClIN3, 3 66.9; m / z observed, 367.9 [M+H] + .
[0402] Step E: 2-(3-iodophenyl)pyrido[3,4-d]pyrimidin-8-amine In a 2L high-pressure reactor, 8-chloro-2-(3-iodophenyl)pyrido[3,4-d] Pyrimidine (43.0 g, 0.12 mol) and NH3 solution (645 mL, 2 M in IPA) The reactor was sealed and heated at 125-130°C for 16 hours. Cool, concentrate to 100 mL, dilute with water (430 mL), and stir at 20-25°C for 2 hours. The product was isolated by filtration, dried and purified to give 2-(3-iodophenyl)pyrido[3 ,4-d]pyrimidin-8-amine (35 g, 84%) was obtained as a pale solid. MS (E SI):C 13 Calculated mass of H9BrN4, 348.0; observed m / z, 349.0 [M +H] + .
[0403] Intermediate 2: (R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one .
[0404] [ka]
[0405] Step A: tert-Butyl 3-(methylamino)propanoate. In a 2 L round-bottom flask equipped with a stirrer, add methylamine (500 mL, 3.48 mol, E After adding EtOH (30% by weight) and EtOH (500 mL), the mixture was stirred at 20-25°C for 3 h. Then, tert-butyl acrylate (100 g, 0.78 mol) was added dropwise. The mixture was stirred at room temperature for 3 hours, then concentrated to dryness to give tert-butyl 3-(methylamino) The propanoate (124 g) was obtained as a colorless oil. MS (ESI): CH 17 N Calculated mass of O2: 159.1; observed m / z: 160.2 [M+H] + . 1 H NMR (400MHz, CDCl3)δ 2.79(t,J=6.5Hz,2H),2.43( s, 3H), 2.41 (t, J=6.5Hz, 2H), 1.44 (s, 9H).
[0406] Step B: tert-Butyl 4-hydroxy-1-methyl-5-oxo-2,5- Dihydro-1H-pyrrole-3-carboxylate. tert-Butyl 3-(methylamino)propanoate was added to a glass-lined reactor (L). diethyl oxalate (900g, 5.65mol), diethyl oxalate (827g, 5.65mol) and and THF (18 L) were added. The resulting mixture was warmed to 50-55°C and then t-BuOK( After stirring for 1 hour, the mixture was cooled to 20°C. Cool, concentrate to dryness, add water (5.00 L) to form a suspension, and add aqueous hydrochloric acid. The H was adjusted to 1-2°C, and the resulting mixture was stirred at 20-25°C for 1 hour, then filtered and dried. tert-butyl 4-hydroxy-1-methyl-5-oxo-2,5-dihydro- 1H-Pyrrole-3-carboxylate (940 g, 78%) was obtained as an off-white solid. I got it. 1 H NMR(300MHz,CDCl3)δ 8.99(s,1H),3.9 4(s,2H),3.10(s,3H),1.56(s,9H).
[0407] Step C: 4-Hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyridin In a 5 L round-bottom flask equipped with an overhead stirrer, add tert -Butyl 4-hydroxy-1-methyl-5-oxo-2,5-dihydro-1H-pyrrole -3-carboxylate (500 g, 2.34 mol) and TFA (2.00 L) were added. The resulting mixture was stirred at 20-25°C for 3 hours and then concentrated to dryness. Nitrile (1.50 L) was added and stirred at 20-25°C for 1 hour. The product was separated by filtration. It is isolated, dried and 4-hydroxy-1-methyl-5-oxo-2,5-dihydro-1H -pyrrole-3-carboxylic acid (357 g, 97%) was obtained as an off-white solid. 1 H NMR(300MHz,CD3OD)δ 4.04-3.98(m,2H),3.0 8(s,3H).
[0408] Step D: 1-Methylpyrrolidine-2,3-dione. In a 20 L round bottom flask, add 4-hydroxy-1-methyl-5-oxo-2,5-dihydro -1H-pyrrole-3-carboxylic acid (1000 g, 6.360 mol) and THF (15 L) was added. The resulting mixture was heated to 65°C. After 4 hours, the mixture was concentrated to dryness. , to give 1-methylpyrrolidine-2,3-dione (712 g, 99%) as a yellow solid . 1 H NMR(400MHz,CDCl3)δ 3.70(t,J=5.7Hz,2H ),3.13(s,3H),2.72(t,J=5.7Hz,2H).
[0409] Step E: (rac)-3-ethynyl-3-hydroxy-1-methylpyrrolidine-2 -on. In a 10 L round bottom flask equipped with an overhead stirrer, add ethynylmagnesium Bromide (3.50 L, 0.5 M in THF) was added. The flask was purged with nitrogen. After cooling to 10°C, 1-methylpyrrolidine-2,3-dione (120g, 1.06mo l) was added over 20 min. The resulting mixture was warmed to 20-25°C and stirred for 16 h. The mixture was stirred for 1 hour. The mixture was quenched with NH4Cl (120 g in 360 mL H2O), followed by DC After slurried for 1 hour, the suspension was filtered and the filtrate was diluted with anhydrous N The mixture was dried over 500 g of sodium hydroxide and treated with activated carbon (24 g). The residue was dissolved in MTBE (360 mL) for 20 minutes. The slurry was left at -25°C for 1 hour. The product was isolated by filtration and drying, and (rac)-3 -Ethynyl-3-hydroxy-1-methylpyrrolidin-2-one (81g, 55%) in yellow Obtained as a colored solid. MS (ESI): mass calculated for C7H9NO2, 139.1; m / z Measured value: 140.1 [M+H] + . 1 H NMR (300 MHz, CD3OD) δ 3. 40(dd,J=7.7,5.3Hz,2H),3.03(s,1H),2.88(s, 3H),2.52-2.41(m,1H),2.21(dt,J=12.7,7.7Hz ,1H).
[0410] Step F: (R)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one (S)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one. (r ac) enantiomer of -3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one The mers were separated by chiral preparative SFC (CHIRALPAK AS-H 5 μm, 5 × 25 cm, transfer The separation was performed using a mobile phase of 80% CO2, 20% IPA (0.1% DEA). UV at λ = 220-254 nM revealed (R)-3-ethynyl-3-hydroxy-1- Methylpyrrolidin-2-one (40%) and (S)-3-ethynyl-3-hydroxy-1 (R)-3-ethynyl-3-methylpyrrolidin-2-one (Intermediate 3, 40%) was obtained. -Hydroxy-1-methylpyrrolidin-2-one data: MS(ESI): C7H9N Calculated mass of O2: 139.1; observed m / z: 140.1 [M+H] + . 1 H NMR (300MHz,CD3OD)δ 3.40(dd,J=7.7,5.3Hz,2H), 3.03(s,1H),2.88(s,3H),2.52-2.41(m,1H),2. 21(dt,J=12.7,7.7Hz,1H). [α] 20 D =-100.1(MeO c=1.01).
[0411] Intermediate 3: (S)-3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one .
[0412] [ka]
[0413] Chiral separation as described in Step F of Intermediate 2 affords (S)-3-ethynyl-3-hydroxybenzoate. The obtained product was 40% methylpyrrolidin-2-one (1-methylpyrrolidin-2-one). MS (ESI): C7H9 Calculated mass of NO2, 139.1; observed m / z, 140.1 [M+H] + . 1 HNM R(300MHz,CD3OD)δ 3.40(dd,J=7.7,5.3Hz,2H) ,3.03(s,1H),2.88(s,3H),2.52-2.41(m,1H),2 .21(dt,J=12.7,7.7Hz,1H). [α] 20 D =+90.5(MeO c=1.19).
[0414] Intermediate 4: (R)-3-hydroxy-1-methyl-3-((3-(4,4,5,5-tetramethyl- tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethynyl)pyrrolidine On-2-on.
[0415] [ka]
[0416] 2-(3-Bromophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxa Borolane (9.22 g, 32.6 mmol), (R)-3-ethynyl-3-hydroxy- 1-Methylpyrrolidin-2-one (5.00 g, 35.9 mmol) and diethylamine The amine (33.7 mL, 326 mmol) was suspended in degassed DMF (217 mL). Nitrogen gas was bubbled through the solution for 5 minutes to allow the reaction to proceed. mol), bis(triphenylphosphine)palladium(II) dichloride (2.29 g , 3.26 mmol) and triphenylphosphine (1.71 g, 6.52 mmol) The reaction was sealed and then heated at 100° C. for 30 minutes. The resulting mixture was then Pass the mixture through a plug of diatomaceous earth such as Celite®, wash with DMF, and concentrate under reduced pressure. The resulting residue was purified by FCC (0% hexane for 3 min, 25% to 100% EtOAc / hexane for 3 min, Purify the (R)-3-hydroxy-1- Methyl-3-((3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane -2-yl)phenyl)ethynyl)pyrrolidin-2-one (7.50 g, 67.5%) Obtained as an off-white solid. MS(ESI): C 19 H 24 Calculated mass of BNO4, 341.18; m / z observed, 342.1 [M+H] + . 1 H NMR (400 MHz, DMSO-d6)δ 7.70-7.68(m,1H),7.66(dt,J=7.4, 1.3Hz,1H),7.54(dt,J=7.8,1.5Hz,1H),7.41(t d,J=7.6,0.7Hz,1H),6.44(s,1H),3.37-3.32(m ,2H),2.80(s,3H),2.46-2.37(m,1H),2.20-2.0 2(m,1H),1.30(s,12H).
[0417] Intermediate 5: (S)-3-hydroxy-1-methyl-3-((3-(4,4,5,5-tetramethyl- tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethynyl)pyrrolidine On-2-on.
[0418] [ka]
[0419] The title compound was synthesized by the reaction of 2-(3-bromophenyl)-4,4,5,5-tetramethyl-1,3 ,2-Dioxaborolane and (S)-3-ethynyl-3-hydroxy-1-methylpyrrolidone Prepared under similar conditions as described in Intermediate 4 using din-2-one to give (S)-3- Hydroxy-1-methyl-3-((3(4,4,5,5-tetramethyl-1,3,2-di Oxaborolan-2-yl)phenyl)ethynyl)pyrrolidin-2-one (880 mg, 85%) as a solid. MS(ESI): C 19 H 24 Calculated mass of BNO4: 34 1.18; m / z observed, 342.1 [M+H] + . 1 H NMR (400 MHz, DM SO-d6)δ 7.70-7.68(m,1H),7.66(dt,J=7.4,1. 3Hz,1H),7.54(dt,J=7.8,1.5Hz,1H),7.41(td, J=7.6,0.7Hz,1H),6.44(s,1H),3.37-3.32(m,2 H),2.80(s,3H),2.46-2.37(m,1H),2.20-2.02( m,1H),1.30(s,12H).
[0420] Intermediate 6: (R)-3-hydroxy-1-methyl-3-((4-methyl-3-(4,4 ,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethynyl 1)pyrrolidin-2-one.
[0421] [ka]
[0422] 2-(5-bromo-2-methylphenyl)-4,4,5,5-tetrabromo- tetramethyl-1,3,2-dioxaborolane (6.67 g, 22.4 mmol), (R) -3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one (3.45 g, 24 0.8 mmol), and diethylamine (23.2 mL, 224 mmol), degassed with nitrogen A solution of iodine in DMF (150 mL) was added. Nitrogen was then bubbled through the solution for 5 minutes, and then iodine was added. Copper(I) chloride (0.86 g, 4.49 mmol), bis(triphenylphosphine)palladium Sodium(II) dichloride (1.58 g, 2.25 mmol) and triphenylphosphine (1.18 g, 4.49 mmol) was added. After sealing the reaction vessel, the mixture was heated at 100°C for 30 minutes. The mixture was cooled to room temperature and a plug of diatomaceous earth, such as Celite®, was added. The resulting residue was purified by FCC (0% hexane for 3 min, 25 min) and washed with DMF. Purify with 100% ethyl acetate / hexane for 25 min, then 100% ethyl acetate for 3 min (R). -3-hydroxy-1-methyl-3-((4-methyl-3-(4,4,5,5-tetramethyl 1,3,2-dioxaborolan-2-yl)phenyl)ethynyl)pyrrolidine-2 -one (5.86 g, 73.5%) was obtained as an off-white solid. MS (ESI): C 20 H 26 Calculated mass of BNO4: 355.2; observed m / z: 356.1 [M+H] + . 1 H NMR(500MHz,CDCl3)δ 7.84(d,J=1.9Hz,1 H),7.37(dd,J=7.9,2.0Hz,1H),7.08(d,J=7.9H z,1H),3.51-3.47(m,1H),3.38-3.34(m,1H),2. 94(d,J=1.8Hz,3H),2.65-2.61(m,1H),2.51(s, 3H), 2.38-2.35(m, 1H), 1.33(s, 12H).
[0423] Intermediate 7: 6-chloro-2-methylpyrido-3,2-pyrimidin-4-amine.
[0424] [ka]
[0425] 3-amino-6-chloronicolinonitrile (100 mg, 0.65 mmol) was added A vial was charged with ethanimidamide hydrochloride (57.0 mg, 0.98 mmol), tribasic riboflavin Potassium phosphate (553 mg, 2.6 mmol) and THF (3 mL) were added to the vial. The vessel was sealed and heated for 16 hours at 80° C. The resulting mixture was cooled to room temperature and concentrated to dryness. Water (3 mL) was added to the residue at 70° C. After stirring for 30 minutes, the resulting mixture was cooled to room temperature. The resulting solid was isolated by filtration and diluted with water (3 mL) and Et HCl (10 mL) to give 6-chloro-2-methylpyrido[3,2-d]pyrimidinium chloride. Zin-4-amine (70 mg, 55%) was obtained as a pale yellow solid. MS (ESI): C Calculated mass for 8H7ClN4: 194.04; observed m / z: 195.04 [M+H] + . 1 H NMR(400MHz,CDCl3)δ 8.00(d,J=8.7Hz,1H ),7.62(d,J=8.7Hz,1H),6.76(s,2H),2.63(s,3 H).
[0426] Intermediate 8: 6-chloropyrido[3,2-d]pyrimidin-2-d-4-amine.
[0427] [ka]
[0428] In a 1 L round-bottom flask, add a stir bar, 3-amino-6-chloropicolinonitrile (22 0.0g, 0.14mol), formamide-d3 (20.6g, 0.43mol), K3 PO4 (122 g, 0.57 mol) and cyclopentyl methyl ether (440 mL) The resulting mixture was stirred at 65°C for 16 hours and then cooled to room temperature. The mixture was filtered and the cake was slurried with water (100 mL) at 20° C. for 3 hours. The solid was isolated by filtration and dried to give 6-chloropyrido[3,2-d]pyrimidine-2-d The resulting amine (23.9 g, 94%) was obtained as a yellow solid. MS (ESI): CH Calculated mass for 4DClN4: 181.0; observed m / z: 182.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.15(d,J=8.8Hz,1H) ,8.05(br s,1H),7.95(br s,1H),7.88(d,J=8. 8Hz,1H).
[0429] Intermediate 9: 2-(5-iodo-2-methylphenyl)thiazolo[5,4-d]pyrimidin phen-7-amine.
[0430] [ka]
[0431] Step A: N-(4-amino-6-oxo-1,6-dihydropyrimidin-5-yl) )-5-iodo-2-methylbenzamide. To the solution, 5,6-diaminopyrimidin-4(3H)-one (47.3 g, 375 mmol) ), 5-iodo-2-methylbenzoic acid (108 g, 412 mmol), DMF (710 m L) and DIEA (153 g, 1.18 mol) were added sequentially. The flask was purged with nitrogen. After cooling to 0-10°C, 1-[bis(dimethylamino)methylene]-1H-1,2 ,3-Triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (148 g, 390 mmol) was added, and the resulting mixture was stirred at 0-10° C. for 1 hour. The mixture was then stirred for 18 hours while warming to room temperature. The mixture was diluted with acetonitrile (709 mL). The resulting solid was filtered and diluted with acetonitrile (190 mL x 3). The filter cake was collected and dried under vacuum at 50-55°C to give N-(4-aminomethyl-N- ... (6-oxo-1,6-dihydropyrimidin-5-yl)-5-iodo-2-methylbenzyl The resulting product was azuramide (108 g, 78.0%) as a light brown solid. 1 H NMR (400M Hz,DMSO-d6)δ 11.68(s,1H),8.89(s,1H),8.01 (s,1H),7.78(s,1H),7.66(d,J=8.0Hz,1H),7.0 5(d,J=8.0Hz,1H),6.39(s,2H),2.35(s,3H).
[0432] Step B: 2-(5-iodo-2-methylphenyl)thiazolo[5,4-d]pyrimidine In a 2 L round bottom flask equipped with an overhead stirrer, add N-(4-aminobenzoate)-7-amine. (6-oxo-1,6-dihydropyrimidin-5-yl)-5-iodo-2-methyl Benzamide (110 g, 297 mmol), pyridine (1.10 L), and P2S5( The resulting mixture was heated at 100°C for 1 hour, and then The mixture was cooled to room temperature, concentrated to dryness, diluted with acetonitrile (550 mL), and diluted with 1N The mixture was neutralized with hydrochloric acid (1.20 L), and the resulting mixture was stirred for 1 hour, after which the suspension was filtered. The solid was washed with MeOH (110 mL × 3) and dried under vacuum at 50-55 °C. Further purification was carried out by adding MeOH (1150 mL) at 0° C. and stirring for 1 hour. The solid was filtered. The 2-(5-iodo-2-methyl) (phenyl)thiazolo[5,4-d]pyrimidin-7-amine (88.4g, 80.8%) was obtained as a pale yellow solid. 1 H NMR (300 MHz, DMSO-d6) δ 8.3 3(s,1H),8.15(d,J=1.9Hz,1H),7.81(d,J=2.0H z,2H),7.78(d,J=1.9Hz,1H),7.23(d,J=8.1Hz, 1H), 2.57(s,3H).
[0433] Intermediate 10: (R)-7-ethynyl-6,7-dihydro-5H-pyrrolo[1,2-a] Imidazol-7-ol.
[0434] [ka]
[0435] Step A: 6,7-Dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol In a 5 L, three-necked, round-bottom flask purged and maintained with nitrogen, 1H-imidazole (20 0g, 2.93mol), prop-2-enal (247g, 4.41mol), Ac OH (12.3 g, 205 mmol) and dioxane (2.00 L) were added. The resulting solution was stirred at 100°C for 4 hours. The resulting mixture was cooled to room temperature and concentrated to dryness. The residue was purified by FCC (DCM / MeOH (30:1)) to obtain 6,7-dihydro-5H-pyrrolidone. Imidazol-7-ol (125 g, 34.3%) as a white solid MS (ESI): calculated mass for C6H8N2O, 124.0; observed m / z, 12 5.0[M+H] + .
[0436] Step B: 5,6-Dihydro-7H-pyrrolo[1,2-a]imidazol-7-one In a 5 L, three-necked round-bottom flask maintained under a nitrogen purge, 6,7-dihydro-5H-pyridinium chloride was added. Imidazol-7-ol (125 g, 1.00 mol), DCM ( 2.5 L) and MnO2 (615 g, 7.10 mol) were added. The resulting solution was The mixture was stirred at 0°C for 72 hours, and the solid was removed by filtration. The resulting mixture was concentrated to give a residue. was purified by FCC (DCM / MeOH (30:1)) to give 5,6-dihydro-7H-pyrrolidone Imidazol-7-one (67 g, 54.5%) was obtained as a yellow solid. MS (ESI): calculated mass for C6H6N2O, 122.0; observed m / z, 123 .0[M+H] + .
[0437] Step C: (R)-7-ethynyl-6,7-dihydro-5H-pyrrolo[1,2-a] Imidazol-7-ol, (S)-7-ethynyl-6,7-dihydro-5H-pyrrolo[ 1,2-a]imidazol-7-ol. 5,6-7H-pyrrolodiol in DCM (1.5 L) To a stirred mixture of [1,2-a]imidazol-7-one (67.0 g, 549 mmol) , bromo(ethynyl)magnesium (213 g, 1.65 mmol) was added at 0°C under a nitrogen atmosphere. ) was added dropwise. The resulting solution was stirred at 25°C for 1 hour. The reaction was then diluted with saturated N The mixture was quenched with aqueous HCl (500 mL). The resulting mixture was concentrated and ethyl acetate ( The combined organic extracts were extracted with water (500 mL) and brine (500 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The resulting residue was purified by FCC (DCM / MeOH (20:1)) to give 7-ethynyl-6 ,7-Dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol (23.9 g, Racemic 7-ethynyl-6,7-dihydro-5H- The enantiomers of pyrrolo[1,2-a]imidazol-7-ol were separated by chiral preparative SFC ( CHIRALPAK AD-33.0×100mm, 3μm, mobile phase, EtOH(0.1 % DEA), 10% to 50% in 4.0 minutes, hold at 50% for 2.0 minutes, 2 mL / min, Column temperature: 35°C. UV at λ = 220-254 nM revealed (R)-7-enantiomers. Thiol-6,7-dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol (6 0.2g) as a white solid to obtain (S)-7-ethynyl-6,7-dihydro-5H-pyrrolo[ 1,2-a]imidazol-7-ol (Intermediate 11, 5.6 g) was obtained as a white solid. (R)-7-ethynyl-6,7-dihydro-5H-pyrrolo[1,2-a]imidazole -7-ol data: MS(ESI): Calculated mass of C8H8N2O, 148.0; m / z measured value: 149.0 [M+H] + . 1 H NMR (400 MHz, CD3OD) δ 7.12-7.00(m,2H),4.19-4.02(m,2H),3.14(s,1 H),3.06-3.01(m,1H),2.83-2.78(m,1H). [α] 20 D =-60.7 (c=0.29 in MeOH).
[0438] Intermediate 11: (S)-7-ethynyl-6,7-dihydro-5H-pyrrolo[1,2-a] Imidazol-7-ol.
[0439] [ka]
[0440] Intermediate 10, chiral separation as described in Step C, affords (S)-7-ethynyl-6,7- Dihydro-5H-pyrrolo[1,2-a]imidazol-7-ol (5.6 g) was obtained as a white solid. MS (ESI): calculated mass for C8H8N2O, 148.0; observed m / z Value, 149.0 [M+H] + . 1 H NMR (400 MHz, CD3OD) δ 7.12 -7.00(m,2H),4.19-4.02(m,2H),3.14(s,1H),3 .06-3.01(m,1H),2.83-2.78(m,1H). [α] 20 D =+5 9.6 (c=0.27 in MeOH).
[0441] Intermediate 12: 2-(3-iodophenyl)-1,7-naphthyridin-8-amine.
[0442] [ka]
[0443] Step A: 6-Chloro-3-methylpicolinamide. 6- in DCM (3.00 L) To a mixture of chloro-3-methylpicolinic acid (450 g, 2.62 mol), (COCl) 2 (466 mL, 5.32 mol) was added dropwise, followed by DMF (38.3 mL, 498 mm ol) was added slowly over 30 minutes at 0°C. After 2 hours, the resulting mixture was allowed to warm to room temperature. The residue was diluted with DCM (500 mL) and added NH3-H2O (3.7 mL) at 0 °C. 0 L, 24.0 mol, 25.0% v / v NH3 solution) was added dropwise. After 3 hours, The resulting mixture was filtered, and the filtrate was concentrated to dryness to give 6-chloro-3-methylpicolinamide. (390 g, 78.5%) was obtained as a yellow solid. 1 H NMR (400 MHz, DM SO-d6)δ 7.89(br s,1H),7.79(d,J=8.2Hz,1H) ,7.59(br s,1H),7.53(d,J=8.2Hz,1H),2.45(s ,3 H).
[0444] Step B: (E)-6-chloro-N-((dimethylamino)methylene)-3-methyl Picolinamide. 6-Chloro-3-methylpicolinamide (1.20 L) in THF (1.20 L) A mixture of 95 g, 1.14 mol) and DMF-DMA (699 mL, 5.26 m ol) was added in one portion. The resulting mixture was heated to 90°C. After 16 hours, the mixture was cooled to room temperature. Cool to rt and concentrate to dryness to give (E)-6-chloro-N-((dimethylamino)methylene)- 3-Methylpicolinamide was obtained as a dark brown oil (540 g), which was directly used in the next step. Used for the top.
[0445] Step C: 2-Chloro-1,7-naphthyridin-8(7H)-one. THF (900 mL) in (E)-6-chloro-N-((dimethylamino)methylene)-3-methylpicoate A mixture of phosphoric acid amide (180 g, 798 mmol) was added to t-BuOK (798 mL) at room temperature. , 1.00 M in THF) was added in one portion. The brown mixture was heated to 90° C. After 3 hours, The mixture was cooled to room temperature and concentrated to dryness. Ice (200 g) was added to the resulting residue, and 1M H The pH was adjusted to 4 with Cl, and MeCN (400 mL) was added. After heating at 0° C. for 4 h, the mixture was slowly cooled to 25° C. and stirred for an additional 8 h. The resulting solid was collected by filtration and dried under vacuum to give 2-chloro-1,7-naphthyl Zin-8(7H)-one (276 g, 63.9% yield) was obtained as a yellow solid. MS( ESI): Calculated mass of C8H5ClN2O: 180.0; Measured m / z: 181.2 [M+ H] + . 1 H NMR(300MHz,DMSO-d6)δ 8.21(d,J=8.4 4Hz,1H),7.77(d,J=8.44Hz,1H),7.32(d,J=6.9 7Hz,1H),6.60(d,J=6.97Hz,1H).
[0446] Step D: 2-(3-aminophenyl)-1,7-naphthyridin-8(7H)-one In toluene (678 mL), MeOH (339 mL), and HO (113 mL) under nitrogen of 2-chloro-1,7-naphthyridin-8(7H)-one (113 g, 626 mmol) To the mixture, (3-aminophenyl)boronic acid (103 g, 751 mmol), NaC O3 (133g, 1.25mol), Pd(PPh3)4 (14.5g, 12.5mmo The resulting mixture was heated at 90°C for 12 hours, then cooled to room temperature, and an organic solvent was added. The mixture was concentrated and the remaining mixture was poured into water (2.5 L). The resulting suspension was filtered and collected. The yellow solid was washed with water (500 mL x 4). The yellow solid was extracted with EtOAc (1.5 L). It is ground and dried to give 2-(3-aminophenyl)-1,7-naphthyridine-8(7H) C-one (304 g, 83.8%) was obtained as a yellow solid. MS (ESI): C 14 H1 Calculated mass of 1N3O: 237.1; observed m / z: 238.2 [M+H] + . 1 HN MR(300MHz,DMSO-d6)δ 11.51(br s,1H),8.05- 8.17(m,2H),7.48(t,J=1.83Hz,1H),7.23-7.32 (m,2H),7.16(t,J=7.76Hz,1H),6.67(dd,J=1.4 7,7.95Hz,1H),6.55(d,J=7.09Hz,1H),5.25(s, 2H).
[0447] Step E: 2-(3-iodophenyl)-1,7-naphthyridin-8(7H)-one 2-(3-aminophenyl)-1,7-naphthyridine-8( 7H)-one (80.0 g, 337 mmol) and CuI (77.1 g, 405 mmol) A mixture of CH2I2 (136 mL, 1.69 mol) and t-BuONO (1 20 mL, 1.01 mol) was added. The resulting mixture was then heated to 70°C. After 2 hours, the mixture was cooled to room temperature, filtered, and the filtrate was concentrated to dryness to give 2-(3-iodophenyl) 200 g of 1,7-naphthyridin-8(7H)-one was obtained as a yellow solid. This was used directly in the next step. MS(ESI):C 14 Calculated mass of H9IN2O, 347.9; m / z observed, 349.0 [M+H] + .
[0448] Step F: 8-chloro-2-(3-iodophenyl)-1,7-naphthyridine. 2- (3-Iodophenyl)-1,7-naphthyridin-8(7H)-one (330g, 948 (mmol) in one portion to POCl3 (1.98 L, 21.3 mol) in a 5 L round-bottom flask The resulting mixture was heated to 120°C. After 12 hours, POC was obtained by distillation at 120°C. The remaining residue was quenched with water (3 L). The pH was adjusted to 9 with CO3, and the resulting mixture was diluted with ethyl acetate (2 L) and water (1 L). The organic layer was separated and washed with ammonium hydroxide (800 mL x 3) and brine (60 0 mL), dried over Na2SO4, filtered, and concentrated to give 8- as a brown solid. Chloro-2-(3-iodophenyl)-1,7-naphthyridine (80.0 g) was obtained, and Used directly in the next step. MS(ESI):C 14 Calculated mass of H8ClIN2: 36 5.9; m / z observed, 366.6 [M+H] + .
[0449] Step G: 2-(3-iodophenyl)-N-(4-methoxybenzyl)-1,7- Naphthyridin-8-amine. 8-Chloro-2-(3-iodophenyl)-1,7-naphthyl Lysine (75.0 g, 205 mmol) was dissolved in (4-methoxyphenyl)methanamine (26 5 mL, 2.05 mol) was added and the resulting mixture was heated to 120° C. for 3 hours. The mixture was cooled to room temperature and adjusted to pH=1 using 1M HCl. L) was added and the mixture was filtered. The collected solid was washed with water and dried under vacuum to give 2-(3-iodophenyl)-N-(4-methoxybenzyl)-1,7-naphthyridine- The 8-amine was obtained as a yellow solid (61.0 g, 89.0%), which was directly carried on to the next step. MS(ESI):C 22 H 18 Calculated mass of IN3O, 467.1; m / z Measured value: 468.1 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 10.27(br s,1H),8.79(s,1H),8.60-8.65(m,1H ),8.56-8.47(m,2H),7.92(d,J=7.82Hz,1H),7. 71(d,J=6.97Hz,1H),7.42-7.47(m,2H),7.41-7 .34(m,1H),7.27(d,J=6.97Hz,1H),6.95-6.90( m,2H),4.98(br d,J=6.4Hz,2H),3.72(s,3H).
[0450] Step H: 2-(3-iodophenyl)-1,7-naphthyridin-8-amine. TF 2-(3-iodophenyl)-N-(4-methoxybenzyl)-1 in A (150 mL) ,7-Naphthyridin-8-amine (60.0 g, 128 mmol) was stirred at 60°C. After 0.75 h, the mixture was concentrated to dryness under reduced pressure. The resulting residue was extracted with ethyl acetate (500 ml). The organic layer was separated and partitioned between saturated aqueous NaHCO3 (200 mL) and saturated aqueous NaHCO3 (200 mL). The organic layer was washed with aqueous HCO3 (200 mL x 2) and brine (100 mL). The resulting residue was dried over Na2SO4, filtered, and concentrated to dryness. The eluate was separated by preparative HPLC (Pheno menex LunaC18 10μm, 250×50mm, mobile phase: 20%ACN:2 Increasing gradient of 50% ACN in water (0.1% TFA) over 8 min. Detection, λ = 220 The 2-(3-iodophenyl)-1,7-naphthalene ester was purified sequentially by UV at 254 nM. Phthyridin-8-amine was obtained as a yellow solid (24.8 g, 52.1%). MS (ES I C 14 H 10 Calculated mass of IN3, 346.9; observed m / z, 348.1 [M+ H] + . 1 H NMR(400MHz,CDCl3)δ 8.48(s,1H),8.0 6(d,J=8.4Hz,2H),7.99-7.91(m,2H),7.81(d,J =7.8Hz,1H),7.28-7.24(m,1H),6.94(d,J=5.9H z,1H),6.31(br s,2H).
[0451] Intermediate 13: (S)-2-(5-methyl-1,3,4-oxadiazol-2-yl) Buta-3-yn-2-ol.
[0452] [ka]
[0453] Step A: 1-(5-methyl-1,3,4-oxadiazol-2-yl)ethane- 1-one. In a 2 L three-necked round-bottom flask, add N-methoxy-N, 5-Dimethyl-1,3,4-oxadiazole-2-carboxamide (56.0 g, 32 The resulting solution was cooled to 0°C and methylmagnesium bromide ( 320 mL of 2M in THF) was added dropwise with stirring. After 1 h at 0 °C, saturated NH Aqueous HCl solution (300 mL) was added, and the mixture was extracted with ethyl acetate (200 mL × 3). The combined organic extracts were washed with brine (200 mL). The organic extracts were washed with anhydrous Na2S The residue was dried over O, filtered, and concentrated to dryness. :1 to 1:2)) and purified to give 1-(5-methyl-1,3,4-oxadiazole-2- (21 g, 51%) was obtained as a yellow solid. MS (ESI): C Calculated mass for 5H6N2O2: 126.0; observed m / z: 127.0 [M+H] + .
[0454] Step B: (S)-2-(5-methyl-1,3,4-oxadiazol-2-yl) But-3-yn-2-ol and (R)-2-(5-methyl-1,3,4-oxadiazo (2-yl)but-3-yn-2-ol. 1 L three-neck round flask maintained under nitrogen purging. To the bottom flask was added bromo(ethynyl)magnesium (500 mL, 2 M in THF). The solution was cooled to 0°C and then diluted with 1-(5-methyl-1,3, 4-oxadiazol-2-yl)ethan-1-one (21.0 g, 167 mmol) The solution was added dropwise. The resulting solution was stirred at room temperature for 2 hours. The reaction mixture was cooled to 0°C. Then, saturated aqueous NH4Cl (300 mL) was added, followed by H2O (200 mL). The mixture was extracted with ethyl acetate (200 mL × 3) and the combined organic extracts were washed with brine (2 The organic extract was dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The residue was purified by FCC (ethyl acetate / petroleum ether (0:1 to 1:2)) and (ra c)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne- 2-ol (15.2 g, 60%) was obtained as a yellow solid. 1,3,4-oxadiazol-2-yl)but-3-yn-2-ol (15.2 The (R) and (S) enantiomers of g) were separated by chiral preparative SFC (Phenomenex L ux 5u Cellulose-4 5μm, 5 x 25cm, mobile phase, CO2 (80% ), IPA (0.1% DEA) (20%). Detector: UV 220 nm. Therefore, (S)-2-(5-methyl-1,3,4-oxadiazol-2-yl)buta- 3-yn-2-ol (5.3 g, 35%, >97% ee) was obtained as a yellow solid (R )-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne-2 -ol was obtained as a yellow solid (Intermediate 14, 5.2 g, 34%, >97% ee). S)-2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne 2-ol data: MS(ESI): mass calculated for C7H8N2O2, 152.0; m / z measured value: 153.0 [M+H] + . 1 H NMR (400 MHz, CDCl3) δ 2.99(s,1H),2.70(s,1H),2.58(s,3H),1.97(s, 3H). [α] 20 D =+23.7 (c=1.06 in MeOH).
[0455] Intermediate 14: (R)-2-(5-methyl-1,3,4-oxadiazol-2-yl) Buta-3-yn-2-ol.
[0456] [ka]
[0457] Chiral separation as described in Step B of Intermediate 13 affords ((R)-2-(5-methyl- 1,3,4-Oxadiazol-2-yl)but-3-yn-2-ol was obtained as a yellow solid. (5.2g, 34%, >97% ee) MS(ESI): Mass of C7H8N2O2 Calculated value, 152.0; m / z observed value, 153.0 [M+H] + . 1 H NMR (400M Hz, CDCl3)δ 2.99(s,1H),2.70(s,1H),2.58(s, 3H), 1.97(s,3H). [α] 20 D =-20.5(c=0.96 in MeOH) .
[0458] Intermediate 15: 7-(3-iodophenyl)-5,6,7,8-tetrahydro-2,7- Naphthyridin-1-amine.
[0459] [ka]
[0460] 5,6,7,8-Tetrahydro-2,7-naphthyridin-1-amine (500 mg, 3 0.35mmol), 3-iodophenylboronic acid (1.08g, 4.36mmol), Cu(OAc)2 (122 mg, 0.672 mmol), powdered 4 Å molecular weight The resulting mixture was added to a stirred suspension of 2.50 g of PEG-400 (C10.5%) and DCM (25 mL). The mixture was stirred at 35 °C under O2 (15 psi) for 24 h. The mixture was cooled to room temperature. , filtered through a pad of diatomaceous earth such as Celite®, and the pad was diluted with DCM (15 mL The filtrate was concentrated to dryness, and the residue was purified by FCC (petroleum ether:ethyl acetate). The compound was purified by ethanol (1:0 to 0:1) to give 7-(3-iodophenyl)-5,6,7,8- Tetrahydro-2,7-naphthyridin-1-amine (260 mg, 21%) as a yellow oil LCMS(ESI):C 14 H 14 Calculated mass of IN3: 351.0; actual m / z Measured value, 351.8[M+H] + .
[0461] Intermediate 16: 5-(3-iodophenyl)-1H-pyrazolo[4,3-b]pyridine 3-Amine.
[0462] [ka]
[0463] Step A: 5-chloro-3-nitro-1H-pyrazolo[4,3-b]pyridine. H2 5-Chloro-1H-pyrazolo[4,3-b]pyridine (47. A solution of 8g, 311mmol) of nitric acid (327g, 3.58mol, purity 69. The mixture was stirred at 25 °C for 2 h, followed by the addition of H2O (100 mL). The resulting mixture was filtered, and the collected solid was washed with H2O (20 mL x 3). The resulting solid was triturated with ethyl acetate and 5-chloro-2-(2-methyl-2-propanol)-2-propanol (DCM) 1:1 at 25°C for 1 hour. 1H-3-nitro-1H-pyrazolo[4,3-b]pyridine (47.0 g, 74.2%) Obtained as a white solid. MS (ESI): mass calculated for C6H3ClN4O2, 197.9 ; m / z measured value, 199.0 [M+H] + .
[0464] Step B: 3-Nitro-5-(3-(trimethylsilyl)phenyl)-1H-pyrazo 5-chloro-3-nitro-1H-pyrazolo[4,3-b]pyridine. Lysine (9.00 g, 45.3 mmol), trimethyl-[3-(4,4,5,5-tetramethyl- tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]silane (31.3 g, 90.6 mmol), K2CO3 (21.9 g, 158 mmol), 1,2-dimethoxy Ethane (160 mL), ethanol (160 mL) and HO (120 mL) were added and the mixture was stirred at room temperature for 1 hour. d(PPh3)2Cl2 (3.18 g, 4.53 mmol) was added. The mixture was heated at 90 °C. After stirring for 24 hours, ethyl acetate (200 mL) was added to the resulting yellow mixture and the mixture was filtered. The filtrate was washed with H2O (200 mL) and brine (100 mL). The residue was dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The resulting solid was collected by filtration and treated with 3-nitro-5-(3-(trimethylsilyl) (phenyl)-1H-pyrazolo[4,3-b]pyridine (12.0 g, 68.3%) Obtained as a yellow solid. 1 H NMR(400MHz,DMSO-d6)δ 8.28(s ,1H),8.19-8.17(m,2H),7.87(d,J=8.8Hz,1H), 7.59-7.49(m,2H),0.32(s,9H).
[0465] Step C: 5-(3-iodophenyl)-3-nitro-1H-pyrazolo[4,3-b ]pyridine. 3-nitro-5-(3-(trimethylsilyl))pyridine in TFA (85.0 mL) (phenyl)-1H-pyrazolo[4,3-b]pyridine (17.0 g, 54.4 mmol) To the solution was added N-iodosuccinimide (13.3 g, 59.1 mmol) and chlorotrimethylsilyl Tisilane (690 L, 5.44 mmol) was added. The resulting mixture was stirred at 25°C. After 1 hour, the resulting mixture was added with saturated aqueous Na2SO3 (20 mL) and ethyl acetate ( The organic layer was washed with brine (20 mL) and dried over anhydrous Na2SO4. After drying, it was filtered and concentrated to dryness. The residue was triturated with MTBE at 25°C for 30 minutes. The resulting solid was collected by filtration and 5-(3-iodophenyl)-3-nitro-1H-pyrazolo[ 4,3-b]pyridine (12.0 g, 55.9%) was obtained as a yellow solid. MS (ESI ):C 12 Calculated mass of H7IN4O2: 365.9; measured m / z: 367.0 [M +H] + .
[0466] Step D: 5-(3-iodophenyl)-1H-pyrazolo[4,3-b]pyridine- 3-Amine 5-(3-iodophenyl)-3-nitro-1H in EtOH (190 mL) -A solution of pyrazolo[4,3-b]pyridine (9.50 g, 25.9 mmol) was added to the solution of sulfuric acid chloride. Zinc(II) dihydrate (23.4 g, 103 mmol) was added, and the mixture was heated at 80° C. for 1 h. To the resulting yellow mixture was added EtOH (100 mL) and the mixture was filtered. The organic layer was concentrated to dryness, and saturated aqueous NaHCO3 solution (100 mL) was added to the residue. The mixture was extracted with ethyl acetate (200 mL × 3). The combined organic extracts were washed with Na2S The mixture was dried over O, filtered, and concentrated to dryness. The residue was diluted with DCM (20 mL) at 25 °C for 30 min. ), and the resulting solid was collected by filtration and treated with 5-(3-iodophenyl)-1-methyl -1H-Pyrazolo[4,3-b]pyridin-3-amine (2.60 g, 29.8%) Obtained as a colored solid. MS(ESI): 12 Calculated mass of H9IN4: 335.9 m / z measured value: 337.1 [M+H]+ . 1 H NMR (400 MHz, DMSO-d6) δ 11.74(s,1H),8.55(s,1H),8.11(d,J=7.8Hz,1 H),7.87-7.84(m,1H),7.77(m,2H),7.28(t,J=7 .8Hz,1H),5.48(br s,2H).
[0467] Intermediate 17: 5-(3-iodophenyl)-1-methyl-1H-pyrazolo[4,3-b ]pyridin-3-amine.
[0468] [ka]
[0469] Step A: 5-chloro-1-methyl-3-nitro-1H-pyrazolo[4,3-b]pi Lysine. 5-Chloro-3-nitro-1H-pyrazolo[4,3-b] in DMF (4 mL) A solution of pyridine (400 mg, 2.01 mmol) was added to iodomethane (286 mg, 2. 01 mmol) and K2CO3 (278 mg, 2.01 mmol) were added to this mixture. The mixture was heated to 50° C. After 3 hours, the resulting mixture was poured into ice water (20 mL), filtered, and the solid The solid was suspended in DCM (10 mL) and ethyl acetate (5 mL) and heated at room temperature. The mixture was stirred at rt for 2 h. The solid was separated by filtration and dried under reduced pressure to give 5-chloro-1-methyl- ethyl-3-nitro-1H-pyrazolo[4,3-b]pyridine (268 mg, 63%) in yellow Obtained as a colored solid. MS (ESI): mass calculated for C7H5ClN4O2, 212.0; m / z measured value: 213.0 [M+H] + .
[0470] Step B: 1-methyl-3-nitro-5-(3-(trimethylsilyl)phenyl)- 1H-Pyrazolo[4,3-b]pyridine. 5-chloro-1-methyl-3-nitro-1H- Pyrazolo[4,3-b]pyridine (20.0 g, 94.0 mmol), trimethyl(3- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl ) Silane (20.0 g, 103 mmol), K2CO3 (26.0 g, 188 mmol) was dissolved in HO (70 mL), EtOH (70 mL) and DME (70 mL) under nitrogen. , [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (3.44 g, 4.70 mmol) was added. The mixture was sparged with nitrogen and then heated to 90°C. After 16 hours, the black mixture was filtered and water (500 mL) was added. The aqueous phase was diluted with ethyl acetate. Extract with chill / IPA (2.5 L / 0.25 L) and wash the organic phase with brine (300 mL). The organic extract was dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The residue was purified by M The mixture was triturated with TBE (100 mL) at 25°C for 16 hours, and the resulting solid was collected by filtration. 1-methyl-3-nitro-5-(3-(trimethylsilyl)phenyl)-1H-pyra Zolo[4,3-b]pyridine (3.80 g, 12.4% yield) was obtained as a brown solid. S(ESI):C 16 H 18 Calculated mass of N4O2: 326.1; observed m / z: 327 .1[M+H] + .
[0471] Step C: 5-(3-iodophenyl)-1-methyl-3-nitro-1H-pyrazolo [4,3-b]pyridine. 1-Methyl-3-nitro-5-(3- (Trimethylsilyl)phenyl)-1H-pyrazolo[4,3-b]pyridine (4.70g To a solution of N-iodosuccinimide (3.24 g, 14.4 mmol) 1.44 mmol) and chlorotrimethylsilane (182 μL, 1.44 mmol) were added to this mixture. The mixture was stirred under nitrogen at 25° C. for 30 minutes. The resulting black mixture was concentrated to dryness. The residue was diluted with DCE (10 mL) and concentrated to dryness three times. The solid was collected by filtration and triturated with 5-(3-iodophenyl)-1-methyl-3 -Nitro-1H-pyrazolo[4,3-b]pyridine (4.2 g, 77%) was obtained as a black solid. C 13 For H9IN4O2, 379.9; m / z observed value, 381.1 [M+H ] + .
[0472] Step D: 5-(3-iodophenyl)-1-methyl-1H-pyrazolo[4,3-b ]pyridin-3-amine. 5-(3-iodophenyl)-1- in EtOH (60 mL) Methyl-3-nitro-1H-pyrazolo[4,3-b]pyridine (6.30 g, 16.5 m mol) solution was added with tin(II) chloride dihydrate (14.9 g, 66.2 mmol). The mixture was stirred at 80 °C for 4 h, and the resulting black mixture was added with saturated aqueous NaHCO3 A solution (200 mL) was added, and the mixture was extracted with ethyl acetate (200 mL x 3). The combined organic extracts were dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by FC Purified by C, 5-(3-iodophenyl)-1-methyl-1H-pyrazolo[4,3-b] Pyridin-3-amine was obtained, which was triturated with MTBE (30 mL) to give 5-(3-iodo) phenyl)-1-methyl-1H-pyrazolo[4,3-b]pyridin-3-amine(2.5 8g, 45%) as a yellow solid. MS(ESI): C 13 H 11 Mass meter of BrN4 Calculated value: 350.0; Measured m / z: 350.8 [M+H] + . 1 H NMR (400MH z,DMSO-d6)δ 8.51-8.61(m,1H),8.13(d,J=8.0 Hz,1H),7.93(s,2H),7.74(d,J=7.8Hz,1H),7.2 8(t,J=7.9Hz,1H),5.58(s,2H),3.79(s,3H).
[0473] Intermediate 18: 6-chloro-4-methylpyrido[3,2-d]pyrimidine.
[0474] [ka]
[0475] Place 4,6-dichloropyrido[3,2-d]pyrimidine (350 mg) in a microwave vial , 1.75 mmol) and THF (12 mL) were added. The mixture was sparged with argon for 5 min. After distillation, it was treated with Pd(PPh3)4 (202 mg, 0.18 mmol). The mixture was sparged with argon for an additional 5 min and then added to 0.42 mL of Al(CH3)3 at 0 °C. , 2M in THF) was added. The mixture was subjected to microwave irradiation at 70°C for 1 hour. After cooling to room temperature, the mixture was poured into saturated aqueous NH4Cl (20 mL) and Extraction was carried out using 3 L each.
[0476] The combined organic extracts were concentrated to dryness and diluted with FCC (petroleum ether: ethyl acetate = 1:0-1 :1) to give 6-chloro-4-methylpyrido[3,2-d]pyrimidine (120m g, 38%) as a yellow solid. MS (ESI): Mass calculated for C8H6ClN3: 1 79.03; m / z measured value 179.9 [M+H] + . 1 H NMR (400 MHz, DM SO-d6)δ 9.25(s,1H),8.48(d,J=9.0Hz,1H),8. 08(d,J=8.8Hz,1H),2.93(s,3H).
[0477] Intermediate 19: 6-chloro-4-ethoxypyrido[3,2-d]pyrimidine.
[0478] [ka]
[0479] 4,6-Dichloropyrido[3,2-d]pyrimidine (300 mg, 1.50 mmol) to a suspension of NaHCO3 (372 mg, 4.43 mmol) and EtOH (20 mL). The resulting mixture was heated to 85°C under a nitrogen atmosphere for 12 hours and then cooled to room temperature. The mixture was concentrated to dryness, and H2O (5 mL) was added at room temperature with stirring. After 2 h, the obtained The resulting suspension was separated by filtration, and the filter cake was washed with water (1 mL x 3), and then the mixture was stirred under reduced pressure. 6-chloro-4-ethoxypyrido[3,2-d]pyrimidine (300 mg 92%) as a white solid. MS (ESI): Mass calculated for C9H8ClN3O: 2 09.04, m / z measured value 210.1 [M+H] + . 1 H NMR (400 MHz, DM SO-d6)δ 8.89(s,1H),8.39(d,J=8.8Hz,1H),8. 03(d,J=8.8Hz,1H),4.64(q,J=7.0Hz,2H),1.47 (t,J=7.0Hz,3H).
[0480] Intermediate 20: 6-Chloro-N,N-dimethylpyrido[3,2-d]pyrimidin-4-a Min.
[0481] [ka]
[0482] 4,6-Dichloropyrido[3,2-d]pyrimidine (300 mg, 1.50 mmol) In a 20 mL vial containing 100 mL of DIEA (0.52 mL, 3.02 m mol) was added at room temperature. The resulting solution was added with 40% N,N-dimethylamine in water (0. 19 mL, 1.5 mmol) was added dropwise over 2 minutes. After 45 minutes, the resulting mixture Concentration and purification of the residue by FCC (100% DCM increased to 5% MeOH-DCM) gave 6 -chloro-N,N-dimethylpyrido[3,2-d]pyrimidin-4-amine (145mg 46%) as a yellow solid. MS (ESI) mass calculated for C9H9ClN4, 2 08.65; m / z observed, 209.05 [M+H] + . 1 H NMR (400 MHz, CDCl3)δ 8.57(s,1H),8.01(d,J=8.8Hz,1H),7. 55(d,J=8.8Hz,1H),3.63(s,6H).
[0483] Intermediate 21: 4-(azetidin-1-yl)-6-chloropyrido[3,2-d]pyrimidin gin.
[0484] [ka]
[0485] Azetidine (71.3 mg, 1.25 mmol) was dissolved in 4,6-dichloropyrido[3,2- d]pyrimidine (250 mg, 1.25 mmol), DIPEA (0.87 mL, 5.0 The resulting mixture was stirred at room temperature. After 1.5 hours, the resulting mixture was filtered and the filter cake was dried under reduced pressure to give 4 -(azetidin-1-yl)-6-chloropyrido[3,2-d]pyrimidine (200mg , 73%) as a white solid. 10 Calculated mass of H9ClN4, 2 20.05; m / z observed, 221.05 [M+H] + . 1 H NMR (400 MHz, CD3OD)δ 8.34(s,1H),7.97(d,J=8.8Hz,1H),7. 69(d,J=8.8Hz,1H),4.88(t,J=7.7Hz,2H),4.36 (t,J=7.7Hz,2H),2.82-2.21(m,2H).
[0486] Intermediate 22: 6-chloro-N-methylpyrido[3,2-d]pyrimidin-4-amine.
[0487] [ka]
[0488] In a 20 mL round-bottom flask, add 6-chloropyrido[3,2-d]pyrimidin-4-amine (200 mg, 1.11 mmol) and DMF (4 mL) were added, followed by NaH (36.0 mg (purity 60%), 0.90 mmol) was added in one portion. Iodomethane (2.20 g, 16.0 mmol) was added dropwise at 0°C. The mixture was stirred for 5 h, allowed to warm gradually to room temperature, and then quenched with aqueous hydrochloric acid (1 mL, 1 M). The resulting solution was purified by preparative HPLC (Xtimate C18×10 μm, 250 mm×5 0 mm, (eluent: 18% to 48% (v / v) CH3CN and HO with 0.04% N HCl and 10 mM NH4HCO3 were added. UV at 220-254 nM) to detect 6-chloro-N-methylpyrido[3,2-d] Pyrimidin-4-amine (100 mg, 47%) was obtained as a white solid. MS (ESI) Calculated mass of C8H7ClNO, measured m / z 194.04, 195.1 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 8.50-8.43(m,2H ),8.11(d,J=8.8Hz,1H),7.83(d,J=8.8Hz,1H), 2.97 (d, J = 4.9 Hz, 3H).
[0489] Intermediate 23: 6-(3-bromophenyl)-N-(2,4-dimethoxybenzyl)pyridine Mido[5,4-d]pyrimidin-4-amine.
[0490] [ka]
[0491] Step A: 8-chloro-2-(methylthio)pyrimido[5,4-d]pyrimidine. 6 -(methylthio)pyrimido[5,4-d]pyrimidin-4-ol (3.80 g, 19. In a 250 mL round-bottom flask containing oxyethyl methyl ketone (6 mmol) and toluene (100 mL), Phosphorus chloride (11.0 mL, 120 mmol) was added, and the resulting mixture was heated at 115° C. for 15 minutes. After stirring for 1 hour under heating, the mixture was cooled to room temperature. The pH of the mixture was adjusted to pH=7-8 with solid K2CO3. The resulting mixture was extracted with ethyl acetate (50 mL x 3). The combined organic extracts were washed with saturated NaHCO3 (35 mL), brine (35 mL), and then cooled to 5°C over anhydrous MgSO4 The resulting residue was diluted with MTBE:ethyl acetate (1:1, 50 mL), and the resulting solid was isolated by filtration to give 8-chloro-2-(methylthio)piperidin. Rimido[5,4-d]pyrimidine (2.5 g, 60%) was obtained as a grey solid. 1 H NMR(400MHz,DMSO-d6)δ 9.11(s,1H),8.14(s,1 H), 2.56(s,3H).
[0492] Step B: N-(2,4-dimethoxybenzyl)-6-(methylthio)pyrimidin[5 ,4-d]pyrimidin-4-amine. In a 250 mL round-bottom flask, add 8-chloro-2-( Methylthio)pyrimido[5,4-d]pyrimidine (3.1g, 15mmol), 1-butadiene ethanol (150 mL), (2,4-dimethoxyphenyl)methanamine (2.7 mg, 16 The resulting mixture was added with 100 mL of HCl (2.5 mmol) and DIPEA (7.3 mL, 44 mmol). After stirring at 120°C for 2.5 hours, the mixture was cooled to room temperature, concentrated to dryness, and then evaporated to dryness. The organic layer was washed with brine (100 mL x 2) and diluted with anhydrous Na Dry over 2SO4, filter, and concentrate to give N-(2,4-dimethoxybenzyl)-6 -(Methylthio)pyrimid[5,4-d]pyrimidin-4-amine (5.16 g) brown Obtained as a solid which was used in the next step without further purification.1 H NMR(4 00MHz,DMSO-d6)δ 9.18(s,1H),8.75(t,J=8.0H z,1H),8.47(s,1H),7.05(d,J=8.8Hz,1H),6.58 (d,J=2.0Hz,1H),6.43(dd,J=2.4,8.4Hz,1H),4 .70-4.64(m,2H),3.84(s,3H),3.72(s,3H),2.6 8(s,3H).
[0493] Step C: 6-(3-bromophenyl)-N-(2,4-dimethoxybenzyl)pyridine In a 100 mL three-neck round-bottom flask, add N- (2,4-Dimethoxybenzyl)-6-(methylthio)pyrimido[5,4-d]pyrimidin phenyl-4-amine (500 mg, 1.46 mmol), (3-bromophenyl)boronic acid ( 585 mg, 2.91 mmol) and 1,4-dioxane (10 mL) were added. The resulting mixture was sparged with argon for 5 minutes, and then [1,1'-bis(diphenylphosphine (( ... I) Treatment with 2-hydroxy-3-methylbenzoate (625 mg, 2.91 mmol) The mixture was then sparged with argon for an additional 5 minutes and then heated at 100°C for 3 hours. The resulting mixture was cooled to room temperature and washed with a pad of diatomaceous earth such as Celite®. The pad was filtered and washed with MeOH (30 mL). The filtrate was concentrated to dryness and (petroleum ether:ethyl acetate=1:0 to 1:1) to obtain 6-(3-bromophenyl )-N-(2,4-dimethoxybenzyl)pyrimido[5,4-d]pyrimidin-4-amine The compound (370 mg, 56%) was obtained as a yellow solid. MS (ESI): C 21 H 18 BrN Calculated mass of 5O2: 451.1; observed m / z: 451.9 [M+H] + .
[0494] Intermediate 24: 6-chloro-8-methylpyrimido[5,4-d]pyrimidin-4-amine .
[0495] [ka]
[0496] Step A: 5-amino-2-chloro-6-methylpyrimidine-4-carbonitrile. Methyl 5-amino-2-chloro-6-methylpyrimidine-4-carboxylate (3.0 g, 1 7 mmol) and CH3CN (30 mL), (5.0 g, 19 mmol) and 1,4-diazabicyclo[2.2.2]octane (2. The resulting mixture was stirred at 50°C for 16 hours and then cooled to room temperature. The mixture was cooled, poured into water (30 mL), and extracted with ethyl acetate (50 mL x 3). The extract was dried over Na2SO4, filtered, and concentrated to dryness. The resulting residue was purified by FCC( The mixture was purified with petroleum ether:ethyl acetate (1:0 to 1:1) to give 5-amino-2-chloro-6 -methylpyrimidine-4-carbonitrile (1.1 g, 38%) was obtained as a yellow solid. MS (ESI): Calculated mass for C6H5ClN4, 168.02 m / z observed, 168. 8[M+H] + . 1 H NMR(400MHz,CDCl3)δ 4.58(br s, 2H), 2.51(s,3H).
[0497] Step B: 6-chloro-8-methylpyrimido[5,4-d]pyrimidin-4-amine 5-amino-2-chloro-6-methylpyrimidine-4-carbonitrile (150 mg, 0.89 mmol), formamidine acetate (185 mg, 1.78 mmol), and To a solution of 1,4-dioxane (3 mL), DIPEA (0.7 mL, 4 mmol) was added. The resulting mixture was stirred at 110° C. for 16 hours, then cooled to room temperature and concentrated to dryness. The resulting residue was purified by FCC (petroleum ether:ethyl acetate=1:0 to 1:1) to give 6- Chloro-8-methylpyrimido[5,4-d]pyrimidin-4-amine (106 mg, 61 %) as a brown solid. MS (ESI): Mass calculated for C7H6ClN5, 195. 03; m / z measured value, 196.1 [M+H] + .
[0498] Intermediate 25: 6-chloro-N-(2,4-dimethoxybenzyl)-2-methylpyrimide [5,4-d]pyrimidin-4-amine.
[0499] [ka]
[0500] Step A: 6-chloro-2-methylpyrimido[5,4-d]pyrimidine-4(3H) In a 250 mL three-necked round-bottom flask, add 5-amino-2-chloropyrimidine-4- Ethyl carboxylate (2.0 g, 9.9 mmol) and CH3CN (70 mL) were added. Hydrochloric acid gas (>1.3 M) was bubbled through the resulting mixture at room temperature for 0.5 hours. The resulting mixture was stirred at 80°C for 2 hours and then cooled to room temperature. The resulting solid was separated by filtration. The filter cake was washed with acetonitrile (20 mL × 2) and then dried under reduced pressure. 6-chloro-2-methylpyrimido[5,4-d]pyrimidin-4(3H)-one (2.0 g) was obtained. MS (ESI): Calculated mass of C7H5ClN4O: 196.02 m / z observed Value 196.8 [M+H] + . 1 H NMR (400 MHz, DMSO-d) δ 9.2 2(s,1H),2.40(s,3H).
[0501] Step B: 6-chloro-N-(2,4-dimethoxybenzyl)-2-methylpyrimide [5,4-d]pyrimidin-4-amine. Oxalyl chloride (968 mg, 7.63 mmol) l) with 6-chloro-2-methylpyrimidin[5,4-d]pyrimidin-4(3H)-one , (500mg, 2.54mmol), DMF (18.0mg, 0.25mmol), and The mixture was stirred at room temperature for 16 hours and then concentrated to dryness. The resulting residue was dissolved in THF (5 mL), and the solution was added with n-BuOH (1 mL), DIPEA ( 3.30 g, 26.0 mmol) and (2,4-dimethoxyphenyl)methanamine (42 After 16 hours, the mixture was poured into water (50 mL). The combined organic extracts were washed with brine (50 mL). L), dried over anhydrous Na2SO4, filtered, and concentrated to dryness. Purify with FCC (petroleum ether: ethyl acetate = 10:1 to 1:1) to obtain 6-chloro-N- (2,4-Dimethoxybenzyl)-2-methylpyrimido[5,4-d]pyrimidine-4- The amine (350 mg, 40%) was obtained as a pale yellow solid. MS (ESI): C 16 H 16 Calculated mass of ClN5O2: 345.10 m / z, measured mass: 346.1 [M+H] + .
[0502] Intermediate 26: 6-(3-iodophenyl)-8-methylpyrido[3,2-d]pyrimidin phen-4-amine.
[0503] [ka]
[0504] Step A: Methyl 3-amino-4-bromo-6-chloropicolinate. DMF (20 Methyl 3-amino-6-chloropicolinate (1.59 g, 8.51 mmol) in mL The solution was treated with N-bromosuccinimide (1.62 g, 8.99 mmol) and then The mixture was heated to 80° C. After 1.5 hours, additional N-bromosuccinimide (0.19 g, 1.0 9 mmol) was added, and the mixture was stirred for 2 hours, and then the resulting mixture was concentrated to dryness. Ethyl acetate (150 mL) and saturated aqueous NaHCO3 (150 mL) were added. The organic layer was separated. The organic extract was dried over anhydrous MgSO4. It is dried, filtered and concentrated to dryness to give methyl 3-amino-4-bromo-6-chloronicolinate. (2.2 g, 96%). MS (ESI): mass calculated for C7H6BrClN2O2 , 263.9; m / z observed value, 264.9 [M+H] + . 1 H NMR (400 MHz, CDCl3)δ 7.59(s,1H),6.40(br s,2H),3.98(s, 3H).
[0505] Step B: Methyl 3-amino-6-chloro-4-methylpicolinate. Round-bottom flask Methyl 3-amino-4-bromo-6-chloropicolinate (1.08 g, 4.08 mmol) l) and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium ( The II) complex and dichloromethane (0.34 g, 0.41 mmol) were added. The flask was sealed with a hose, evacuated, and then purged with nitrogen three times. The solution was then poured into a flask containing 25 mL of PBS, followed by degassed K2CO3 (12 mL, 2 M in H2O) and 1 mL of PBS. Trimethylboroxine (0.61 mL, 4.32 mmol) was added. The resulting mixture was It was heated to 0° C. After 1 hour, the mixture was cooled to room temperature and diluted with ethyl acetate (150 mL). The organic extract was dried over anhydrous MgSO4 and washed with brine (150 mL x 2). The residue was purified by FCC to give 3-amino-6-chloro-4-methyl Methyl picolinate (422 mg, 52%) was obtained. MS (ESI): C8H9ClNO Calculated mass of 2: 200.0; observed m / z: 201.0 [M+H] + . 1 H NMR( 400MHz, CDCl3)δ 7.16(s,1H),5.91(br s,2H), 3.96(s,3H),2.22(s,3H).
[0506] Step C: Methyl 3-amino-4-methyl-6-(3-(trimethylsilyl)phenyl)phenyl In a flask, add 3-amino-6-chloro-4-methylpicolinate methyl (0.41 g, 2.06 mmol), (3-(trimethylsilyl)phenyl)boronic acid (0.52g, 2.67mmol), chloro(2-dicyclohexylphosphino-2', 4',6'-triisopropyl-1,1'-biphenyl) [2-(2'-amino-1,1 [(4-biphenyl)]palladium(II) (0.16 g, 0.20 mmol) was added. The vessel was sealed with a septum, evacuated, and then purged with nitrogen three times. 4-Dioxane (10 mL) was added, followed by degassed K2CO3 (5 mL, 2 M in H2O). The mixture was cooled to room temperature and diluted with ethyl acetate (150 mL). The organic extract was diluted and washed with brine (150 mL x 2). The residue was purified by FCC to give 3-amino-4-methyl -6-(3-(trimethylsilyl)phenyl)methyl picolinate (600 mg, 93%) MS(ESI):C 17 H 22 Calculated mass of N2O2Si, 314.2; m / z Measured value: 315.1 [M+H] + . 1 H NMR (400 MHz, CDCl3) δ 8. 00(s,1H),7.91-7.86(m,1H),7.60(s,1H),7.52 -7.48(m,1H),7.42(t,J=7.5Hz,1H),5.88(s,2H ),3.99(s,3H),2.30(s,3H),0.31(s,9H).
[0507] Step D: Methyl 3-amino-6-(3-iodophenyl)-4-methylpicolinate Methyl 3-amino-4-methyl-6-(3-(trimethylsilyl)methyl)- ... A solution of (methylsilyl)phenyl)picolinic acid (0.5 g, 1.6 mmol) was added to iodine monochloride. Ion (8.0 mL, 1 M in DCM) was added. The resulting mixture was allowed to warm to room temperature. After 2 hours The mixture was concentrated and directly purified by FCC to give 3-amino-6-(3-iodophenyl )-4-methylpicolinate methyl ester (135 mg, 23%) was obtained. MS (ESI): C1 4H 13 Calculated mass of IN2O2, 368.00; observed m / z, 369.0 [M+H] + . 1 H NMR(400MHz,CDCl3)δ 8.27(s,1H),7.95- 7.80(m,1H),7.66(d,J=7.3Hz,1H),7.56(s,1H) ,7.22-7.08(m,1H),5.93(br s,2H),4.00(s,3H ),2.28(s,3H).
[0508] Step E: 6-(3-iodophenyl)-8-methylpyrido[3,2-d]pyrimidin 3-amino-6-(3-iodophenyl)-4(3H)-one in THF (2 mL) A mixture of methyl 4-methylpicolinate (0.14 g, 0.37 mmol) and formaldehyde was After treatment with 4 mL of methyl methylpropional, the mixture was heated at 175°C for 30 min, then at 200°C for another 30 min. The resulting mixture was diluted with H2O (10 mL) and the resulting solid was filtered. and dried under vacuum to give 6-(3-iodophenyl)-8-methylpyridin [3, 2-d]pyrimidin-4(3H)-one (75 mg, 56%) was obtained. MS (ESI): C 14 H 10 Calculated mass of IN3O, 362.99; observed m / z, 364.0 [M+H ] + .
[0509] Step F: 4-chloro-6-(3-iodophenyl)-8-methylpyrido[3,2- d] Pyrimidine. 6-(3-iodophenyl)-8-methylpyrimidine in phosphorus oxychloride (3 mL) Rupirido[3,2-d]pyrimidin-4(3H)-one (0.14 g, 0.39 mmol A suspension of ) was treated with DIPEA (0.15 mL) and then microwaved at 100 °C for 30 min. The resulting mixture was then concentrated to dryness, and the residue was dissolved in DCM (10 mL) and DI The resulting mixture was concentrated to dryness and dissolved in MeCN (15 mL). The resulting solid was collected by filtration to give chloro-6-(3-iodophenyl)-8- Methylpyrido[3,2-d]pyrimidine (126 mg, 83%) was obtained. MS(ESI) :C 14 Calculated mass of H9ClIN3, 380.95; observed m / z, 382.0 [M+ H] + .
[0510] Step G: 6-(3-iodophenyl)-8-methylpyrido[3,2-d]pyrimidin 4-chloro-6-(3-iodophenyl)-8-methylpyrido[3,2 -d]pyrimidine (0.13 g, 0.33 mmol) and NH3 (3 mL, 2 in MeOH) A solution of M) was microwaved at 100°C for 30 minutes. The resulting mixture was concentrated to dryness and Purification by CC gave 6-(3-iodophenyl)-8-methylpyrido[3,2-d]pyrimidine. The obtained azine-4-amine (53 mg, 44%). MS (ESI): C 14 H9ClIN3 Calculated mass: 362.00; observed m / z: 363.0 [M+H] + .
[0511] Intermediate 27: (R)-3-hydroxy-1-methyl-3-((3-(4,4,5,5- Tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethacrylate) (Ci)phenyl)ethynyl)pyrrolidin-2-one.
[0512] [ka]
[0513] Step A: 2-(5-chloro-2-(difluoromethoxy)phenyl)-4,4,5, 5-Tetramethyl-1,3,2-dioxaborolane. (5-Br) in THF (260 mL) bromo-2-(trifluoromethoxy)phenyl)boronic acid (29.5 g, 104 mmol ) and 2,3-dimethylbutane-2,3-diol (12.4 g, 105 mmol) The mixture was purged with N2 and then stirred under nitrogen at 25 °C for 36 h. The reaction mixture was concentrated to dryness. The title compound, 2-(5-bromo-2-(trifluoromethoxy)phenyl)-4 ,4,5,5-tetramethyl-1,3,2-dioxaborolane (38.0g, 95.0%) ) was obtained as a white solid. MS(ESI): C 13 H 15 Calculated mass of BBrF3O3, 366.02; m / z observed, 342.1 [M+H]+.
[0514] Step B: (R)-3-hydroxy-1-methyl-3-((3-(4,4,5,5- Tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethacrylate) Pd(PPh) 3) 4 (7.9 g, 6.8 mmol), 2-[5-bromo-2-(trifluoromethoxy) )phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (25g , 68mmol), (R)-3-ethynyl-3-hydroxy-1-methylpyrrolidine-2 -ion (14.2 g, 102.2 mmol), CuI (2.6 g, 14 mmol), tri Butylphosphonium tetrafluoroborate (1.9 g, 6.8 mmol), piperidinium tetrafluoroborate (1.9 g, 6.8 mmol), The reaction mixture was heated under reduced pressure for 1 hour at 200°C for 1 hour at 200°C for 1 hour at 200°C. The mixture was degassed with 2 and stirred under nitrogen at 60°C for 16 hours. The reaction mixture was diluted with water (1500 mL). The mixture was diluted and extracted with EtOAc (2 x 200 mL) and DCM (5 x 100 mL). The combined organic layer was washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated. The crude residue was purified by FCC (0-40% ethyl acetate / petroleum ether) and then fractionated. HPLC (Welch Xtimate C18 10μm, 250x50mm, moving Phase: [water (0.1% TFA)-ACN]; B%: 30%-66%, purified by 20 min Detection was by UV at λ = 220-254 nM. 3-[2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborola phenyl-2-yl)-4-(trifluoromethoxy)phenyl]ethynyl]pyrrolidine-2- The compound (4.3 g, 14%) was obtained as a brown solid. MS (ESI): C 20 H 23 BF3 Calculated mass of NO5: 425.16; observed m / z: 426.0 [M+H] + . 1 HN MR(400MHz,CDCl3)δ 7.80(d,J=2.2Hz,1H),7.4 5(dd,J=8.5,2.3Hz,1H),7.10(d,J=7.8Hz,1H), 3.47-3.36(m,1H),3.35-3.23(m,1H),2.89(s,3 H),2.64-2.46(m,1H),2.37-2.20(m,1H),1.27( s,12H).
[0515] Intermediate 28: 2-(3-Bromophenyl)pyrido[3,4-d]pyrimidin-8-amine hmm.
[0516] [ka]
[0517] Step A: tert-Butyl (2-chloropyridin-3-yl)carbamate. Nitrogen Into a 2 L, 3-necked round-bottom flask purged and maintained at 100°C inert atmosphere was added THF (700 mL). A solution of 2-chloropyridin-3-amine (60 g, 467 mmol) in water was then added. Add sodium bis(trimethylsilyl)amide (516 mL) to the flask and stir at -10°C. , 1027 mmol, 0.5 M in THF) was added dropwise. The mixture was stirred at -10°C for 3 The mixture was stirred for 10 minutes. To this was added BocO (112 g, 516 mmHg) in THF (100 mL). A solution of 100 ml of 1 ml of HCl was added dropwise with stirring at -10°C. The mixture was stirred for 1 hour, then partitioned with hydrogen chloride solution (500 mL, 2N). The combined organic layer was extracted with brine (200 mL x 3). The resulting organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was purified by FCC to give tert-butyl N-(2-chloropyridin-3-yl) The carbamate (89 g, 83%) was obtained as an off-white solid.
[0518] Step B: tert-Butyl(2-bromo-4-nitropyridin-3-yl)carba In a 3 L, 4-neck round-bottom flask purged and maintained with an inert atmosphere of nitrogen, add THF tert-Butyl N-(2-chloropyridin-3-yl)carba in (1600 mL) A solution of methyl methyl ester (105 g, 459 mmol) and tetramethylethylenediamine (11 The resulting solution was cooled to -78°C with stirring, and n- BuLi (405 mL, 2.5 M) was added dropwise. The solution was warmed to -40°C and stirred for 1 hour. The resulting solution was cooled to -78°C and N,N-dimethylformamide (84 g 1.2 mol) was added dropwise and stirred for 1 hour. The resulting solution was diluted with saturated ammonium chloride. The mixture was partitioned with aqueous ethanol (500 mL) and extracted with ethyl acetate (200 mL x 3). The organic layer was washed with brine (200 mL x 3), dried over anhydrous sodium sulfate, and filtered. The residue was purified by FCC to give tert-butyl N-(2-chloro-4 -formylpyridin-3-yl)carbamate (75 g, 64%) was obtained as a pale yellow solid. Ta.
[0519] Step C: 3-amino-2-chloroisonicotinaldehyde. In a purged and maintained 3 L 4-neck round bottom flask was added tert- Butyl N-(2-chloro-4-formylpyridin-3-yl)carbamate (75g, A solution of 292 mmol of trifluoroacetic acid (3 00 mL) was added dropwise with stirring. The resulting solution was warmed to room temperature and stirred for 12 hours. Afterwards, the mixture was partitioned with a saturated solution of sodium carbonate (800 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was suspended in n-hexane (200 mL) and stirred for 20 minutes. was collected by filtration to give 3-amino-2-chloropyridine-4-carbaldehyde (30 g, 66%) as a yellow solid. MS (ESI): mass calculated for C6H5ClN2O, 1 56.01; m / z observed, 157 [M+H] + . 1 H NMR (300 MHz, CDC) l3)δ 9.99(s,1H),7.89(d,J=4.8Hz,1H),7.38( d,J=5.1HZ,1H),6.56(br s,2H).
[0520] Step D: 2-(3-Bromophenyl)-8-chloropyrido[3,4-d]pyrimidin In a 250 mL three-neck round-bottom flask purged and maintained with an inert atmosphere of nitrogen, add water ( 3-Amino-2-chloropyridine-4-carbaldehyde (28 g, 179 mL) in 56 mL (3-bromophenyl)methanamine (83 g, 446 mmol), t ert-butyl hydrogen peroxide (32 g, 359 mmol), pyridine (1.5 g, 19 mmol), 1000 mg of HCl (1.25 g, 18 mmol) and I2 (4.6 g, 18 mmol) were added. The resulting solution was heated to 90 °C. After 12 hours, the resulting mixture was cooled to room temperature and ethyl acetate (500 mL) was added. The resulting mixture was washed with brine (100 mL x 3), and the organic layer was extracted with anhydrous sodium sulfate The residue was purified by FCC to give 2-(3-bromophenoxyethanol). (3,4-d)pyrimidine (18 g, 31%) as a pale yellow solid And got it.
[0521] Step E: 2-(3-bromophenyl)pyrido[3,4-d]pyrimidin-8-amine In a 250 mL sealed tube, add 2-(3-bromophenyl)-8-chloropyridin [3,4-d ]pyrimidine (18 g, 56 mmol) and a solution of NH3 in IPA (180 mL, 2 M) The resulting solution was heated to 145°C. After 12 hours, the resulting mixture was cooled to room temperature. The resulting residue was diluted with DCM (1000 mL) and 0 mL × 3), and the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The resulting solid was recrystallized from ethyl acetate, and the solid was collected by filtration to give 2-(3-bromo-2-methyl-2-propanol). (bromophenyl)pyrido[3,4-d]pyrimidin-8-amine (10.1 g, 60%) Obtained as a light brown solid. MS(ESI):C 13 Calculated mass of H9BrN4: 300.0 ; m / z measured value, 301.1 [M+H] + . 1 H NMR (300 MHz, DMSO-d 6)δ 9.61(s,1H),8.94(s,1H),8.69(d,J=8.1Hz ,1H),8.35(br s,2H),7.95(d,J=6.1Hz,1H),7. 78(d,J=7.8Hz,1H),7.54(t,J=7.9Hz,1H),7.13 (d, J = 6.0 Hz, 1 H).
[0522] Intermediate 29: 2-(3-bromophenyl)pyrido[3,4-d]pyrimidine-8(7H )-on.
[0523] [ka]
[0524] 2-(3-bromophenyl)-8-chloropyrido[3,4-d]pyrimidine in a flask [Intermediate 28: Step D, 2.0 g, 6.2 mmol], hydrogen chloride (10 mL, 6N) , and THF (10 mL) were added. The resulting solution was stirred at 80° C. for 2 hours. The mixture was cooled to room temperature and the pH was adjusted to 8 with saturated aqueous sodium bicarbonate. The mixture was extracted with ethyl acetate (50 mL × 3), and the combined organic layer was concentrated to brown color to give 2-( 3-bromophenyl)pyrido[3,4-d]pyrimidin-8(7H)-one (1.6 g, 85%) as a pale yellow solid. MS(ESI): C 13 Calculated mass of H8BrN3O , 301.0; m / z actual value, 302.0 [M+H] + .
[0525] Intermediate 30: (R)-2-Thiazol-2-ylbut-3-yn-2-ol.
[0526] [ka]
[0527] In a 5 L, four-necked round-bottom flask, add ethynylmagnesium bromide under an inert atmosphere of nitrogen. A solution of 1-(1,3-thiazolinone) was added to the solution. (azol-2-yl)ethan-1-one (60 g, 472 mmol) was added to the mixture at room temperature with stirring. After 2 hours, the resulting solution was added dropwise to a saturated aqueous solution of ammonium chloride (900 mL The resulting mixture was partitioned with ethyl acetate (600 mL × 3). The extracted and combined organic layers were washed with brine (600 mL x 2) and anhydrous sodium sulfate. The crude residue of the (R) and (S) enantiomers (65 g, 90%) was subjected to chiral preparative SFC (CHIRALPAK IG 4.6 × 50 mm, 3 Further purification was performed with the mobile phase CO2 (80%), MeOH (0.1% DEA). (R)-2-(1,3-thiazol-2-yl)buta- 3-yn-2-ol (21 g, 32%, >97% ee) as a yellow solid, (S)-2 -(1,3-thiazol-2-yl)but-3-yn-2-ol (Intermediate 31, 21g (R)-2-(1,3-thiazol-2-yl)butadiene (32%) was obtained as a yellow solid. Data for 3-yn-2-ol: MS (ESI): mass calculated for C7H7NOS, 15 3.0; m / z observed, 153.9 [M+H] + . 1 H NMR (400 MHz, CDC) l3)δ 7.78(d,J=3.3Hz,1H),7.36(d,J=3.3Hz,1 H),3.66(s,1H),2.72(s,1H),1.98(s,3H). [α] 2 0 D =-34.6.5 (c=0.54 in MeOH).
[0528] Intermediate 31: (S)-2-Thiazol-2-ylbut-3-yn-2-ol.
[0529] [ka]
[0530] Chiral separation as described in Intermediate 30 affords (S)-2-(1,3-thiazol-2-yl) ) but-3-yn-2-ol (21 g, 32%, >97% ee) was obtained as a yellow solid. MS (ESI): Calculated mass for C7H7NOS, 153.0; observed m / z, 153. 9[M+H] + . 1 H NMR(400MHz,CDCl3)δ 7.78(d,J=3 .3Hz,1H),7.36(d,J=3.3Hz,1H),3.66(s,1H),2 .72(s,1H), 1.98(s,3H). [α] 20 D =+35.3(c in MeOH =0.51).
[0531] Intermediate 32: (R)-2-(5-methylisoxazol-3-yl)but-3-yne -2-all.
[0532] [ka]
[0533] In a 1 L round bottom flask purged and maintained with an inert atmosphere of nitrogen, ethynylmagnesium bromide was added. The vessel was cooled to 0° C. and THF (20 1-(5-methyl-1,2-oxazol-3-yl)ethan-1-one ( A solution of 20 g (160 mmol) of HCl was added dropwise with stirring. The resulting solution was warmed and The mixture was stirred at 25°C for 2 hours. The resulting solution was cooled to 0°C and a saturated aqueous solution of ammonium chloride ( 300 mL) was added, followed by water (200 mL). The resulting mixture was diluted with ethyl acetate ( The mixture was extracted with 200 mL of water and the combined organic layer was washed with brine (200 mL). The layer was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The resulting residue was purified by FCC( Purification with 0:1 to 1:10 ethyl acetate and petroleum ether gradient gave racemic 2-(5-methyl-2 ... ethyl-1,2-oxazol-3-yl)but-3-yn-2-ol (19.7 g, 8 2%) as a yellow oil. 18 g of the resulting material was analyzed by preparative chiral SFC (Pheno menex Lux 5u Cellulose-4, 5x25cm, 5μm, mobile phase, CO2 (70%), IPA:HEX = 1:1 (30%); detection at λ = 220 nm This was further purified to give (R)-2-(5-methyl-1,2-oxazol-3-yl)but- 3-yn-2-ol (5.1 g, 28%, >97 ee) as a yellow solid, (S)-2 -(5-methyl-1,2-oxazol-3-yl)but-3-yn-2-ol (intermediate Compound 33 (5.1 g, 28%, >97 ee) was obtained as a yellow solid. Data for (ethyl-1,2-oxazol-3-yl)but-3-yn-2-ol: MS( ESI): calculated mass of C8H9NO2, 151.1; observed M / z, 152.0 [M +H] + 。 1 H NMR(400MHz,DMSO-d6)δ 6.36(s,1H), 6.25(d,J=0.6Hz,1H),3.51(s,1H),2.38(s,3H) ,1.67(s,3H) 。 [α] 20 D =-11.3 (c=0.51 in MeOH).
[0534] Intermediate 33: (S)-2-(5-methylisoxazol-3-yl)but-3-yne -2-all.
[0535] [ka]
[0536] Chiral separation as described in Intermediate 32 afforded (S)-2-(5-methyl-1,2-oxa-1,4-diol). (3-yl)but-3-yn-2-ol (5.1 g, 28%, >97% ee) Obtained as a yellow solid. MS (ESI): Mass calculated for C8H9NO2, 151.1; m / Actual z value: 152.0 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 6.36(s,1H),6.25(d,J=0.6Hz,1H),3.51(s,1H ),2.38(s,3H),1.67(s,3H). [α] 20D =+8.27(MeO c=0.54).
[0537] Intermediate 34: 2-(3-iodophenyl)-4-methylpyrido[3,4-d]pyrimidin phen-8-amine.
[0538] [ka]
[0539] Step A: tert-Butyl(2-chloro-4-(1-hydroxyethyl)pyridine (3-yl)carbamate. In a 500 mL four-neck round-bottom flask, an inert atmosphere was maintained with nitrogen. To the solution, tert-butyl N-(2-chloropyridine-3-yl)pyridine in THF (200 mL) was added. (yl) carbamate (20 g, 87 mmol), TMEDA (22 g, 191 mmol) The resulting solution was cooled to -78°C, and then n-BuLi (76.8 mL, The resulting solution was warmed to -30°C and stirred for 30 minutes. After that, it was cooled to -78°C and acetaldehyde in THF (43.6 mL, 5 M) was added. The resulting solution was stirred at -78°C for 30 minutes. The resulting solution was warmed to 0°C, followed by addition of saturated sodium chloride solution. Aqueous ammonium chloride solution (300 mL) was added, and the resulting solution was diluted with ethyl acetate (500 mL) The combined organic layers were washed with brine (500 mL) and anhydrous sodium sulfate. The mixture was dried over silica gel, filtered, and concentrated to dryness. The residue was purified by FCC (1:3, ethyl acetate / petroleum ethanol). tert-butyl N-[2-chloro-4-(1-hydroxyethyl ether] )pyridin-3-yl]carbamate (21 g, 88%) as a white solid.
[0540] Step B: tert-Butyl(4-acetyl-2-chloropyridin-3-yl)carbamate In a 500 mL three-neck round-bottom flask purged and maintained with an inert atmosphere of nitrogen, , tert-butyl N-[2-chloro-4-(1-hydroxyethyl)pyridine-3- [yl]carbamate (21 g, 77 mmol), DMSO (210 mL), and 2-iodopropyl Isobenzoic acid (43.2 g, 154 mmol) was added, and the resulting solution was stirred at room temperature for 3 hours. The resulting mixture was extracted with ethyl acetate (500 mL × 2). The combined organic layers were washed with brine (500 mL) and extracted with anhydrous sodium sulfate. The mixture was dried over ice, filtered, and concentrated to dryness. This gave tert-butyl N-(4-amyl) Cetyl-2-chloropyridin-3-yl)carbamate (18 g, 86%) was obtained as a yellow solid. This was used directly in the next step.
[0541] Step C: 1-(3-amino-2-chloropyridin-4-yl)ethan-1-one. In a 500 mL three-neck round bottom flask purged and maintained with an intermediate atmosphere of nitrogen, DCM (1 tert-Butyl N-(4-acetyl-2-chloropyridin-3-yl) ) carbamate (18 g, 66 mmol) and trifluoroacetic acid (90 mL) After 12 hours, the resulting mixture was concentrated to dryness, and the pH of the residue was adjusted to 100 with saturated sodium bicarbonate. The acid value was adjusted to 7 with an aqueous thorium solution. The resulting mixture was extracted with ethyl acetate (500 mL × 2). The combined organic layers were washed with brine (300 mL) and dried over anhydrous sodium sulfate. The mixture was dried, filtered, and concentrated to dryness. 4-yl)ethan-1-one (8.5 g, 75%) was obtained as a yellow solid and carried on to the next step. Used as is.
[0542] Step D: N-(4-acetyl-2-chloropyridin-3-yl)-3-iodobenzyl In a 250 mL three-neck round bottom flask purged and maintained with an inert atmosphere of nitrogen, 1-(3-amino-2-chloropyridine-4-yl)-2-isopropyl ether in 1,4-dioxane (240 mL) A solution of 3-iodobenzoyl chloride ( 19 g, 70 mmol), and DIEA (9.1 g, 70 mmol) were added. The solution was heated at 110° C. After 12 hours, the resulting solution was cooled and water (300 mL) was added. The resulting mixture was extracted with ethyl acetate (300 mL × 2). The combined organic layer was Wash with brine (300 mL), dry over anhydrous sodium sulfate, filter, and concentrate to dryness The residue was purified by FCC (1:5, ethyl acetate / petroleum ether) to give N-(4-acetate). (2-chloropyridin-3-yl)-3-iodobenzamide (9.3 g, 66%) was obtained as a yellow solid.
[0543] Step E: 8-chloro-2-(3-iodophenyl)-4-methylpyrido[3,4- d] Pyrimidine. In a 40 mL three-necked round-bottom flask, add N-(4-acetyl-2-chloropyrimidine) Lysin-3-yl)-3-iodobenzamide (1.9 g, 4.7 mmol) and IPA NH3 in (25 mL, 2 M) was added. The resulting solution was heated at 90 °C. After 2 h, The resulting mixture was cooled, filtered, and the collected solid was washed with IPA (50 mL) to give 8- Chloro-2-(3-iodophenyl)-4-methylpyrido[3,4-d]pyrimidine (6 0.2g, 70%) as a yellow solid.
[0544] Step F: 2-(3-iodophenyl)-4-methylpyrido[3,4-d]pyrimidin In a 300 mL pressure tank reactor, add 8-chloro-2-(3-iodophenyl)-8-amine. (4-methylpyrido[3,4-d]pyrimidine (6.2 g, 16 mmol), IP NH3 in A (120 mL, 2 M) and condensed ammonia (60 mL) were added. The resulting solution was stirred in an autoclave at 145°C. After 12 hours, the vessel was cooled to room temperature and the solid was The solid was collected by filtration. The resulting solid was washed with MeOH (100 mL) and dried to give , 2-(3-iodophenyl)-4-methylpyrido[3,4-d]pyrimidin-8-amine The compound (3.7 g, 63%) was obtained as a red solid. MS(ESI): C 14 H 11 IN4 Calculated mass, 362.0; observed m / z, 363.0 [M+H] + . 1 H NMR (30 0MHz,DMSO-d6)δ 9.03(s,1H),8.70(d,J=8.1Hz ,1H),7.99(d,J=5.7Hz,1H),7.90(d,J=7.8Hz,1 H),7.44(s,2H),7.35(t,J=7.8Hz,1H),7.07(d, J = 5.7 Hz, 1H), 2.87 (s, 3H).
[0545] Intermediate 35: 2-(3-bromophenyl)-4-(trifluoromethyl)pyridin [3, 4-d]pyrimidin-8-amine.
[0546] [ka]
[0547] Step A: tert-Butyl (2-chloropyridin-3-yl)carbamate. Nitrogen In a 2 L, three-necked round-bottom flask, maintained at 4°C under an inert atmosphere, was added 2-chloropyridine-3-amine. A solution of 50 g (389 mmol) of ethanol in 500 mL of THF was added. Cool to 10°C, followed by sodium bis(trimethylsilyl)amide (430 mL, 85 6 mmol) was added over 30 min. Then, (Boc)2O in THF (200 mL) (94 g, 429 mmol) was added dropwise and the resulting solution was stirred at -10°C. After a period of time, the pH of the resulting solution was adjusted to 7 with hydrogen chloride (2N) and ethyl acetate (1000 mL) was added. The combined organic layers were washed with brine (1000 mL) and anhydrous sodium sulfate. The mixture was dried over sodium, filtered, and concentrated to dryness. The resulting residue was diluted with FCC (1:10, acetic acid Ethyl acetate / petroleum ether) to obtain tert-butyl N-(2-chloropyridine-3 -yl)carbamate (70 g, 79%) was obtained as a white solid.
[0548] Step B: tert-Butyl N-[2-chloro-4-(2,2,2-trifluoro- 1,1-dihydroxyethyl)pyridin-3-yl]carbamate. Nitrogen inert atmosphere In a 500 mL three-necked round bottom flask purged and maintained with tert-butyl N-(2 -chloropyridin-3-yl)carbamate (20 g, 87 mmol), TMEDA (2 2g, 192mmol) and THF (200mL) were added. Then, the mixture was stirred at -78°C. While stirring, n-BuLi (76.8 mL, 1.5 M) was added dropwise. The mixture was stirred at 78°C for 30 minutes, and then at -40°C for 30 minutes. ,2-trifluoro-N-methoxy-N-methylacetamide (34 g, 218 mmol) ) was added dropwise with stirring at -78°C. The resulting mixture was stirred at -40°C for 30 minutes. The mixture was then partitioned with saturated aqueous ammonium chloride (100 mL). The mixture was extracted with ethyl acetate (200 mL x 2). The combined organic layer was washed with brine (100 mL). The residue was washed, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. 0, ethyl acetate / petroleum ether) to obtain tert-butyl N-[2-chloro-4 -(2,2,2-trifluoro-1,1-dihydroxyethyl)pyridin-3-yl]ca The carbamate (26 g, 87%) was obtained as a white solid.
[0549] Step C: 1-(3-amino-2-chloropyridine-4-yl)-as trifluoroacetate salt (yl)-2,2,2-trifluoroethane-1,1-diol. In a 1 L three-necked round-bottom flask kept agitated, tert-butyl N-[2-chloro- 4-(2,2,2-trifluoro-1,1-dihydroxyethyl)pyridin-3-yl] Carbamate (26 g, 76 mmol), trifluoroacetic acid (130 mL), and DCM (260 mL) was added and heated at room temperature. After 4 hours, the resulting mixture was concentrated to dryness and 1- (3-amino-2-chloropyridin-4-yl)-2,2,2-trifluoroethane-1 ,1-diol, trifluoroacetate (28 g, crude) was obtained as a yellow solid.
[0550] Step D: 2-(3-bromophenyl)-8-chloro-4-(trifluoromethyl) -1H,2H-pyrido[3,4-d]pyrimidine. In a 500 mL pressure tank reactor, 1-(3-amino-2-chloropyridin-4-yl)-2,2-trifluoroacetate ,2-Trifluoroethane-1,1-diol (10 g, 28 mmol), 3-bromobenzyl Ammonia aldehyde (38 g, 206 mmol), 30% aqueous ammonia (12 g), and A CN (200 mL) was added, and the resulting solution was stirred at 52°C for 16 hours, then heated to 90°C. The resulting mixture was concentrated to dryness and diluted with FCC (1:5, ethyl acetate). Purification with ethanol / petroleum ether gave 2-(3-bromophenyl)-8-chloro-4-(trimethylsilyl)-2-(3-bromophenyl)- Fluoromethyl)-1H,2H-pyrido[3,4-d]pyrimidine (13 g, crude) Obtained as a coloured solid.
[0551] Step E: 2-(3-bromophenyl)-8-chloro-4-(trifluoromethyl) Pyrido[3,4-d]pyrimidine. 250 mL of ethanol was purged and maintained under an inert atmosphere of nitrogen. In a three-necked round-bottom flask, add 2-(3-bromophenyl)-8-chloro-4-(trifluoromethyl) Methyl)-1H,2H-pyrido[3,4-d]pyrimidine (12 g, 31 mmol), C H3CN (120 mL), and 2,3-dichloro-5,6-dicyanobenzoquinone (6. 96 g) was added. The resulting solution was stirred at 25°C for 2 hours. Saturated aqueous sodium bicarbonate The pH of the solution was adjusted to 8 with HCl. The resulting mixture was extracted with DCM (100 mL × 3). The combined organic layers were washed with brine (100 mL) and dried over anhydrous sodium sulfate. The residue was extracted with FCC (1:10, ethyl acetate / petroleum ether) Purification yielded 2-(3-bromophenyl)-8-chloro-4-(trifluoromethyl)pyridine. Do[3,4-d]pyrimidine (5.5 g, 46%) was obtained as a yellow solid.
[0552] Step F: 2-(3-bromophenyl)-4-(trifluoromethyl)pyridin [3, 4-d]pyrimidin-8-amine. In a 250 mL pressure tank reactor, 2-(3-bromo (phenyl)-8-chloro-4-(trifluoromethyl)pyrido[3,4-d]pyrimidine (4.5 g, 12 mmol) and NH3 in IPA (90 mL, 2 M) were added. The resulting solution was stirred for 16 hours at 145° C. The reaction mixture was cooled and the solid was collected by filtration. To the solid was added MeOH (30 mL) and the mixture was stirred for 1 hour. The solid was collected by filtration. 2-(3-bromophenyl)-4-(trifluoromethyl)pyrido[3,4-d] ... Imidine-8-amine (3.9 g, 91%) was obtained as a yellow solid. MS (ESI): C 14 Calculated mass for HBrFN: 367.9; observed m / z: 369.0 [M+H] + . 1 H NMR(300MHz,DMSO-d6)δ 8.92(s,1H),8.6 6(d,J=8.1Hz,1H),8.12(d,J=6.0Hz,1H),7.91( br s,2H),7.79(d,J=7.2Hz,1H),7.56(t,J=7.8 Hz,1H),7.00-6.97(m,1H). 19 F NMR (282 MHz, DM SO-d6,ppm):δ-65.26.
[0553] Intermediate 36: 2-(3-bromophenyl)-5-methylpyrido[3,4-d]pyrimidin phen-8-amine.
[0554] [ka]
[0555] Step A: tert-Butyl N-(2-chloro-5-methylpyridin-3-yl)carbonyl In a 1 L, 3-necked round-bottom flask maintained under an inert purged atmosphere of nitrogen, add T 2-Chloro-5-methylpyridin-3-amine (19 g, 133 mL) in HF (190 mL) The resulting solution was cooled to -10°C and then a solution of sodium bis(trimethylsilyl) Trimethylsilyl)amide (147 mL, 2 M) was added over 30 minutes. (Boc)2O (32 g, 147 mmol) in 320 mL of water was added dropwise. The resulting solution was stirred at −10° C. After 2 h, the pH of the resulting solution was adjusted to 7 with hydrogen chloride (2N). The combined organic layer was washed with brine (50 0 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was purified by FCC (1:11, ethyl acetate / petroleum ether) to give tert-butyl N-(2-chloro-5-methylpyridin-3-yl)carbamate (32 g, 99%) Obtained as a pale yellow solid.
[0556] Step B: tert-Butyl N-(2-chloro-4-formyl-5-methylpyridine) (-3-yl)carbamate. A 500 mL three-necked flask was purged and maintained with an inert atmosphere of nitrogen. In a round-bottom flask, tert-butyl N-(2-chloro-5-methyl-2-methylpropional) in THF (200 mL) was added A solution of ethyl pyridin-3-yl)carbamate (20 g, 82 mmol) and TMEDA (21 g, 181 mmol) was added. The vessel was cooled to -78 °C and n-BuLi (72 m L, 2.5 M) was added dropwise. The resulting solution was stirred at -35°C for 30 minutes. The resulting solution was cooled to -78°C and N,N-dimethylformamide (15 g, 205 mmol) was added. was added dropwise with stirring. After 30 minutes, saturated aqueous ammonium chloride solution (200 mL) The resulting mixture was extracted with ethyl acetate (500 mL x 2). , washed with brine (500 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was purified by FCC (1:5, ethyl acetate / petroleum ether) to give tert-bromo-2-methylpropional. ethyl N-(2-chloro-4-formyl-5-methylpyridin-3-yl)carbamate (11.9 g, 53%) was obtained as a yellow solid.
[0557] Step C: 3-amino-2-chloro-5-methylpyridine-4-carbaldehyde. In a 500 mL three-neck round-bottom flask, which had been purged and maintained at room temperature, was added DCM (120 ml). tert-Butyl N-(2-chloro-4-formyl-5-methylpyridine-3 A solution of 12 g (44 mmol) of 2-methyl-2-thiazolinone (12 g, 44 mmol) and trifluoroacetic acid (60 m After 12 hours, the resulting mixture was concentrated to dryness, and the residue was dissolved in saturated sodium bicarbonate. The mixture was diluted with aqueous thorium hydroxide solution until the pH reached 7. The resulting mixture was diluted with ethyl acetate (500 ml) The combined organic layer was washed with brine (500 mL) and anhydrous sodium sulfate. Dry over sodium, filter, and concentrate to dryness with 3-amino-2-chloro-5-methyl Pyridine-4-carbaldehyde (7 g, 93%) was obtained as a yellow solid.
[0558] Step D: 2-(3-bromophenyl)-8-chloro-5-methylpyrido[3,4- d] Pyrimidine. In a 50 mL sealed tube, add 3-amino-2-chloro-5-methylpyridine- 4-Carboxaldehyde (1.0 g, 5.8 mmol), 3-bromobenzene-1-carboxylate Cimidamide hydrochloride (1.7 g, 7.1 mmol), tert-butanol (20 mL), TEA (0.6 g) and pyridine (1.2 g) were added, and the resulting solution was heated at 90° C. for 14 hours. This procedure was repeated five times, and the combined reaction mixture was cooled to room temperature and diluted with water (50 The resulting mixture was extracted with ethyl acetate (500 mL x 3). The organic layer was washed with hydrogen chloride (500 mL, 1N) and brine (500 mL) and The residue was dried over sodium sulfate, filtered, and concentrated to dryness. Purify with ethyl acetate / petroleum ether to obtain 2-(3-bromophenyl)-8-chloro-5-methyl Rupirido[3,4-d]pyrimidine (4.2 g, 35%) was obtained as a yellow solid.
[0559] Step E: 2-(3-bromophenyl)-5-methylpyrido[3,4-d]pyrimidin In a 250 mL pressure tank reactor, 2-(3-bromophenyl)-8-amine was added. Chloro-5-methylpyrido[3,4-d]pyrimidine (4.2 g, 13 mmol) and I NH3 in PA (84 mL, 2 M) was added, and the resulting solution was heated in an oil bath at 145 °C for 16 h. The reaction mixture was cooled, concentrated to dryness, and the solid was collected by filtration. A 250 mL pressure tank reactor was charged with NH3 in MeOH (84 mL, 7N) The resulting mixture was stirred in an oil bath at 145° C. for 16 hours. The reaction mixture was cooled and the solid was filtered off. The solid was added to Et2O (30 mL) and the mixture was stirred for 1 h and then filtered. The solid was recovered by Pyrimidin-8-amine (2.5 g, 63%) was obtained as a yellow solid. MS (ESI): C 14 H11 Calculated mass of BrN4, 314.0; observed m / z, 315.0 [M+H] + . 1 H NMR(300MHz,DMSO-d6)δ 9.62(s,1H),8.9 0(s,1H),8.68(d,J=7.8Hz,1H),7.83(s,1H),7. 75(d,J=8.7Hz,1H),7.53(t,J=7.8Hz,1H),7.29 (s,2H),2.46(s,3H).
[0560] Intermediate 37: 2-(3-iodophenyl)-6-methylpyrido[3,4-d]pyrimidin phen-8-amine.
[0561] [ka]
[0562] Step A: tert-Butyl N-(2-chloropyridin-3-yl)carbamate. In a 2 L, three-necked, round-bottom flask, maintained under an inert atmosphere with nitrogen, was added 500 mL of THF A solution of 2-chloropyridin-3-amine (50 g, 389 mmol) was added. The solution was cooled to -10°C and then sodium bis(trimethylsilyl)amide (430 mL (Boc)2O in THF (200 mL) was added over 30 min. (94 g, 428 mmol) was added dropwise and the resulting solution was stirred at -10°C. After a period of time, the pH of the resulting solution was adjusted to 7 with hydrogen chloride (2N) and ethyl acetate (1000 mL) was added. The combined organic layers were washed with brine (1000 mL) and The resulting residue was dried over sodium, filtered, and concentrated to dryness. ethyl acetate / petroleum ether) to give tert-butyl N-(2-chloropyridine-3- To the obtained product was obtained the methyl (methyl)carbamate (80 g, 90%) as a white solid.
[0563] Step B: tert-Butyl N-(2-chloro-4-formylpyridin-3-yl) Carbamate. A 500 mL, three-neck, round-bottom flask was purged and maintained with an inert atmosphere of nitrogen. In a solution of tert-butyl N-(2-chloropyridine-3-yl)-2-isopropyl ether in THF (200 mL) A solution of 20 g of methylcarbamate (87 mmol) and TMEDA (22.3 g, 191 mmol) was added. The vessel was cooled to -78°C and n-BuLi (78 mL, 2.5 M) was added. The resulting solution was stirred at -35°C for 30 minutes. The resulting solution was then heated to -78°C. Cool to RT, add N,N-dimethylformamide (16 g, 218 mmol) dropwise with stirring. After 30 minutes, saturated aqueous ammonium chloride solution (500 mL) was added, and the resulting The mixture was extracted with ethyl acetate (500 mL × 2). The combined organic layers were washed with brine (500 The residue was washed with FC C (1:5, ethyl acetate / petroleum ether) to give tert-butyl N-(2-chloro- (4-formylpyridin-3-yl)carbamate (28 g, 82%) was obtained as a white solid. And got it.
[0564] Step C: 3-amino-2-chloropyridine-4-carbaldehyde. 1000 mL In a three-necked round-bottom flask, tert-butyl N-(2-chloro- a solution of 4-formylpyridin-3-yl)carbamate (55 g, 214 mmol) Trifluoroacetic acid (270 mL) was added. After 12 hours, the resulting mixture was concentrated to dryness. The residue was diluted with saturated aqueous sodium bicarbonate solution until pH=7. The mixture was extracted with ethyl acetate (500 mL × 2). The combined organic layer was washed with brine (500 mL). The residue was washed, dried over anhydrous sodium sulfate, filtered and concentrated to dryness. 3, ethyl acetate / petroleum ether) to give 3-amino-2-chloropyridine-4-carboxylate. Rubaldehyde (19 g, 57%) was obtained as a yellow solid.
[0565] Step D: 3-Amino-6-bromo-2-chloropyridine-4-carbaldehyde. In a 500 mL three-neck round-bottom flask purged and maintained under an inert atmosphere of 1000 kJ / L, N,N-dimethylformamide was added. 3-Amino-2-chloropyridine-4-carbamates in ethylformamide (190 mL) A solution of borane (19 g, 121 mmol) and borane (2 After 1 hour, the resulting mixture was poured into ice water (1 000 mL), and the solid was collected by filtration and treated with 3-amino-6-bromo-2-chloro C. The resulting product was 4-methyl-4-pyridine-4-carbaldehyde (25 g, 87%) as a yellow solid.
[0566] Step E: 3-amino-2-chloro-6-methylpyridine-4-carbaldehyde. Into a 500 mL three-necked round-bottom flask purged and maintained under an inert atmosphere was added 1,4-dichloromethane. 3-Amino-6-bromo-2-chloropyridine-4-carbamate in xanthene (250 mL) A solution of methyl boronic acid (19 g, 106 mmol), water (50 mL), and methyl boronic acid (19 g, 319 mmol), potassium carbonate (71 g, 509 mmol), and Pd(dppf)C l2 (3.9 g, 5.3 mmol) was added. The resulting solution was stirred at 90 °C. After a period of time, the reaction mixture was cooled to room temperature and water (300 mL) was added. The combined organic layer was washed with brine (200 mL). The residue was diluted with FCC (1:5, acetic acid) and concentrated to dryness. Purify with ethyl acetate / petroleum ether to obtain 2-chloro-6-methylpyridine-4-carbamate. The aldehyde (6.6 g, 36%) was obtained as a yellow solid.
[0567] Step F: 8-chloro-2-(3-iodophenyl)-6-methylpyrido[3,4- d]pyrimidine. In a 40 mL sealed tube, add 3-aminopyrimidine in tert-butanol (26 mL). 2-chloro-6-methylpyridine-4-carbaldehyde (1.3 g, 7.6 mmol) ), 3-iodobenzene-1-carboximidamide (2.3 g, 9.2 mmol) , TEA (0.8 g, 7.6 mmol), and pyridine (1.5 g, 19 mmol) were added. The resulting solution was stirred at 90°C. After 12 hours, the resulting mixture was cooled to room temperature and Water (40 mL) was added, and the resulting mixture was extracted with ethyl acetate (60 mL x 3). The combined organic layers were washed with hydrogen chloride (50 mL, 2N) and brine (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The residue was purified by FCC( 1:10, ethyl acetate / petroleum ether) to give 8-chloro-2-(3-iodophenyl)- (3,4-d)pyrimidine (1.2 g, 33%) as a yellow solid And got it.
[0568] Step G: 2-(3-iodophenyl)-6-methylpyrido[3,4-d]pyrimidin In a 300 mL vial purged and maintained with an inert atmosphere of nitrogen, 8- Chloro-2-(3-iodophenyl)-6-methylpyrido[3,4-d]pyrimidine(4 0.8 g, 13 mmol), NH3 in IPA (90 mL, 2 M), and NH4OH (45 mL of 28% NH3 in water) was added. The resulting solution was stirred at 145°C. After 12 hours, The mixture was cooled, the solid collected by filtration, and the solid (3.5 g) was further purified by preparative HPLC. 2-(3-iodophenyl)-6-methylpyrido[3,4-d]pyrimidine-8- The amine (2 g, 45%) was obtained as a yellow solid. MS (ESI): C 14 H 11 IN4 Calculated mass, 362.2; observed m / z, 363.0 [M+H] + . 1 H NMR (30 0MHz,DMSO-d6)δ 9.42(s,1H),9.03(s,1H),8.6 7(d,J=8.1Hz,1H),7.89(d,J=7.8Hz,1H),7.55( br s,2H),7.35(t,J=5.7Hz,1H),6.86(s,1H),2 .42(s,3H).
[0569] Intermediate 38: (R)-7-ethynyl-6,7-dihydro-5H-cyclopenta[b]pi Lysin-7-ol.
[0570] [ka]
[0571] Step A: 6,7-Dihydro-5H-cyclopenta[b]pyridine 1-oxide. D (1Z)-N-(cyclopent-1-en-1-yl)ethane in CM (5000 mL) A stirred solution of meth-1-imine (250 g, 2.29 mol) was added to the reaction mixture under nitrogen atmosphere at 0°C. Chloroperoxybenzoic acid (454 g, 2.10 mol, 80% purity) was added in portions. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 2 hours. The resulting mixture was concentrated to dryness. The resulting residue was purified by FCC (20:1, CH2Cl2 / MeOH) to give 6,7- Dihydro-5H-cyclopenta[b]pyridine 1-oxide (220g, 71.08%) was obtained as a white solid. MS (ESI): mass calculated for C8H9NO, 135.0; m / z measured value: 136.2 [M+H] + .
[0572] Step B: 6,7-Dihydro-5H-cyclopenta[b]pyridin-7-ylacetate 6,7-Dihydro-5H-cyclopenta[b]pyridine 1- in Ac2O (2 L) A solution of 220 g of methyl 2-(2-hydroxybenzoate, 1.63 mol) of methyl 2-(2-hydroxybenzoate) was stirred at 100°C for 2 hours under a nitrogen atmosphere. The resulting mixture was concentrated to dryness and purified with FCC (3:1, petroleum ether / ethyl acetate). 6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl acetate ( 215 g, 74.5%) was obtained as an orange oil.
[0573] Step C: 6,7-Dihydro-5H-cyclopenta[b]pyridin-7-ol. E 6,7-Dihydro-5H-cyclopenta[b]pyridine-7- in tOH (500 mL) To a stirred solution of methyl methyl acetate (215 g, 1.21 mol) was added Et A solution of KOH (68.1 g, 1.21 mol) in OH (1.2 L) was added dropwise. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 1 hour. The mixture was concentrated to a volume of 1 L and extracted with DCM (1 L x 3). The combined organic layers were washed with brine (1 L). The residue was washed, dried over anhydrous Na2SO4, filtered and concentrated to dryness. (20:1, CH2Cl2 / MeOH) to give 5H,6H,7H-cyclopenta[ b]Pyridin-7-ol (140 g, 85.3%) was obtained as a light brown solid.
[0574] Step D: 5,6-Dihydro-7H-cyclopenta[b]pyridin-7-one. DC 6,7-Dihydro-5H-cyclopenta[b]pyridin-7-ol in M (1.5 L) (140 g, 1.04 mol) was added to a stirred solution of dioxomanganese ( The resulting mixture was stirred at room temperature under a nitrogen atmosphere. After 12 hours, the solid was collected by filtration and washed with DCM (500 mL x 3). The filtrate was concentrated to dryness, and the resulting residue was purified by FCC (5:1, petroleum ether / ethyl acetate). 5,6-dihydro-7H-cyclopenta[b]pyridin-7-one (80g, 58% ) as a dark green solid. MS (ESI): mass calculated for C8H7NO, 133.0; m / z measured value: 134.2 [M+H] + .
[0575] Step E: (R)-7-ethynyl-6,7-dihydro-5H-cyclopenta[b]pi Lysin-7-ol. Bromo(ethynyl)magnesium (1.4 L, 0.7 mol) was stirred. To the stirred solution, add 5,6-dihydro-7H-cyclopenta[b]pyridinium chloride in THF (800 mL). A solution of di-7-one (80 g, 0.7 mol) was added dropwise at 0°C under a nitrogen atmosphere. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 2 hours. The mixture was cooled to 0°C, and saturated aqueous ammonium chloride solution (1 L) was added. The combined organic layer was washed with brine (1 L) and extracted with anhydrous NaCl. After drying over 2SO4, it was filtered and concentrated to dryness. The resulting residue was diluted with FCC (20:1, CH2Cl2 / MeOH) to give racemic 7-ethynyl-6,7-dihydro-5H- Cyclopenta[b]pyridin-7-ol (56 g, 62%) was obtained as an off-white solid. Racemic 7-ethynyl-6,7-dihydro-5H-cyclopenta[b]pyridine- The (R) and (S) enantiomers of 7-ol (28g) were separated by chiral preparative SFC (Chir al-IC 4.6 x 100 mm, 5 μm; cosolvent: MeOH (0.1% DEA); gradient (B%): 10% to 50% in 4.0 min, hold at 50% for 2.0 min; flow rate: 4 ml / min; Temperature: 35°C; detector, UV 220nm) to separate (R)-7-ethynyl- 6,7-Dihydro-5H-cyclopenta[b]pyridin-7-ol (13.1 g, 47 %, 97% ee) as an off-white solid, bro-5H-cyclopenta[b]pyridin-7-ol (Intermediate 39, 13.1 g, 47%) (R)-7-ethynyl-6,7-dihydrochloride (97% ee) was obtained as an off-white solid. Data for dolo-5H-cyclopenta[b]pyridin-7-ol: MS(ESI): C1 Calculated mass for OHNO: 159.0; observed m / z: 160.0 [M+H] + . 1 H NMR(400MHz,CDCl3)δ 8.61-8.41(m,1H),7.68- 7.52(m,1H),7.24-7.15(m,1H),4.36(s,1H),3. 14-2.91(m,2H),2.78-2.68(m,1H),2.66(s,1H) ,2.58-2.36(m,1H). [α]20 D =-81.9(c=0.3 in MeOH 4).
[0576] Intermediate 39: (S)-7-ethynyl-6,7-dihydro-5H-cyclopenta[b]pi Lysin-7-ol.
[0577] [ka]
[0578] Chiral separation as described in Intermediate 38 affords (S)-7-ethynyl-6,7-dihydro-5 H-Cyclopenta[b]pyridin-7-ol (13.1 g, 47%, 97% ee) Obtained as a white solid. MS(ESI): 10 Calculated mass of H9NO: 159. 0; m / z measured value, 160.0 [M+H] + . 1 H NMR (400 MHz, CDCl3 )δ 8.61-8.41(m,1H),7.68-7.52(m,1H),7.24- 7.15(m,1H),4.36(s,1H),3.14-2.91(m,2H),2. 78-2.68(m,1H),2.66(s,1H),2.58-2.36(m,1H) [α] 20 D =+81.1(c=0.33 in MeOH).
[0579] Intermediate 40: 2-(3-iodophenyl)pyrido[3,4-d]pyrimidine-8(7H )-on.
[0580] [ka]
[0581] Step A: 2-(3-iodophenyl)-8-methoxypyrido[3,4-d]pyrimidine 3-iodophenyl)methanamine (7.7 g, 33 mmol), 4-hydroxy- TEMPO (450 mg, 2.61 mmol) and o-xylene (30 mL) were added at room temperature. To the mixed solution, 3-amino-2-methoxyisonicotinaldehyde (2.0 g, 13 m The resulting mixture was stirred at 120 °C under O2 (15 psi) for 16 h. After that, the suspension was filtered and the filter cake was washed with ethyl acetate (20 mL x 3). After rinsing, the product was dried under reduced pressure to give the title compound (1 g, 22%). was recrystallized from ethyl acetate (5 mL) to give 2-(3-iodophenyl)-8-methoxy Pyrido[3,4-d]pyrimidine (770 mg, 17%) was obtained as a yellow solid. MS (ESI):C 14 H 10 Calculated mass of IN3O: 363.0; measured m / z: 363. 9[M+H] + .
[0582] Step B: 2-(3-iodophenyl)pyrido[3,4-d]pyrimidine-8(7H )-one. In a 100 mL round-bottom flask, add pyridine hydrochloride (13.0 g, 112 mmol) ) and 2-(3-iodophenyl)-8-methoxypyrido[3,4-d]pyrimidine (1 The resulting mixture was stirred under N2 at 170 °C for 3 h. After stirring, the mixture was cooled to room temperature. Purification with ethanol / ethyl acetate yielded 2-(3-iodophenyl)pyrido[3,4-d]pyrimidinium. Zin-8(7H)-one (1.2 g, 70%) was obtained as a yellow solid. MS (ESI): C 13Calculated mass of H8IN3O, 349.0; observed m / z, 349.9 [M+H] + .
[0583] Intermediate 41: 2-Methylsulfanylpyrido[3,4-d]pyrimidin-8-amine.
[0584] [ka]
[0585] Step A: Methyl 5-[(E)-2-ethoxyethenyl]-2-(methylsulfanilide) (I)pyrimidine-4-carboxylate. 3 L of sucrose was purged and maintained under an inert atmosphere of nitrogen. In a four-necked round-bottom flask, add 5-bromo-2-(methylsulfanyl)pyrimidine-4-carboxylate. Methyl benzoate (130 g, 494 mmol), 1,4-dioxane (1.5 L), 2-[ (E)-2-ethoxyethenyl]-4,4,5,5-tetramethyl-1,3,2-diox Saborolane (198 g, 999 mmol), Pd(dppf)Cl2 (10.9 g, 14 0.9 mmol), water (300 mL), and K3PO4 (233 g, 1.10 mol) were added. The resulting solution was stirred at 80°C. After 16 hours, the resulting mixture was diluted with water (1.7 L). The combined organic layer was concentrated and the residue was purified by FCC( 5:95, ethyl acetate / petroleum ether) to give methyl 5-[(E)-2-ethoxy] ethenyl]-2-(methylsulfanyl)pyrimidine-4-carboxylate (87,6 9%) as a yellow solid. MS(ESI): C 11 H 14 Calculated mass of N2O3S , 254.3; m / z observed value, 255.0 [M+H] + .
[0586] Step B: 5-[(E)-2-ethoxyethenyl]-2-(methylsulfanyl)piperidin Imidine-4-carboxamide. In a 1 L sealed tube, add methyl 5-[(E)-2-ethoxyethyl] Thenyl]-2-(methylsulfanyl)pyrimidine-4-carboxylate (50g, 1 97 mmol) and NH3 in MeOH (500 mL, 7N). The mixture was stirred at 55° C. After 2 hours, the resulting mixture was concentrated to dryness to give 5-[(E)-2-ethoxybenzoate]. [xethenyl]-2-(methylsulfanyl)pyrimidine-4-carboxamide (47g , solid) was obtained, which was used in the next step without further purification. MS (ESI): C 10 H 13 Calculated mass of N3O2S, 239.3; observed m / z, 240.0 [M+H] + .
[0587] Step C: 2-(methylsulfanyl)-7H,8H-pyrido[3,4-d]pyrimidine In a 2 L round bottom flask, add 5-[(E)-2-ethoxyethenyl]-2- (Methylsulfanyl)pyrimidine-4-carboxamide (46g, 192), toluene (920 mL) and p-toluenesulfonic acid monohydrate (3.3 g, 19 mmol) were added. The resulting solution was stirred at 90°C. After 2 hours, the resulting mixture was cooled to 0°C in an ice / salt bath. After cooling, the resulting solution was diluted with 2 L of petroleum ether and the resulting solid was collected by filtration. The resulting organic filtrate was concentrated to dryness and washed with petroleum ether (100 mL x 3). -(methylsulfanyl)-7H,8H-pyrido[3,4-d]pyrimidin-8-one ( 31.4%, 85%) as a yellow solid. MS (ESI): C8H7N3OS Calculated value, 193.2; m / z observed value, 194.0 [M+H]+ .
[0588] Step D: 8-Chloro-2-(methylsulfanyl)pyrido[3,4-d]pyrimidin In a 1 L round-bottom flask, add 2-(methylsulfanyl)-7H,8H-pyrido[3,4 -d]pyrimidin-8-one (31.4 g, 163 mmol), ACN (500 mL), and POCl3 (73.7 g, 481 mmol) were added. The resulting solution was heated at 70 °C. After 2 hours, the resulting mixture was concentrated to dryness. Water (1 L) was added to the resulting residue in portions. The pH of the solution was adjusted to 8 with saturated aqueous sodium carbonate. The solid was collected by filtration. The filtrate was concentrated to dryness to give 8-chloro-2-(methylsulfanyl)pyrido[3,4-d] The pyrimidine (32.1 g, 93%) was obtained as a brown solid. MS (ESI): CHC Calculated mass of lN3S, 211.0; observed m / z, 212.0 [M+H] + .
[0589] Step E: 2-(methylsulfanyl)pyrido[3,4-d]pyrimidin-8-amine In a 1 L sealed tube, add 8-chloro-2-(methylsulfanyl)pyrido[3,4-d]pyridin. Imidine (32.1 g, 152 mmol) and NH3 in IPA (320 mL, 2 M) The resulting solution was heated at 145°C. After 16 hours, the resulting mixture was concentrated to dryness. , purified by FCC (3:1, DCM / ethyl acetate) to give 2-(methylsulfanyl)pyridine. Do[3,4-d]pyrimidin-8-amine (11.3 g, 39%) was obtained as a yellow solid. MS (ESI): Calculated mass for C8H8N4S, 192.1; observed m / z, 193. 0[M+H] + . 1 H NMR(300MHz,DMSO-d6)δ 9.3-9.2( m,1H),7.97-7.87(m,1H),7.06(s,2H),7.0-6.9 (m,1H), 2.7-2.6(m,3H).
[0590] Intermediate 42: 2-(5-bromo-2-isobutylphenyl)pyrido[3,4-d]pyridyl Mydi...
Claims
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof 【Chemical 1】 During the ceremony, R 1 is H or -CH 3 and R 2 is H or -CH 3 and R 3 is H, -C 1 -C 5 Alkyl, —OCH 3 , or -O-C 1 -C 3 Haloalkyl and R 4 is H or -CH 3 and portion 【Chemistry 2】 teeth, 【Chemistry 3】 and R aa is H or -CH 3 and R bb is H, -CH 3 , or -CF 3 and R cc is -CH 3 , -CD 3 , or -CH 2 CF 3 and portion 【Chemistry 4】 teeth, 【Chemistry 5】 and E is N or CH; F is O, S, NH, or NCH 3 and R a is H or -CH 3 and R b are H, D, -OH, F, and -C. 1 -C 5 Alkyl, —CH 2 OCH 3 , -C 1 -C 5 Haloalkyl, —NH 2 , cyclopropyl, or —CH 2 OH, R c is H, D, or CH 3 and R d is H, -CN, -CF 3 , -C 1 -C 5 Alkyl, —C 3 -C 6 cycloalkyl , —O—C 1 -C 3 Alkyl, —N(R 6 ) R 7 , 【Chemistry 6】 and During the ceremony, R 6 is H or -C 1 -C 3 is alkyl, R 7 is H, -C 1 -C 3 Alkyl, —SO 2 CH 3 , -COCH 3 , -C 1 -C 4 Ha alkyl, or -CH 2 CN or R 6 and R 7 is that they are combined Together with the nitrogen, portion 【Chemistry 7】 wherein m is 0 or 1 and p is 0 or 1; R 8 is H, F, or -C 1 -C 3 is alkyl, R 9 is H, F, or -C 1 -C 3 is alkyl, R e is H, -CD 3 , Br, -C 1 -C 5 Alkyl 、 -C 3 -C 6 cycloalkyl, 【Chemistry 8】 1 to 3 R g -C substituted with a group 1 -C 5 alkyl, wherein R g Ha-NH 2 , or F, R 10 is H or F, R 11 is H or F, R f is H, -CH 3 , or 【Chemistry 9】 and R h is -CH 3 , -NH 2 , or 【Chemistry 10】 and R i is H, -CH 3 , -CN, Br, 【Chemistry 11】 and R j is -NH 2 or 【Chemistry 12】 and R k is H, -CF 3 , I, Cl, Br, -CN, -C 1 -C 6 Alkyl, 【Chemistry 13】 and R 12 is H or -CH 3 and R 13 is H, -CH 3 , -CH 2 (C) (CH 3 ) 2 OH, -(CH 2 ) 3 CN, also Ha-(CH 2 ) 2 NH 2 and R 14 is H or -CH 3 and R l is H, -C 1 -C 4 Alkyl, —CF 3 , 【Chemistry 14】 and R m is H or -CH 3 and R n is -NH 2 and R o is H or -CH 3 and R p is H or -CH 3 and R q is H, -CN, F, Cl, -OCH 3 , -CF 3 , or -CH 3 and R s is -NH 2 or 【Chemistry 15】 and However, part 【Chemistry 16】 but 【Chemistry 17】 and each R 1 , R 2 , R 3 and R 4 If H, the part 【Chemistry 18】 teeth 【Chemistry 19】 or a pharmaceutically acceptable salt thereof, provided that:
2. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof. 【Chemistry 20】 During the ceremony, R 1 is H or -CH 3 and R 2 is H or -CH 3 and R 3 is H, -C 1 -C 5 Alkyl, —OCH 3 , or -O-C 1 -C 3 Haloalkyl and R 4 is H or -CH 3 and portion 【Chemical 21】 teeth, 【Chemical 22】 and R cc is -CH 3 , -CD 3 , or -CH 2 CF 3 and portion 【Chemical 23】 teeth, 【Chemistry 24】 and E is N or CH; F is O, S, NH, or NCH 3 and R a is H or -CH 3 and R b are H, D, -OH, F, and -C. 1 C 5 Alkyl, —CH 2 OCH 3 , -C 1 -C 5 Haloalkyl, —NH 2 , cyclopropyl, or —CH 2 OH, R c is H, D, or CH 3 and R d is H, -CN, -CF 3 , -C 1 -C 5 Alkyl, —C 3 -C 6 cycloalkyl , —O—C 1 -C 3 Alkyl, —N(R 6 ) R 7 , 【Chemistry 25】 and During the ceremony, R 6 is H or -C 1 -C 3 is alkyl, R 7 is H, -C 1 -C 3 Alkyl, —SO 2 CH 3 , -COCH 3 , -C 1 -C 4 Ha alkyl, or -CH 2 CN or R 6 and R 7 is that they are combined Together with the nitrogen, portion 【Chemical 26】 wherein m is 0 or 1 and p is 0 or 1; R 8 is H, F, or -C 1 -C 3 is alkyl, R 9 is H, F, or -C 1 -C 3 is alkyl, R e is H, -CD 3 , Br, -C 1 -C 5 Alkyl 、 -C 3 -C 6 cycloalkyl, 【Chemical 27】 1 to 3 R g -C substituted with a group 1 -C 5 alkyl, wherein R g Ha-NH 2 , or F, R 10 is H or F, R 11 is H or F, R f is H, -CH 3 , or 【Chemical Formula 28】 and R h is -CH 3 , -NH 2 , or 【Chemical 29】 and R i is H, -CH 3 , -CN, Br, 【Chemistry 30】 and R j is -NH 2 or 【Chemical 31】 and R k is H, -CF 3 , I, Cl, Br, -CN, -C 1 -C 6 Alkyl, 【Chemical 32】 and R 12 is H or -CH 3 and R 13 is H, -CH 3 , -CH 2 (C) (CH 3 ) 2 OH, -(CH 2 ) 3 CN, also Ha-(CH 2 ) 2 NH 2 and R 14 is H or -CH 3 and R l is H, -C 1 -C 4 alkyl, —CF3, 【Chemical 33】 and R m is H or -CH 3 and R n is -NH 2 and R o is H or -CH 3 and R p is H or -CH 3 and R q is H, -CN, F, Cl, -OCH 3 , -CF 3 , or -CH 3 and R s is -NH 2 or 【Chemical 34】 and However, part 【Chemistry 35】 but 【Chemical 36】 and each R 1 , R 2 , R 3 and R 4 If H, the part 【Chemical 37】 teeth 【Chemical Formula 38】 or a pharmaceutically acceptable salt thereof, provided that:
3. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof. 【Chemical 39】 During the ceremony, portion 【Chemistry 40】 teeth, 【Chemistry 41】 and portion 【Chemistry 42】 teeth, 【Chemistry 43】 and However, the above part 【Chemical 44】 but 【Chemistry 45】 and each R 1 , R 2 , R 3 and R 4 If H, the part 【Chemistry 46】 teeth, 【Chemistry 47】 or a pharmaceutically acceptable salt thereof, provided that:
4. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof. 【Chemistry 48】 During the ceremony, portion 【Chemistry 49】 teeth, 【Chemistry 50】 and portion 【Chemistry 51】 teeth, 【Chemistry 52】 or a pharmaceutically acceptable salt thereof.
5. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof. 【Chemistry 53】 During the ceremony, portion 【Chemical 54】 teeth, 【Chemistry 55】 and portion 【Chemical 56】 teeth, 【Chemical 57】 or a pharmaceutically acceptable salt thereof.
6. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof. 【Chemistry 58】 During the ceremony, portion 【Chemical Formula 59】 teeth, 【Chemistry 60】 and portion 【Hua 61】 teeth, 【Hua 62】 or a pharmaceutically acceptable salt thereof.
7. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof. 【Chemistry 63】 During the ceremony, R 1 is H, R 2 is H, R 3 is H, R 4 is H, portion 【Hua 64】 teeth, 【Chemistry 65】 and portion 【Hua 66】 teeth, 【Hua 67】 or a pharmaceutically acceptable salt thereof.
8. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof. 【Chemistry 68】 During the ceremony, R 1 is H, R 2 is H, R 3 is H or C 1 -C 5 is alkyl, R 4 is H, portion 【Chemical 69】 teeth, 【Chemistry 70】 and portion 【Chemical Formula 71】 teeth, 【Chemical 72】 or a pharmaceutically acceptable salt thereof.
9. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof. 【Chemical 73】 During the ceremony, R 1 is H, R 2 is H, R 3 is H or C 1 -C 5 is alkyl, R 4 is H, portion 【Chemical 74】 teeth, 【Chemistry 75】 and portion 【Chemical 76】 teeth, 【Chemical 77】 or a pharmaceutically acceptable salt thereof.
10. A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein: minutes 【Chemical Formula 78】 teeth 【Chemical Formula 79】 or a pharmaceutically acceptable salt thereof.
11. 2. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the moiety 【Chemistry 80】 teeth 【Chemistry 81】 or a pharmaceutically acceptable salt thereof.
12. 2. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the moiety 【Chemistry 82】 teeth 【Chemistry 83】 or a pharmaceutically acceptable salt thereof.
13. 2. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the moiety 【Chemistry 84】 teeth 【Chemistry 85】 or a pharmaceutically acceptable salt thereof.
14. 2. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the moiety 【Chemistry 86】 teeth 【Hua 87】 or a pharmaceutically acceptable salt thereof.
15. 10. The compound of claim 1 or a pharmaceutically acceptable salt thereof, In the formula, part 【Hua 88】 teeth 【Chemistry 89】 or a pharmaceutically acceptable salt thereof.
16. 2. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the moiety 【Chemistry 90】 teeth 【Chemistry 91】 and the part 【Chemistry 92】 teeth 【Chemistry 93】 or a pharmaceutically acceptable salt thereof.
17. 2. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the moiety 【Chemistry 94】 teeth 【Chemistry 95】 and the part 【Chemistry 96】 teeth 【Chemistry 97】 or a pharmaceutically acceptable salt thereof.
18. (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) -4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- yl)-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl ) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-6-methylpyrimido[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopteridin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-aminoquinazolin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) [phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl] -2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne- 2-all, (R)-3-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl] ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-3,4-dihydro-2,7-naphthyridine-2( 1H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-[2-[3-(3-amino-1-methyl-pyrazolo[4,3-b]pyridin phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-3-[2-[3-(3-amino-1H-pyrazolo[4,3-b]pyridine-5 -yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-ethoxypyrido[3,2-d]pyrimidin-6-yl)pyrimidin-6-yl)pyrimidin-6-yl)pyrimidin-6-yl (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-hydroxy-1-methyl-3-((3-(4-(methylamino)pyrido[ 3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) -4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one, (S)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl] -2-thiazol-2-yl-but-3-yn-2-ol, 1-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl ]ethynyl]cyclopentanol, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl] -2-(5-methylisoxazol-3-yl)but-3-yn-2-ol, 4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2 -methyl-but-3-yn-2-ol, (R)-3-[2-[3-(1-amino-7-isoquinolyl)phenyl]ethynyl]- 3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d ]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((5-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-5 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (R)-2-[3-[2-(7-hydroxy-5,6-dihydrocyclopenta[[b] pyridin-7-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidine- 8-on, (R)-4-(3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2- (thiazol-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-4-(3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d] (pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yne-2 - All, (R)-4-(3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2- (thiazol-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-4-(3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2- (thiazol-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) -5-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridine- 7-all, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 (-isobutylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin (3H)-(3-(3-yl)ethynyl)phenyl)pyrido[3,4-d]pyrimidine-4(3H)- on, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-((3-(8-amino-4-morpholinopyrido[3,4-d]pyrimidine (2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-3-((3-(8-amino-4-(dimethylamino)pyrido[3,4-d]pyridin (2-imidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-[2-[3-(4-amino-1H-imidazo[4,5-c]pyridine-2 -yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 (-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-7-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d ]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[pi]yl ta[b]pyridin-7-ol, (R)-7-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2 (-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-7-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2 (-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] [phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidinyl] phenyl-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl- rolidin-2-one, (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidine- 2-on, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidine- 2-on, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -thiazol-2-yl-but-3-yn-2-ol, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- (methylphenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one 、 (S)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one 、 (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidone lysin-2-one, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidone lysin-2-one, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- Methylphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)butanol -3-in-2-all, (R)-7-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 (-methylphenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidinyl] phenyl)ethynyl]-3-hydroxy-1-methyl-phenyl rolidin-2-one, (R)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidine- 2-on, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -(5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- methylphenyl)-2-(5-methylisoxazol-3-yl)but-3-yne-2 - All, (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d 3 ) Pyrrolidine-2 -on, (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imida zoll-7-ol, (R)-3-((3-(8-amino-4-(methylamino)pyrido[3,4-d]pyridyl (2-(2-(4 ... -on, (R)-7-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidinyl] [1,2-a]imidazo[2-phenyl-2-yl]phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazo 7-ol, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidinyl] phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl) ) pyrrolidin-2-one, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -(5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -thiazol-2-yl-but-3-yn-2-ol, (R)-7-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl ]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol, (R)-3-[2-[3-(8-amino-4-methyl-pyrido[3,4-d]pyrimidinyl] phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluorophenyl)ethynyl (triethyl)pyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(8-amino-5-bromopyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl (5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-3-[2-[3-(4-aminophthalazin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl -2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne- 2-all, (R)-3-((3-(8-amino-4-isopropylpyrido[3,4-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-[2-[3-[8-amino-5-(trifluoromethyl)pyrido[3,4 -d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrimidin-2-yl rolidin-2-one, (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin (3,4-d)pyrimidine-5-carbonyl Trill, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)pyrimidin-2-yl)pyrimidin-2-yl)pyrimidin-2-yl (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-iodopyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methyl isoxazol-3-yl)but-3-yn-2-ol, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-thiazole -2-yl-but-3-yn-2-ol, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methyl (1,3,4-oxadiazol-2-yl)but-3-yn-2-ol, 2-(3-((1H-pyrazol-5-yl)ethynyl)phenyl)-4-methylpyrazole do[3,4-d]pyrimidin-8-amine, (R)-4-(3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-methylquinazolin-6-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrido[3,4-d]pyrimidin-6-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-5-bromo-1,7-naphthyridin-2-yl] [phenyl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-8-fluoro-quinazolin-6-yl)phenyl] nyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-8-methoxyquinazolin-6-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(trifluoromethyl)quinazoline-6-yl) (phenyl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminothiazolo[4,5-c]pyridin-2-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-chloroquinazolin-6-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-8-amino-2-[3-[2-(3-hydroxy-1-methyl-2-oxo- Pyrrolidin-3-yl)ethynyl]phenyl]-1,7-naphthyridine-5-carbonite Lil, (R)-3-[2-[3-(5-amino-2,6-naphthyridin-3-yl)phenyl]phenyl ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-5-methyl-1,7-naphthyridin-2-yl] [phenyl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-5-phenylpyrido[3,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(1-methylpyrazol-4-yl)pyrazole Lido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1 -methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-[1-(2-hydroxy-2-methyl- propyl)pyrazol-4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl yl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(1H-pyrazol-4-yl)pyridin [3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl thyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(3,5-dimethyl-1-1H-pyrazoline [3,4-d]pyrimidin-2-yl]phenyl]ethynyl]- 3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-4-amino-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin (din-3-yl)ethynyl)phenyl)quinazoline-8-carbonitrile, (R)-3-[2-[3-[8-amino-5-(5-methyl-1H-pyrazole-4- pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydro hydroxy-1-methyl-pyrrolidin-2-one, (R)-phenyl 8-amino-2-[3-[2-(3-hydroxy-1-methyl-2 -oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidin benzophenone-5-carboxylate, (R)-3-((3-(8-amino-5-ethylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-isobutylpyrido[3,4-d]pyrimidine (2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone, (S)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone, (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)pyridin [3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl thyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-[1-(2-aminoethyl)pyrazole -4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3- hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)pyrido[3, 4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-8-methyl-pyrido[3,4-d]pyrimidinyl] phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-4-(3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl) (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(8-amino-4,5-dimethylpyrido[3,4-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[4-[8-amino-2-[3-[2-(3-hydroxy-1-methyl- 2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidin di-5-yl]pyrazol-1-yl]butanenitrile, (R)-3-((3-(4-aminothieno[2,3-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminooxazolo[5,4-d]pyrimidin-2-yl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(6-amino-9-methyl-9H-purin-8-yl)phenyl )ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl)- (phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol Lu, (R)-3-[2-[3-[8-amino-5-(1-piperidylmethyl)pyrido[3, 4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-7-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl ) phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Rule, (R)-3-[2-[3-[8-amino-5-[6-(trifluoromethyl)-3-pi lysyl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-2-methyl-pteridin-6-yl)phenyl ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) -4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-((3-(8-amino-5-neopentylpyrido[3,4-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((5-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 5-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl)- (phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol Lu, (R)-3-((3-(8-amino-4,6-dimethylpyrimido[5,4-d]pyrimidinyl) (2-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (2-methylthiazol-5-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (2-methylthiazol-5-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidinyl) (6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) -4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 (-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-5-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-5-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (thiazol-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, Racemic-8-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-5,6,7,8-tetrahydroquinolin-8-ol, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methylthiazol-2-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methylthiazol-2-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidine- 2-yl-6-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, (R)-tert-butyl 3-amino-5-[3-[2-(3-hydroxy-1-methyl) [0033] (2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]indazole-1-carboxylate carboxylate, (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pyridin (imidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)-1, 7-naphthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- rolidin-2-one, (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)-1,7-na Phthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-((3-(4-amino-2-(hydroxymethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-[2-[3-(3-amino-1H-indazol-5-yl)phenyl] ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-2-cyclopropylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-2-(trifluoromethyl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)- 4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-3-((3-(4-amino-2,7-dimethylpyrido[3,2-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-2H-pyrazolo[3,4-d]pyrimidine-2- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-2-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol Lu, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-2-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-3-[2-[3-(7-amino-5-methyl-thiazolo[5,4-d]pyrimidinyl] ethynyl)-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-methyl-phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imida zoll-7-ol, (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridine -7-all, 1-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4- methyl-phenyl]ethynyl]cyclopentanol, (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-7-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-(trifluoromethyl)thiazol-2-yl)buta-3 -in-2-all, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-(trifluoromethyl)thiazol-2-yl)buta-3 -in-2-all, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 1-Allyl-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one, Racemic-1-allyl-3-((3-(4-aminopyrido[3,2-d]pyrimidine-6 -yl-2-d)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol, Racemic-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- 1H-imidazol-4-yl)phenyl)-2-(1H-imidazol-4-yl)but-3-yn-2-ol 、 (R)-3-((3-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl )phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-(methoxymethyl)pyrido[3,2-d]pyridin (imidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-methoxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pyridin rimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d 3 ) Pi rolidin-2-one, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol, (R)-3-((3-(4-amino-2-ethylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-hydroxypyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methyl-1,3,4-oxadiazol-2-yl)butanol -3-in-2-all, (R)-3-((3-(7-aminothiazolo[4,5-d]pyrimidin-2-yl)pyrimidin-2-yl)pyrimidin-2-yl (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-methyl-7,8-dihydropyrido[4,3- d]pyrimidin-6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl) 1)pyrrolidin-2-one, (R)-4-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4 -methyl-phenyl]-2-(5-methylisoxazol-3-yl)but-3-yne -2-all, (R)-6-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-imidazo[1,5-a]pyrazin-8-one, (R)-3-((3-(8-amino-1,5-naphthyridin-2-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidinyl) (5H)-phenyl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) phenyl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4(3H)-one, (R)-3-hydroxy-1-methyl-3-((3-(4-(pyrrolidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-ol hmm, ((R)-3-hydroxy-1-methyl-3-((3-(pyrido[3,2-d]pyrimidinyl) (6-phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-amino-5,7,8,9-tetrahydro-6H-pyrimido) [5,4-c]azepin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-(piperidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-ol hmm, (R)-3-((3-(4-(3,3-dimethylazetidin-1-yl)pyrido[3, 2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrimidin rolidin-2-one, (R)-3-((3-(4-(ethylamino)pyrido[3,2-d]pyrimidine-6- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-hydroxy-3-((3-(4-(3-hydroxyazetidin-1-yl ) pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrro lysin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-(oxetan-3-yl) pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidine- 2-on, (R)-3-hydroxy-3-((3-(4-(3-methoxyazetidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidone Jin-2-On, (S)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-(3,3-difluoroazetidin-1-yl)pyrido[3 ,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-((3-(8-(azetidin-1-yl)-1,7-naphthyridine-2- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(1-(azetidin-1-yl)isoquinolin-7-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(azetidin-1-yl)quinolin-6-yl)phenyl )ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(cyclobutylamino)pyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1- methylpyrrolidin-2-one, (R)—N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)acetate Mido, (R)-3-((3-(4-(3-fluoroazetidin-1-yl)pyrido[3,2- d] pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-2-((6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine (3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)amino ) acetonitrile, (R)-3-((3-(4-((2,2-difluoroethyl)amino)pyrido[3,2 -d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrro lysin-2-one, (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)azetidin benzo-3-carbonitrile, (R)-3-((3-(4-(azetidin-1-yl)quinazolin-6-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(3-chloroazetidin-1-yl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-hydroxy-1-methyl-3-((3-(4-(3-(methylsulfonyl ) azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethyl nyl)pyrrolidin-2-one, (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- (3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)-N-methyl thiazetidine-3-carboxamide, (R)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (S)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(5-bromo-8-methyl-1,7-naphthyridin-2-yl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4,8-dimethylpyrido[3,2-d]pyrimidin-6-yl )phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) (phenyl)ethynyl)phenyl)-8-methyl-1,7-naphthyridine-5-carbonitrile, (R)-3-((3-(5,8-dimethyl-1,7-naphthyridin-2-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy- 1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy- 1-methylpyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-phenylpyrido[3,2- d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)—N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl acetamide, (R)—N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d) acetamide, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (3R,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3R,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3S,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3S,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3R,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3S,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidinyl) (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3S,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidinyl) (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3R,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (R)—N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d) methanesulfonamide, (R)-3-((3-(4-cyclopropylpyrido[3,2-d]pyrimidin-6-yl) (phenyl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-hydroxy-3-((3-(4-isopropylpyrido[3,2-d]pyridyl) (6-methyl-2-pyrrolidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidin-2-one, (1R,4R,5S)-4-((3-(4-amino-2-methylpyrido[3,2-d] pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (1S,4S,5R)-4-((3-(4-amino-2-methylpyrido[3,2-d] pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (1S,4S,5R)-4-((3-(4-aminopyrido[3,2-d]pyrimidine- 6-yl-2-d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[4.1.2.1] chloro[3.1.0]hexan-3-one, (1R,4R,5S)-4-((3-(4-aminopyrido[3,2-d]pyrimidine- 6-yl-2-d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[4.1.2.1] chloro[3.1.0]hexan-3-one, (R)-3-((3-(4-amino-8-cyclopentylpyrido[3,2-d]pyrimidin phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-hydroxy-1-methyl-3-((3-(4-(trifluoromethyl)pyrrolidone) Lido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one 、 (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) (phenyl)ethynyl)phenyl)pyrido[3,2-d]pyrimidine-4-carbonitrile, (R)-3-hydroxy-1-methyl-3-((3-(8-methyl-1,7-naphthyl) (phenyl)ethynyl)pyrrolidin-2-one, (1R,4R,5S)-4-((3-(4-amino-8-methylpyrido[3,2-d] pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (R)-3-((3-(4-amino-8-(aminomethyl)pyrido[3,2-d]pyridyl 2-(2-(phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-6-yl)phenylethynyl Jin-2-On, (R)-3-((3-(4-amino-8-isopropylpyrido[3,2-d]pyrimidinyl) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-((3-(4-amino-8-(trifluoromethyl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(4-amino-2,8-dimethylpyrido[3,2-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-8-(methyl-d 3 ) pyrido[3,2-d]pyri (6-(2 ...3-(2-(2-(2-(2-(3-(2-(2-(2-(2-( -on, (R)-3-((3-(4-amino-8-(piperidin-4-yl)pyrido[3,2- d]pyrimidin-6-yl-2-(phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-((3-(4-amino-2-fluoropyrido[3,2-d]pyrimidine- 6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (S)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (3R, 4S * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3rd and 4th rounds * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3S, 4S * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3S, 4R * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (R)-3-[2-[3-[4-amino-8-(dimethylamino)pyrido[3,2-d ]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine Jin-2-On, (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d] pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-[2-[3-[4-amino-8-(isopropylamino)pyrido[3,2 -d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrimidin-6-yl rolidin-2-one, (R)-3-[2-[3-[4-amino-8-(cyclopropylamino)pyrido[3, 2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(difluoromethoxy)pyrido[3,2 -d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrimidin-6-yl rolidin-2-one, (R)-3-[2-[3-[4-amino-8-(3,3-difluoroazetidine-1- pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydro hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-4-methyl-pyrimido[5,4-d]pyrimidinyl] ethynyl)-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-((3-(4-amino-8-cyclopropylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-[2-[3-(4-amino-8-pyrazol-1-yl-pyrido[3,2 -d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl- rolidin-2-one, (R)-3-[2-[3-[4-amino-8-(cyclopropoxy)pyrido[3,2- d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrro lysin-2-one, (R)-3-[2-[3-[4-amino-8-[1-(difluoromethyl)pyrazole -4-yl]oxy-pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl ]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(3,3,3-trifluoropropoxy ) pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy -1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(2,2-difluoro-5-azaspiro [2.3]hexan-5-yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-8-ethylpyrido[3,2-d]pyrimidine-6 -yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-8-cyclobutylpyrido[3,2-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-8-phenylpyrido[3,2-d]pyrimidine- 6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(thiophen-2-yl)pyrido[3,2- d] pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-((3-(4-amino-8-(furan-2-yl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (3R)-3-((3-(4-amino-8-(azetidin-2-yl)pyrido[3,2 -d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methyl thylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-vinylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-[3-(trifluoromethyl)azetidin phenyl]pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3 -hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(azetidin-1-yl)pyrido[3, 2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-((3-(4-amino-8-((2,2,2-trifluoroethyl)amino) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy thio-1-methylpyrrolidin-2-one, (1R,4R,5S)-4-((3-(7-aminothiazolo[5,4-d]pyrimidine -2-yl)-4-methylphenyl)ethynyl)-4-hydroxy-2-methyl-2-a Zabicyclo[3.1.0]hexan-3-one, (3R,5R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidine-2- (yl)-4-methylphenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine thion-2-one, and A compound selected from pharmaceutically acceptable salts thereof.
19. The compound is (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) -4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl ) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-6-methylpyrimido[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopteridin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-aminoquinazolin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) [phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl] -2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne- 2-all, (R)-3-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl] ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-3,4-dihydro-2,7-naphthyridine-2( 1H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-[2-[3-(3-amino-1-methyl-pyrazolo[4,3-b]pyridin phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-3-[2-[3-(3-amino-1H-pyrazolo[4,3-b]pyridine-5 -yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-ethoxypyrido[3,2-d]pyrimidin-6-yl)pyrimidin-6-yl)pyrimidin-6-yl)pyrimidin-6-yl (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-hydroxy-1-methyl-3-((3-(4-(methylamino)pyrido[ 3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) -4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one, (S)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl] -2-thiazol-2-yl-but-3-yn-2-ol, 1-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl ]ethynyl]cyclopentanol, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl] -2-(5-methylisoxazol-3-yl)but-3-yn-2-ol, 4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2 -methyl-but-3-yn-2-ol, (R)-3-[2-[3-(1-amino-7-isoquinolyl)phenyl]ethynyl]- 3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d ]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((5-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-5 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (R)-2-[3-[2-(7-hydroxy-5,6-dihydrocyclopenta[[b] pyridin-7-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidine- 8-on, (R)-4-(3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2- (thiazol-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-4-(3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d] (pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yne-2 - All, (R)-4-(3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2- (thiazol-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-4-(3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2- (thiazol-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) -5-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridine- 7-all, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 (-isobutylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin (3H)-(3-(3-yl)ethynyl)phenyl)pyrido[3,4-d]pyrimidine-4(3H)- on, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-((3-(8-amino-4-morpholinopyrido[3,4-d]pyrimidine (2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-3-((3-(8-amino-4-(dimethylamino)pyrido[3,4-d]pyridin (2-imidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-[2-[3-(4-amino-1H-imidazo[4,5-c]pyridine-2 -yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 (-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-7-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d ]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[pi]yl ta[b]pyridin-7-ol, (R)-7-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2 (-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-7-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2 (-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] [phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidinyl] phenyl-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl- rolidin-2-one, (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidine- 2-on, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidine- 2-on, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -thiazol-2-yl-but-3-yn-2-ol, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- (methylphenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one 、 (S)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one 、 (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidone lysin-2-one, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidone lysin-2-one, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- Methylphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)butanol -3-in-2-all, (R)-7-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 (-methylphenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidinyl] phenyl)ethynyl]-3-hydroxy-1-methyl-phenyl rolidin-2-one, (R)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidine- 2-on, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -(5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- methylphenyl)-2-(5-methylisoxazol-3-yl)but-3-yne-2 - All, (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d 3 ) Pyrrolidine-2 -on, (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imida zoll-7-ol, (R)-3-((3-(8-amino-4-(methylamino)pyrido[3,4-d]pyridyl (2-(2-(4 ... -on, (R)-7-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidinyl] [1,2-a]imidazo[2-phenyl-2-yl]phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazo 7-ol, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidinyl] phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl) ) pyrrolidin-2-one, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -(5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -thiazol-2-yl-but-3-yn-2-ol, (R)-7-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl ]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol, (R)-3-[2-[3-(8-amino-4-methyl-pyrido[3,4-d]pyrimidinyl] phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluorophenyl)ethynyl (triethyl)pyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(8-amino-5-bromopyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl (5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-3-[2-[3-(4-aminophthalazin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl -2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne- 2-all, (R)-3-((3-(8-amino-4-isopropylpyrido[3,4-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-[2-[3-[8-amino-5-(trifluoromethyl)pyrido[3,4 -d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrimidin-2-yl rolidin-2-one, (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin (3,4-d)pyrimidine-5-carbonyl Trill, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)pyrimidin-2-yl)pyrimidin-2-yl)pyrimidin-2-yl (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-iodopyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methyl isoxazol-3-yl)but-3-yn-2-ol, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-thiazole -2-yl-but-3-yn-2-ol, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methyl (1,3,4-oxadiazol-2-yl)but-3-yn-2-ol, 2-(3-((1H-pyrazol-5-yl)ethynyl)phenyl)-4-methylpyrazole do[3,4-d]pyrimidin-8-amine, (R)-4-(3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-methylquinazolin-6-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrido[3,4-d]pyrimidin-6-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-5-bromo-1,7-naphthyridin-2-yl] [phenyl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-8-fluoro-quinazolin-6-yl)phenyl] nyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-8-methoxyquinazolin-6-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(trifluoromethyl)quinazoline-6-yl) (phenyl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminothiazolo[4,5-c]pyridin-2-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-chloroquinazolin-6-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-8-amino-2-[3-[2-(3-hydroxy-1-methyl-2-oxo- Pyrrolidin-3-yl)ethynyl]phenyl]-1,7-naphthyridine-5-carbonite Lil, (R)-3-[2-[3-(5-amino-2,6-naphthyridin-3-yl)phenyl]phenyl ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-5-methyl-1,7-naphthyridin-2-yl] [phenyl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-5-phenylpyrido[3,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(1-methylpyrazol-4-yl)pyrazole Lido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1 -methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-[1-(2-hydroxy-2-methyl- propyl)pyrazol-4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl yl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(1H-pyrazol-4-yl)pyridin [3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl thyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(3,5-dimethyl-1-1H-pyrazoline [3,4-d]pyrimidin-2-yl]phenyl]ethynyl]- 3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-4-amino-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin (din-3-yl)ethynyl)phenyl)quinazoline-8-carbonitrile, (R)-3-[2-[3-[8-amino-5-(5-methyl-1H-pyrazole-4- pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydro hydroxy-1-methyl-pyrrolidin-2-one, (R)-phenyl 8-amino-2-[3-[2-(3-hydroxy-1-methyl-2 -oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidin benzophenone-5-carboxylate, (R)-3-((3-(8-amino-5-ethylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-isobutylpyrido[3,4-d]pyrimidine (2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone, (S)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone, (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)pyridin [3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl thyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-[1-(2-aminoethyl)pyrazole -4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3- hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)pyrido[3, 4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-8-methyl-pyrido[3,4-d]pyrimidinyl] phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-4-(3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl) (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(8-amino-4,5-dimethylpyrido[3,4-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[4-[8-amino-2-[3-[2-(3-hydroxy-1-methyl- 2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidin di-5-yl]pyrazol-1-yl]butanenitrile, (R)-3-((3-(4-aminothieno[2,3-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminooxazolo[5,4-d]pyrimidin-2-yl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(6-amino-9-methyl-9H-purin-8-yl)phenyl )ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl)- (phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol Lu, (R)-3-[2-[3-[8-amino-5-(1-piperidylmethyl)pyrido[3, 4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-7-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl ) phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Rule, (R)-3-[2-[3-[8-amino-5-[6-(trifluoromethyl)-3-pi lysyl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-2-methyl-pteridin-6-yl)phenyl ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) -4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-((3-(8-amino-5-neopentylpyrido[3,4-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((5-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 5-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl)- (phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol Lu, (R)-3-((3-(8-amino-4,6-dimethylpyrimido[5,4-d]pyrimidinyl) (2-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (2-methylthiazol-5-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (2-methylthiazol-5-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidinyl) (6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) -4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 (-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-5-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-5-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (thiazol-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, Racemic-8-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-5,6,7,8-tetrahydroquinolin-8-ol, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methylthiazol-2-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methylthiazol-2-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidine- 2-yl-6-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, (R)-tert-butyl 3-amino-5-[3-[2-(3-hydroxy-1-methyl) [0033] (2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]indazole-1-carboxylate carboxylate, (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pyridin (imidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)-1, 7-naphthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- rolidin-2-one, (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)-1,7-na Phthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-((3-(4-amino-2-(hydroxymethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-[2-[3-(3-amino-1H-indazol-5-yl)phenyl] ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-2-cyclopropylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-2-(trifluoromethyl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)- 4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-3-((3-(4-amino-2,7-dimethylpyrido[3,2-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-2H-pyrazolo[3,4-d]pyrimidine-2- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-2-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol Lu, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-2-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-3-[2-[3-(7-amino-5-methyl-thiazolo[5,4-d]pyrimidinyl] ethynyl)-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-methyl-phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imida zoll-7-ol, (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridine -7-all, 1-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4- methyl-phenyl]ethynyl]cyclopentanol, (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-7-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-(trifluoromethyl)thiazol-2-yl)buta-3 -in-2-all, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-(trifluoromethyl)thiazol-2-yl)buta-3 -in-2-all, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 1-Allyl-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one, Racemic-1-allyl-3-((3-(4-aminopyrido[3,2-d]pyrimidine-6 -yl-2-d)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol, Racemic-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- 1H-imidazol-4-yl)phenyl)-2-(1H-imidazol-4-yl)but-3-yn-2-ol 、 (R)-3-((3-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl )phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-(methoxymethyl)pyrido[3,2-d]pyridin (imidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-methoxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pyridin rimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d 3 ) Pi rolidin-2-one, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol, (R)-3-((3-(4-amino-2-ethylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-hydroxypyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methyl-1,3,4-oxadiazol-2-yl)butanol -3-in-2-all, (R)-3-((3-(7-aminothiazolo[4,5-d]pyrimidin-2-yl)pyrimidin-2-yl)pyrimidin-2-yl (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-methyl-7,8-dihydropyrido[4,3- d]pyrimidin-6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl) 1)pyrrolidin-2-one, (R)-4-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4 -methyl-phenyl]-2-(5-methylisoxazol-3-yl)but-3-yne -2-all, (R)-6-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-imidazo[1,5-a]pyrazin-8-one, (R)-3-((3-(8-amino-1,5-naphthyridin-2-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidinyl) (5H)-phenyl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) phenyl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4(3H)-one, (R)-3-hydroxy-1-methyl-3-((3-(4-(pyrrolidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-ol hmm, ((R)-3-hydroxy-1-methyl-3-((3-(pyrido[3,2-d]pyrimidinyl) (6-phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-amino-5,7,8,9-tetrahydro-6H-pyrimido) [5,4-c]azepin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-(piperidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-ol hmm, (R)-3-((3-(4-(3,3-dimethylazetidin-1-yl)pyrido[3, 2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrimidin rolidin-2-one, (R)-3-((3-(4-(ethylamino)pyrido[3,2-d]pyrimidine-6- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-hydroxy-3-((3-(4-(3-hydroxyazetidin-1-yl ) pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrro lysin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-(oxetan-3-yl) pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidine- 2-on, (R)-3-hydroxy-3-((3-(4-(3-methoxyazetidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidone Jin-2-On, (S)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-(3,3-difluoroazetidin-1-yl)pyrido[3 ,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-((3-(8-(azetidin-1-yl)-1,7-naphthyridine-2- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(1-(azetidin-1-yl)isoquinolin-7-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(azetidin-1-yl)quinolin-6-yl)phenyl )ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(cyclobutylamino)pyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1- methylpyrrolidin-2-one, (R)—N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)acetate Mido, (R)-3-((3-(4-(3-fluoroazetidin-1-yl)pyrido[3,2- d] pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-2-((6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine (3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)amino ) acetonitrile, (R)-3-((3-(4-((2,2-difluoroethyl)amino)pyrido[3,2 -d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrro lysin-2-one, (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)azetidin benzo-3-carbonitrile, (R)-3-((3-(4-(azetidin-1-yl)quinazolin-6-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(3-chloroazetidin-1-yl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-hydroxy-1-methyl-3-((3-(4-(3-(methylsulfonyl ) azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethyl nyl)pyrrolidin-2-one, (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- (3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)-N-methyl thiazetidine-3-carboxamide, (R)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (S)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(5-bromo-8-methyl-1,7-naphthyridin-2-yl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4,8-dimethylpyrido[3,2-d]pyrimidin-6-yl )phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) (phenyl)ethynyl)phenyl)-8-methyl-1,7-naphthyridine-5-carbonitrile, (R)-3-((3-(5,8-dimethyl-1,7-naphthyridin-2-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy- 1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy- 1-methylpyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-phenylpyrido[3,2- d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)—N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl acetamide, (R)—N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d) acetamide, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (3R,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3R,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3S,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3S,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3R,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3S,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidinyl) (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3S,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidinyl) (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3R,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (R)—N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d) methanesulfonamide, (R)-3-((3-(4-cyclopropylpyrido[3,2-d]pyrimidin-6-yl) (phenyl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-hydroxy-3-((3-(4-isopropylpyrido[3,2-d]pyridyl) (6-methyl-2-pyrrolidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidin-2-one, (1R,4R,5S)-4-((3-(4-amino-2-methylpyrido[3,2-d] pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (1S,4S,5R)-4-((3-(4-amino-2-methylpyrido[3,2-d] pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (1S,4S,5R)-4-((3-(4-aminopyrido[3,2-d]pyrimidine- 6-yl-2-d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[4.1.2.1] chloro[3.1.0]hexan-3-one, (1R,4R,5S)-4-((3-(4-aminopyrido[3,2-d]pyrimidine- 6-yl-2-d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[4.1.2.1] chloro[3.1.0]hexan-3-one, (R)-3-((3-(4-amino-8-cyclopentylpyrido[3,2-d]pyrimidin phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-hydroxy-1-methyl-3-((3-(4-(trifluoromethyl)pyrrolidone) Lido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one 、 (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) (phenyl)ethynyl)phenyl)pyrido[3,2-d]pyrimidine-4-carbonitrile, (R)-3-hydroxy-1-methyl-3-((3-(8-methyl-1,7-naphthyl) (phenyl)ethynyl)pyrrolidin-2-one, (1R,4R,5S)-4-((3-(4-amino-8-methylpyrido[3,2-d] pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (R)-3-((3-(4-amino-8-(aminomethyl)pyrido[3,2-d]pyridyl 2-(2-(phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-6-yl)phenylethynyl Jin-2-On, (R)-3-((3-(4-amino-8-isopropylpyrido[3,2-d]pyrimidinyl) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-((3-(4-amino-8-(trifluoromethyl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(4-amino-2,8-dimethylpyrido[3,2-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-8-(methyl-d 3 ) pyrido[3,2-d]pyri (6-(2 ...3-(2-(2-(2-(2-(3-(2-(2-(2-(2-( -on, (R)-3-((3-(4-amino-8-(piperidin-4-yl)pyrido[3,2- d]pyrimidin-6-yl-2-(phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-((3-(4-amino-2-fluoropyrido[3,2-d]pyrimidine- 6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (S)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (3R, 4S * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3rd and 4th rounds * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3S, 4S * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3S, 4R * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (R)-3-[2-[3-[4-amino-8-(dimethylamino)pyrido[3,2-d ]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine Jin-2-On, (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d] pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-[2-[3-[4-amino-8-(isopropylamino)pyrido[3,2 -d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrimidin-6-yl rolidin-2-one, (R)-3-[2-[3-[4-amino-8-(cyclopropylamino)pyrido[3, 2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(difluoromethoxy)pyrido[3,2 -d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrimidin-6-yl rolidin-2-one, (R)-3-[2-[3-[4-amino-8-(3,3-difluoroazetidine-1- pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydro hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-4-methyl-pyrimido[5,4-d]pyrimidinyl] ethynyl)-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-((3-(4-amino-8-cyclopropylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-[2-[3-(4-amino-8-pyrazol-1-yl-pyrido[3,2 -d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl- rolidin-2-one, (R)-3-[2-[3-[4-amino-8-(cyclopropoxy)pyrido[3,2- d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrro lysin-2-one, (R)-3-[2-[3-[4-amino-8-[1-(difluoromethyl)pyrazole -4-yl]oxy-pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl ]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(3,3,3-trifluoropropoxy ) pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy -1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(2,2-difluoro-5-azaspiro [2.3]hexan-5-yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-8-ethylpyrido[3,2-d]pyrimidine-6 -yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-8-cyclobutylpyrido[3,2-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-8-phenylpyrido[3,2-d]pyrimidine- 6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(thiophen-2-yl)pyrido[3,2- d] pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-((3-(4-amino-8-(furan-2-yl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (3R)-3-((3-(4-amino-8-(azetidin-2-yl)pyrido[3,2 -d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methyl thylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-vinylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-[3-(trifluoromethyl)azetidin phenyl]pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3 -hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(azetidin-1-yl)pyrido[3, 2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, and 19. The compound of claim 18 selected from pharmaceutically acceptable salts thereof.
20. The compound is (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) -4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl ) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-6-methylpyrimido[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopteridin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-aminoquinazolin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) [phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl] -2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne- 2-all, (R)-3-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl] ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-3,4-dihydro-2,7-naphthyridine-2( 1H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-[2-[3-(3-amino-1-methyl-pyrazolo[4,3-b]pyridin phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-3-[2-[3-(3-amino-1H-pyrazolo[4,3-b]pyridine-5 -yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-ethoxypyrido[3,2-d]pyrimidin-6-yl)pyrimidin-6-yl)pyrimidin-6-yl)pyrimidin-6-yl (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-hydroxy-1-methyl-3-((3-(4-(methylamino)pyrido[ 3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) -4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, and 19. The compound of claim 18 selected from pharmaceutically acceptable salts thereof.
21. The compound is (3R,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl ) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-5-ethylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d] pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-((3-(8-amino-5-ethylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-ethylpyrido[3,2-d]pyrimidine-6 -yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-cyclopentylpyrido[3,2-d]pyrimidin phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminoquinazolin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-8-cyclopropylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidinyl) (5H)-phenyl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-((3-(4-amino-8-(methyl-d 3 ) pyrido[3,2-d]pyri (6-(2 ...3-(2-(2-(2-(2-(3-(2-(2-(2-(2-( -on, and 19. The compound of claim 18 selected from pharmaceutically acceptable salts thereof.
22. The compound is (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d] pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-8-(methyl-d 3 ) pyrido[3,2-d]pyri (6-(2 ...3-(2-(2-(2-(2-(3-(2-(2-(2-(2-( -on, and 22. The compound of claim 21 selected from pharmaceutically acceptable salts thereof.
23. The compound is (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d] pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and pharmaceutically acceptable salts thereof.
24. The compound is (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and 22. The compound of claim 21 selected from pharmaceutically acceptable salts thereof.
25. The compound is (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d] pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine thion-2-one, and 22. The compound of claim 21 selected from pharmaceutically acceptable salts thereof.
26. The compound is (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and Beauty 22. The compound of claim 21 selected from pharmaceutically acceptable salts thereof.
27. The compound is (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and 22. The compound of claim 21 selected from pharmaceutically acceptable salts thereof.
28. The compound is (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and 22. The compound of claim 21 selected from pharmaceutically acceptable salts thereof.
29. The compound is (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, and Beauty 22. The compound of claim 21 selected from pharmaceutically acceptable salts thereof.
30. The compound is (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, and 22. The compound of claim 21 selected from pharmaceutically acceptable salts thereof.
31. The compound is (R)-3-((3-(4-amino-8-(methyl-d 3 ) pyrido[3,2-d]pyri (6-(2 ...3-(2-(2-(2-(2-(3-(2-(2-(2-(2-( -on, and 22. The compound of claim 21 selected from pharmaceutically acceptable salts thereof.
32. 10. Therapeutically effective at least one compound of claim 1 or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising an amount of
33. Therapeutically useful compounds of at least one compound according to claim 18 or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising an effective amount of
34. 22. Therapeutically useful compounds of at least one compound of claim 21 or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising an effective amount of
35. 23. The therapeutically useful compound of claim 22 or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprising an effective amount of
36. suffers from a disease, disorder, or medical condition mediated by NIK activity; or is a method of treating a subject diagnosed with a leukemia, the method comprising administering to a subject in need of such treatment: administering an effective amount of at least one compound of formula (I), or a pharmaceutically acceptable salt thereof; This includes 【Chemistry 98】 During the ceremony, R 1 is H or -CH 3 and R 2 is H or -CH 3 and R 3 is H, -C 1 -C 5 Alkyl, —OCH 3 , or -O-C 1 -C 3 Haloalkyl and R 4 is H or -CH 3 and portion 【Hua99】 teeth, 【Chemistry 100】 and R aa is H or -CH 3 and R bb is H, -CH 3 , or -CF 3 and R cc is -CH 3 , -CD 3 , or -CH 2 CF 3 and portion 【Chemistry 101】 teeth, 【Chemistry 102】 and E is N or CH; F is O, S, NH, or NCH 3 and R a is H or -CH 3 and R b are H, D, -OH, F, and -C. 1 C 5 Alkyl, —CH 2 OCH 3 , -C 1 -C 5 Haloalkyl, —NH 2 , cyclopropyl, or —CH 2 OH, R c is H, D, or CH 3 and R d is H, -CN, -CF 3 , -C 1 -C 5 Alkyl, —C 3 -C 6 cycloalkyl , —O—C 1 -C 3 Alkyl, —N(R 6 ) R 7 , 【Chemistry 103】 and During the ceremony, R 6 is H or -C 1 -C 3 is alkyl, R 7 is H, -C 1 -C 3 Alkyl, —SO 2 CH 3 , -COCH 3 , -C 1 -C 4 Ha alkyl, or -CH 2 CN or R 6 and R 7 is that they are combined Together with the nitrogen, portion 【Chemistry 104】 wherein m is 0 or 1 and p is 0 or 1; R 8 is H, F, or -C 1 -C 3 is alkyl, R 9 is H, F, or -C 1 -C 3 is alkyl, R e is H, -CD 3 , Br, -C 1 -C 5 Alkyl 、 -C 3 -C 6 cycloalkyl, 【Chemistry 105】 1 to 3 R g -C substituted with a group 1 -C 5 alkyl, wherein R g Ha-NH 2 , or F, R 10 is H or F, R 11 is H or F, R f is H, -CH 3 , or 【Chemistry 106】 and R h is -CH 3 , -NH 2 , or 【Chemistry 107】 and R i is H, -CH 3 , -CN, Br, 【Chemistry 108】 and R j is -NH 2 or 【Chemistry 109】 and R k is H, -CF 3 , I, Cl, Br, -CN, -C 1 -C 6 Alkyl, 【Chemistry 110】 and R 12 is H or -CH 3 and R 13 is H, -CH 3 , -CH 2 (C) (CH 3 ) 2 OH, -(CH 2 ) 3 CN, also Ha-(CH 2 ) 2 NH 2 and R 14 is H or -CH 3 and R l is H, -C 1 -C 4 alkyl, —CF3, 【Chemistry 111】 and R m is H or -CH 3 and R n is -NH 2 and R o is H or -CH 3 and R p is H or -CH 3 and R q is H, -CN, F, Cl, -OCH 3 , -CF 3 , or -CH 3 and R s is -NH 2 or 【Chemistry 112】 and However, part 【Chemistry 113】 but 【Chemistry 114】 and each R 1 , R 2 , R 3 and R 4 If H, the part 【Chemistry 115】 teeth 【Chemistry 116】 The method is provided that
37. The disease, disorder, or medical condition is cancer, an inflammatory disorder, an autoimmune disorder, an immune-cutaneous disorder, and metabolic disorders.
38. The disease, disorder, or medical condition is selected from the group consisting of SLE, RA, GvHD, graft rejection, Shagman syndrome, and the like. Selected from Renn's syndrome, pemphigus vulgaris, palmoplantar pustulosis, hidradenitis suppurativa, obesity, and diabetes 38. The method of claim 37.
39. suffering from or having a disease, disorder, or condition mediated by NIK activity 1. A method of treating a subject diagnosed with rhesus macular degeneration, comprising administering to a subject in need of such treatment: (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) -4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- yl)-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl ) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-6-methylpyrimido[5,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopteridin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-aminoquinazolin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) [phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl] -2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne- 2-all, (R)-3-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl] ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-3,4-dihydro-2,7-naphthyridine-2( 1H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-[2-[3-(3-amino-1-methyl-pyrazolo[4,3-b]pyridin phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-3-[2-[3-(3-amino-1H-pyrazolo[4,3-b]pyridine-5 -yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-methylpyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-ethoxypyrido[3,2-d]pyrimidin-6-yl)pyrimidin-6-yl)pyrimidin-6-yl)pyrimidin-6-yl (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(dimethylamino)pyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-hydroxy-1-methyl-3-((3-(4-(methylamino)pyrido[ 3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-amino-8-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) -4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one, (S)-2-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidin-8-one, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl] -2-thiazol-2-yl-but-3-yn-2-ol, 1-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl ]ethynyl]cyclopentanol, (R)-4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl] -2-(5-methylisoxazol-3-yl)but-3-yn-2-ol, 4-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)phenyl]-2 -methyl-but-3-yn-2-ol, (R)-3-[2-[3-(1-amino-7-isoquinolyl)phenyl]ethynyl]- 3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d ]pyrimidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((5-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-2 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-5 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (R)-2-[3-[2-(7-hydroxy-5,6-dihydrocyclopenta[[b] pyridin-7-yl)ethynyl]phenyl]-7H-pyrido[3,4-d]pyrimidine- 8-on, (R)-4-(3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2- (thiazol-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-4-(3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d] (pyrimidin-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yne-2 - All, (R)-4-(3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2- (thiazol-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-4-(3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2- (thiazol-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) -5-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridine- 7-all, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 (-isobutylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin (3H)-(3-(3-yl)ethynyl)phenyl)pyrido[3,4-d]pyrimidine-4(3H)- on, (R)-3-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 -(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-((3-(8-amino-4-morpholinopyrido[3,4-d]pyrimidine (2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-3-((3-(8-amino-4-(dimethylamino)pyrido[3,4-d]pyridin (2-imidin-2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-[2-[3-(4-amino-1H-imidazo[4,5-c]pyridine-2 -yl)phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 (-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-7-((3-(8-amino-4-(trifluoromethyl)pyrido[3,4-d ]pyrimidin-2-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[pi]yl ta[b]pyridin-7-ol, (R)-7-((3-(8-amino-5-methylpyrido[3,4-d]pyrimidine-2 (-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-7-((3-(8-amino-6-methylpyrido[3,4-d]pyrimidine-2 (-yl)phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (S)-7-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl] [phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Lu, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidinyl] phenyl-2-yl)-4-methyl-phenyl]ethynyl]-3-hydroxy-1-methyl- rolidin-2-one, (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidine- 2-on, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidine- 2-on, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -thiazol-2-yl-but-3-yn-2-ol, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- (methylphenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, (R)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one 、 (S)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(trideuteriomethyl)pyrrolidin-2-one 、 (R)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidone lysin-2-one, (S)-3-[2-[3-(8-aminopyrido[3,4-d]pyrimidin-2-yl) Phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidone lysin-2-one, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- Methylphenyl)-2-(5-methyl-1,3,4-oxadiazol-2-yl)butanol -3-in-2-all, (R)-7-((3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4 (-methylphenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridine -7-all, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidinyl] phenyl)ethynyl]-3-hydroxy-1-methyl-phenyl rolidin-2-one, (R)-3-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-3-hydroxy-1-(2,2,2-trifluoroethyl)pyrrolidine- 2-on, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl]-2 -(5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-5,6-dihydrocyclopenta[b]pyridin-7-ol, (R)-7-[2-[3-(1-amino-7-isoquinolyl)-4-methyl-phenyl ]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol, (R)-4-(3-(8-aminopyrido[3,4-d]pyrimidin-2-yl)-4- methylphenyl)-2-(5-methylisoxazol-3-yl)but-3-yne-2 - All; (R)-3-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d 3 ) Pyrrolidine-2 -on, (R)-7-((3-(8-amino-4-methylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-6,7-dihydro-5H-pyrrolo[1,2-a]imida zoll-7-ol, (R)-3-((3-(8-amino-4-(methylamino)pyrido[3,4-d]pyridyl (2-(2-(4 ... -on, (R)-7-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidinyl] [1,2-a]imidazo[2-phenyl-2-yl]phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazo 7-ol, (R)-3-[2-[3-(8-amino-5-methyl-pyrido[3,4-d]pyrimidinyl] phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl) ) pyrrolidin-2-one, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -(5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-4-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl]-2 -thiazol-2-yl-but-3-yn-2-ol, (R)-7-[2-[3-(8-amino-1,7-naphthyridin-2-yl)phenyl ]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol, (R)-3-[2-[3-(8-amino-4-methyl-pyrido[3,4-d]pyrimidinyl] phenyl]ethynyl]-3-hydroxy-1-(2,2,2-trifluorophenyl)ethynyl (triethyl)pyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(8-amino-5-bromopyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl (5-methylisoxazol-3-yl)but-3-yn-2-ol, (R)-3-[2-[3-(4-aminophthalazin-6-yl)phenyl]ethynyl] -3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-4-(3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl -2-(5-methyl-1,3,4-oxadiazol-2-yl)but-3-yne- 2-all, (R)-3-((3-(8-amino-4-isopropylpyrido[3,4-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-[2-[3-[8-amino-5-(trifluoromethyl)pyrido[3,4 -d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrimidin-2-yl rolidin-2-one, (R)-8-amino-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin (3,4-d)pyrimidine-5-carbonyl Trill; (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)pyrimidin-2-yl)pyrimidin-2-yl)pyrimidin-2-yl (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-iodopyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-chloropyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methyl isoxazol-3-yl)but-3-yn-2-ol, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-thiazole -2-yl-but-3-yn-2-ol, (R)-4-[3-(4-aminoquinazolin-6-yl)phenyl]-2-(5-methyl (1,3,4-oxadiazol-2-yl)but-3-yn-2-ol, 2-(3-((1H-pyrazol-5-yl)ethynyl)phenyl)-4-methylpyrazole do[3,4-d]pyrimidin-8-amine, (R)-4-(3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(4-aminopyrido[2,3-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-methylquinazolin-6-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-(4-aminopyrido[3,4-d]pyrimidin-6-yl) phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-5-bromo-1,7-naphthyridin-2-yl] [phenyl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-8-fluoro-quinazolin-6-yl)phenyl] nyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-8-methoxyquinazolin-6-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(trifluoromethyl)quinazoline-6-yl) (phenyl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminothiazolo[4,5-c]pyridin-2-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-chloroquinazolin-6-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-8-amino-2-[3-[2-(3-hydroxy-1-methyl-2-oxo- Pyrrolidin-3-yl)ethynyl]phenyl]-1,7-naphthyridine-5-carbonite Lil; (R)-3-[2-[3-(5-amino-2,6-naphthyridin-3-yl)phenyl]phenyl ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-5-methyl-1,7-naphthyridin-2-yl] [phenyl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(8-amino-5-phenylpyrido[3,4-d]pyrimidine- 2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(1-methylpyrazol-4-yl)pyrazole Lido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1 -methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-[1-(2-hydroxy-2-methyl- propyl)pyrazol-4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl yl]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(1H-pyrazol-4-yl)pyridin [3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl thyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(3,5-dimethyl-1-1H-pyrazoline [3,4-d]pyrimidin-2-yl]phenyl]ethynyl]- 3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-4-amino-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidin (din-3-yl)ethynyl)phenyl)quinazoline-8-carbonitrile; (R)-3-[2-[3-[8-amino-5-(5-methyl-1H-pyrazole-4- pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydro hydroxy-1-methyl-pyrrolidin-2-one, (R)-phenyl 8-amino-2-[3-[2-(3-hydroxy-1-methyl-2 -oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidin benzophenone-5-carboxylate, (R)-3-((3-(8-amino-5-ethylpyrido[3,4-d]pyrimidine-2 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(8-amino-5-isobutylpyrido[3,4-d]pyrimidine (2-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone, (S)-2-[2-[3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) phenyl]ethynyl]-2-hydroxy-5,5-dimethyl-cyclopentanone, (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)pyridin [3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl thyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-[1-(2-aminoethyl)pyrazole -4-yl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3- hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)pyrido[3, 4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-8-methyl-pyrido[3,4-d]pyrimidinyl] phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine-2- on, (R)-4-(3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl) (thiazol-2-yl)but-3-yn-2-ol, (R)-3-((3-(8-amino-4,5-dimethylpyrido[3,4-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[4-[8-amino-2-[3-[2-(3-hydroxy-1-methyl- 2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]pyrido[3,4-d]pyrimidin di-n-5-yl]pyrazol-1-yl]butanenitrile; (R)-3-((3-(4-aminothieno[2,3-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminooxazolo[5,4-d]pyrimidin-2-yl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(6-amino-9-methyl-9H-purin-8-yl)phenyl )ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl)- (phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol Lu, (R)-3-[2-[3-[8-amino-5-(1-piperidylmethyl)pyrido[3, 4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-7-[2-[3-(4-aminopyrimido[5,4-d]pyrimidin-6-yl ) phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imidazol-7-ol Rule, (R)-3-[2-[3-[8-amino-5-[6-(trifluoromethyl)-3-pi lysyl]pyrido[3,4-d]pyrimidin-2-yl]phenyl]ethynyl]-3-hydroxy hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(4-amino-2-methyl-pteridin-6-yl)phenyl ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) -4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-((3-(8-amino-5-neopentylpyrido[3,4-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((5-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 5-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 2-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-7-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)phenyl)- (phenyl)ethynyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-ol Lu, (R)-3-((3-(8-amino-4,6-dimethylpyrimido[5,4-d]pyrimidinyl) (2-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (2-methylthiazol-5-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (2-methylthiazol-5-yl)phenyl)-2-(2-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidinyl) (6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) -4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 (-yl)-4-methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-5-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-5-yl)phenyl)-2-(4-methylthiazol-5-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (thiazol-2-yl)phenyl)-2-(thiazol-2-yl)but-3-yn-2-ol, Racemic-8-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-5,6,7,8-tetrahydroquinolin-8-ol, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methylthiazol-2-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methylthiazol-2-yl)phenyl)-2-(5-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-3-((3-(8-amino-4-methylpyrimido[5,4-d]pyrimidine- 2-yl-6-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2 -on, (R)-tert-butyl 3-amino-5-[3-[2-(3-hydroxy-1-methyl) [0033] (2-oxo-pyrrolidin-3-yl)ethynyl]phenyl]indazole-1-carboxylate carboxylate, (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pyridin (imidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-[2-[3-[8-amino-5-(pyrrolidin-1-ylmethyl)-1, 7-naphthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- rolidin-2-one, (R)-3-[2-[3-[8-amino-5-(dimethylaminomethyl)-1,7-na Phthyridin-2-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-((3-(4-amino-2-(hydroxymethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-[2-[3-(3-amino-1H-indazol-5-yl)phenyl] ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-2-cyclopropylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-2-(trifluoromethyl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)- 4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-3-((3-(4-amino-2,7-dimethylpyrido[3,2-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-2H-pyrazolo[3,4-d]pyrimidine-2- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-2-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol Lu, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-methylthiazol-2-yl)phenyl)-2-(4-methylthiazol-2-yl)but-3-yn-2-ol Lu, (R)-3-[2-[3-(7-amino-5-methyl-thiazolo[5,4-d]pyrimidinyl] ethynyl)-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-methyl-phenyl]ethynyl]-5,6-dihydropyrrolo[1,2-a]imida zoll-7-ol, (R)-7-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-methyl-phenyl]ethynyl]-5,6-dihydrocyclopenta[b]pyridine -7-all, 1-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4- methyl-phenyl]ethynyl]cyclopentanol, (S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-3-((3-(8-aminopyrimido[5,4-d]pyrimidin-2-yl)- 4-methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-7-methylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-(2-pyridyl)but-3-yn-2-ol, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-(trifluoromethyl)thiazol-2-yl)buta-3 -in-2-all, (S)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (4-(trifluoromethyl)thiazol-2-yl)buta-3 -in-2-all, (R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)- 4-Methoxyphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 1-Allyl-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one, Racemic-1-allyl-3-((3-(4-aminopyrido[3,2-d]pyrimidine-6 -yl-2-d)phenyl)ethynyl)-3-hydroxypyrrolidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrimidin-2-yl-but-3-yn-2-ol, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl-2- d) phenyl)ethynyl)-3-hydroxy-1-methylpiperidin-2-one, (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-pyrazin-2-yl-but-3-yn-2-ol, Racemic-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- 1H-imidazol-4-yl)phenyl)-2-(1H-imidazol-4-yl)but-3-yn-2-ol 、 (R)-3-((3-(2,4-diaminopyrido[3,2-d]pyrimidin-6-yl )phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-(difluoromethyl)-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-(methoxymethyl)pyrido[3,2-d]pyridin (imidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine- 2-on, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)phenyl) (ethynyl)-3-methoxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-(fluoromethyl)pyrido[3,2-d]pyridin rimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-(methyl-d 3 ) Pi rolidin-2-one, (S)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol, (R)-3-((3-(4-amino-2-ethylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-hydroxypyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-4-[3-(4-amino-2-methyl-pyrido[3,2-d]pyrimidine-6 -yl)phenyl]-2-thiazol-4-yl-but-3-yn-2-ol, (R)-4-(3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6- (5-methyl-1,3,4-oxadiazol-2-yl)butanol -3-in-2-all, (R)-3-((3-(7-aminothiazolo[4,5-d]pyrimidin-2-yl)pyrimidin-2-yl)pyrimidin-2-yl (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-2-methyl-7,8-dihydropyrido[4,3- d]pyrimidin-6(5H)-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-[2-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl )-4-methyl-phenyl]ethynyl]-3-hydroxy-1-(trideuteriomethyl) 1)pyrrolidin-2-one, (R)-4-[3-(7-aminothiazolo[5,4-d]pyrimidin-2-yl)-4 -methyl-phenyl]-2-(5-methylisoxazol-3-yl)but-3-yne -2-all, (R)-6-[3-[2-(3-hydroxy-1-methyl-2-oxo-pyrrolidine- 3-yl)ethynyl]phenyl]-7H-imidazo[1,5-a]pyrazin-8-one, (R)-3-((3-(8-amino-1,5-naphthyridin-2-yl)phenyl)e (thionyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-7,8-dihydropyrido[4,3-d]pyrimidinyl) (5H)-phenyl)-4-methylphenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) phenyl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4(3H)-one, (R)-3-hydroxy-1-methyl-3-((3-(4-(pyrrolidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-ol hmm, ((R)-3-hydroxy-1-methyl-3-((3-(pyrido[3,2-d]pyrimidinyl) (6-phenyl)ethynyl)pyrrolidin-2-one, (R)-3-((3-(4-amino-5,7,8,9-tetrahydro-6H-pyrimido) [5,4-c]azepin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-(piperidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-ol hmm, (R)-3-((3-(4-(3,3-dimethylazetidin-1-yl)pyrido[3, 2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrimidin rolidin-2-one, (R)-3-((3-(4-(ethylamino)pyrido[3,2-d]pyrimidine-6- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-hydroxy-3-((3-(4-(3-hydroxyazetidin-1-yl ) pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrro lysin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-(oxetan-3-yl) pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidine- 2-on, (R)-3-hydroxy-3-((3-(4-(3-methoxyazetidin-1-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidone Jin-2-On, (S)-3-((3-(4-(azetidin-1-yl)pyrido[3,2-d]pyrimidin (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-(3,3-difluoroazetidin-1-yl)pyrido[3 ,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-((3-(8-(azetidin-1-yl)-1,7-naphthyridine-2- yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(1-(azetidin-1-yl)isoquinolin-7-yl)phenyl) (ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(azetidin-1-yl)quinolin-6-yl)phenyl )ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(cyclobutylamino)pyrido[3,2-d]pyrimidine -6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one 、 (R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidine-6 -yl)-4-(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1- methylpyrrolidin-2-one, (R)—N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)acetate Mido, (R)-3-((3-(4-(3-fluoroazetidin-1-yl)pyrido[3,2- d] pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-2-((6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine (3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)amino ) acetonitrile, (R)-3-((3-(4-((2,2-difluoroethyl)amino)pyrido[3,2 -d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrro lysin-2-one, (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)azetidin benzo-3-carbonitrile, (R)-3-((3-(4-(azetidin-1-yl)quinazolin-6-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-(3-chloroazetidin-1-yl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-hydroxy-1-methyl-3-((3-(4-(3-(methylsulfonyl ) azetidin-1-yl)pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethyl nyl)pyrrolidin-2-one, (R)-1-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- (3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl)-N-methyl thiazetidine-3-carboxamide, (R)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (S)-3-((3-(8-(azetidin-1-yl)pyrido[3,4-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(5-bromo-8-methyl-1,7-naphthyridin-2-yl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4,8-dimethylpyrido[3,2-d]pyrimidin-6-yl )phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-2-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) (phenyl)ethynyl)phenyl)-8-methyl-1,7-naphthyridine-5-carbonitrile, (R)-3-((3-(5,8-dimethyl-1,7-naphthyridin-2-yl)phenyl) ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-8-bromopyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy- 1-methylpyrrolidin-2-one, (S)-3-((3-(4-amino-8-(tetrahydro-2H-pyran-4-yl) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy- 1-methylpyrrolidin-2-one, (R)-3-hydroxy-1-methyl-3-((3-(4-phenylpyrido[3,2- d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one, (R)—N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)-2-methylpyrido[3,2-d]pyrimidin-4-yl acetamide, (R)—N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d) acetamide, (S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -methylphenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (3R,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3R,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3S,5S)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3S,5R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl) 2-d)phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine-2 -on, (3R,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3S,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidinyl) (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3S,5R)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidinyl) (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (3R,5S)-3-((3-(4-amino-2-methylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine -2-on, (R)—N-(6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine- 3-yl)ethynyl)phenyl)pyrido[3,2-d]pyrimidin-4-yl-2-d) Methanesulfonamide; (R)-3-((3-(4-cyclopropylpyrido[3,2-d]pyrimidin-6-yl) (phenyl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-aminopyrido[3,2-d]pyrimidin-6-yl)-4 -(trifluoromethoxy)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-hydroxy-3-((3-(4-isopropylpyrido[3,2-d]pyridyl) (6-methyl-2-pyrrolidin-6-yl)phenyl)ethynyl)-1-methylpyrrolidin-2-one, (1R,4R,5S)-4-((3-(4-amino-2-methylpyrido[3,2-d] pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (1S,4S,5R)-4-((3-(4-amino-2-methylpyrido[3,2-d] pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (1S,4S,5R)-4-((3-(4-aminopyrido[3,2-d]pyrimidine- 6-yl-2-d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[4.1.2.1] chloro[3.1.0]hexan-3-one, (1R,4R,5S)-4-((3-(4-aminopyrido[3,2-d]pyrimidine- 6-yl-2-d)phenyl)ethynyl)-4-hydroxy-2-methyl-2-azabicyclo[4.1.2.1] chloro[3.1.0]hexan-3-one, (R)-3-((3-(4-amino-8-cyclopentylpyrido[3,2-d]pyrimidin phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-hydroxy-1-methyl-3-((3-(4-(trifluoromethyl)pyrrolidone) Lido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)pyrrolidin-2-one 、 (R)-6-(3-((3-hydroxy-1-methyl-2-oxopyrrolidine-3-yl) (phenyl)ethynyl)phenyl)pyrido[3,2-d]pyrimidine-4-carbonitrile, (R)-3-hydroxy-1-methyl-3-((3-(8-methyl-1,7-naphthyl) (phenyl)ethynyl)pyrrolidin-2-one, (1R,4R,5S)-4-((3-(4-amino-8-methylpyrido[3,2-d] pyrimidin-6-yl)phenyl)ethynyl)-4-hydroxy-2-methyl-2-aza bicyclo[3.1.0]hexan-3-one, (R)-3-((3-(4-amino-8-(aminomethyl)pyrido[3,2-d]pyridyl 2-(2-(phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-6-yl)phenylethynyl Jin-2-On, (R)-3-((3-(4-amino-8-isopropylpyrido[3,2-d]pyrimidinyl) phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (R)-3-((3-(4-amino-8-(trifluoromethyl)pyrido[3,2-d ]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine On-2-on, (R)-3-((3-(4-amino-2,8-dimethylpyrido[3,2-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-8-(methyl-d 3 ) pyrido[3,2-d]pyri (6-(2 ...3-(2-(2-(2-(2-(3-(2-(2-(2-(2-( -on, (R)-3-((3-(4-amino-8-(piperidin-4-yl)pyrido[3,2- d]pyrimidin-6-yl-2-(phenyl)ethynyl)-3-hydroxy-1-methyl pyrrolidin-2-one, (R)-3-((3-(4-amino-2-fluoropyrido[3,2-d]pyrimidine- 6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (S)-3-((3-(4-amino-8-(difluoromethyl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (3R, 4S * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3rd and 4th rounds * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3S, 4S * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (3S, 4R * )-3-((3-(4-amino-2-methylpyrido[3,2-d]pyridyl (6-(phenyl)ethynyl)-3-hydroxy-1,4-dimethylpyrrolidine On-2-on, (R)-3-[2-[3-[4-amino-8-(dimethylamino)pyrido[3,2-d ]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine Jin-2-On, (R)-3-[2-[3-[4-amino-8-(methylamino)pyrido[3,2-d] pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrrolidine On-2-on, (R)-3-[2-[3-[4-amino-8-(isopropylamino)pyrido[3,2 -d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrimidin-6-yl rolidin-2-one, (R)-3-[2-[3-[4-amino-8-(cyclopropylamino)pyrido[3, 2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(difluoromethoxy)pyrido[3,2 -d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrimidin-6-yl rolidin-2-one, (R)-3-[2-[3-[4-amino-8-(3,3-difluoroazetidine-1- pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydro hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-(8-amino-4-methyl-pyrimido[5,4-d]pyrimidinyl] ethynyl)-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-((3-(4-amino-8-cyclopropylpyrido[3,2-d]pyrimidin (6-phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-[2-[3-(4-amino-8-pyrazol-1-yl-pyrido[3,2 -d]pyrimidin-6-yl)phenyl]ethynyl]-3-hydroxy-1-methyl- rolidin-2-one, (R)-3-[2-[3-[4-amino-8-(cyclopropoxy)pyrido[3,2- d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl-pyrro lysin-2-one, (R)-3-[2-[3-[4-amino-8-[1-(difluoromethyl)pyrazole -4-yl]oxy-pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl ]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(3,3,3-trifluoropropoxy ) pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy -1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(2,2-difluoro-5-azaspiro [2.3]hexan-5-yl)pyrido[3,2-d]pyrimidin-6-yl]phenyl ]ethynyl]-3-hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-((3-(4-amino-8-ethylpyrido[3,2-d]pyrimidine-6 -yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine-2- on, (R)-3-((3-(4-amino-8-cyclobutylpyrido[3,2-d]pyrimidinyl) (phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-ol hmm, (R)-3-((3-(4-amino-8-phenylpyrido[3,2-d]pyrimidine- 6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-(thiophen-2-yl)pyrido[3,2- d] pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidone Jin-2-On, (R)-3-((3-(4-amino-8-(furan-2-yl)pyrido[3,2-d] Pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidine -2-on, (3R)-3-((3-(4-amino-8-(azetidin-2-yl)pyrido[3,2 -d]pyrimidin-6-yl-2-d)phenyl)ethynyl)-3-hydroxy-1-methyl thylpyrrolidin-2-one, (R)-3-((3-(4-amino-8-vinylpyrido[3,2-d]pyrimidine-6 -yl)phenyl)ethynyl)-3-hydroxy-1-methylpyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-[3-(trifluoromethyl)azetidin phenyl]pyrido[3,2-d]pyrimidin-6-yl]phenyl]ethynyl]-3 -hydroxy-1-methyl-pyrrolidin-2-one, (R)-3-[2-[3-[4-amino-8-(azetidin-1-yl)pyrido[3, 2-d]pyrimidin-6-yl]phenyl]ethynyl]-3-hydroxy-1-methyl- pyrrolidin-2-one, (R)-3-((3-(4-amino-8-((2,2,2-trifluoroethyl)amino) Pyrido[3,2-d]pyrimidin-6-yl)phenyl)ethynyl)-3-hydroxy thio-1-methylpyrrolidin-2-one, (1R,4R,5S)-4-((3-(7-aminothiazolo[5,4-d]pyrimidine -2-yl)-4-methylphenyl)ethynyl)-4-hydroxy-2-methyl-2-a Zabicyclo[3.1.0]hexan-3-one, (3R,5R)-3-((3-(7-aminothiazolo[5,4-d]pyrimidine-2- (yl)-4-methylphenyl)ethynyl)-3-hydroxy-1,5-dimethylpyrrolidine thion-2-one, and administering an effective amount of at least one compound selected from the group consisting of pharmaceutically acceptable salts thereof; A method comprising:
40. The disease, disorder, or medical condition is cancer, an inflammatory disorder, an autoimmune disorder, an immune-cutaneous disorder, and metabolic disorders.
41. The disease, disorder, or medical condition is selected from the group consisting of SLE, RA, GvHD, graft rejection, Shagman syndrome, and the like. Selected from Renn's syndrome, pemphigus vulgaris, palmoplantar pustulosis, hidradenitis suppurativa, obesity, and diabetes 41. The method of claim 40.
Citation Information
Patent Citations
Compound with 2-aminopyrimidine structure as well as preparation method and purpose thereof
CN109810110A
Alkinyl alcohols as kinase inhibitors
JP2011525915A
6,5-Heterocyclic propargyl alcohol compounds and their uses
JP2014508183A
Protein kinase inhibitors
JP2015523402A
Alkynyl alcohol and method of use
JP2016531127A
